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ABSTRACT 
 
Cataia L. Ives: Annotating Adverse Outcome Pathways to Organize  
Toxicological Information for Risk Assessment 
 (Under the direction of Stephen Edwards) 
 
The Adverse Outcome Pathway (AOP) framework connects molecular perturbations with 
organism and population level endpoints used for regulatory decision-making by providing a 
conceptual construct of the mechanistic basis for toxicity. Development of an AOP typically 
begins with the adverse outcome, and intermediate effects connect the outcome with a molecular 
initiating event amenable to high-throughput toxicity testing (HTT). Publicly available controlled 
vocabularies were used to provide terminology supporting AOP’s at all levels of biological 
organization. The resulting data model contains terms from 22 ontologies and controlled 
vocabularies annotating currently existing AOP’s. The model provides the ability to attach 
evidence in support of the AOP, supports data aggregation, and promotes the development of 
AOP networks. Long term, this structured description of the AOP will enable logical reasoning 
for hazard identification and for dose-response assessment. Case studies showcase how the 
model informs AOP development in the context of chemical risk assessment. 
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CHAPTER 1: INTRODUCTION, THE ADVERSE OUTCOME PATHWAY 
FRAMEWORK, OBJECTIVES, AND HYPOTHESES 
 
Introduction 
Traditional toxicity testing has focused on in vivo testing for whole-organism outcomes 
of exposure, such as a clinical sign or pathologic state resulting from exposure to a toxicant 
(OECD, 2013a). Traditional testing is costly, time-consuming, and uses live animal models; 
while alternative in vitro and in silico approaches increase the efficiency of testing and reduce 
the use of live animals. Today, there are 82,000 chemicals in industry, and 700 new ones 
introduced each year; as opposed to 62,000 chemicals in 1979 (as cited in Krewski et al., 2010, 
p.13). The need to assess an ever-increasing number of chemicals while reducing animal use and 
decreasing cost and time of testing, requires a plan for predictive toxicity testing and for 
organizing the data created in a manner useful for regulatory assessment. 
In a 2007 report entitled, Toxicity Testing in the 21st Century, the National Academies of 
Sciences described the future of toxicity testing to support human health risk assessment (NRC, 
2007). The report envisions “increased efficiency in toxicity testing and decreased animal usage 
by transitioning from current expensive and lengthy in vivo testing with qualitative endpoints to 
in vitro toxicity pathway assays on human cells or cell lines using robotic high-throughput 
screening with mechanistic quantitative parameters” (Krewski et al., 2010). Some limitations that 
the NRC committee concluded needed to be addressed were: 1) The need to focus resources on 
the evaluation of the most sensitive adverse effects of exposures of greatest concern, rather than 
fully characterizing all adverse effects regardless of risk assessment needs. 2) Setting priorities as 
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a component of any testing strategy designed to address a large number of chemicals. 3) Major 
gaps in current toxicity-testing approaches, and the promise of emerging screening technologies. 
4) Evaluation of testing strategies with respect to value of information in regards to depth, 
breadth, animal welfare, and conservation (Krewski et al., 2010).  
Programs in the USA and in Europe have focused on addressing some of these 
limitations. The Regulation, Evaluation, Authorization and Restriction of Chemicals (REACH) 
legislation in 2007 required information on chemical safety while limiting animal testing in favor 
of alternative testing methods (Commission, E.) The Tox-21 (Attene-Ramos et al., 2013) and 
SEURAT-1 (Berggren et al., 2015) initiatives favor the use of high throughput, in vitro testing 
methods for chemical safety evaluation over traditional in vivo animal toxicity studies (Collins et 
al., 2008). The EU COSMOS project addresses the safety assessment needs of the cosmetics 
industry without the use of animals. 
Joint efforts by the EPA’s National Center for Computational Toxicology (NCCT), 
National Toxicology Program (NTP), and National Center for Advancing Translational Sciences 
(NCATS) address increased needs for chemical screening based on alternative predictive 
methods that are target-specific, mechanism-based, biological observations in vitro (Collins et 
al., 2008).  In vitro methods examine chemical effects at molecular targets on the basis of 
toxicity pathways, “cellular response pathways that, when sufficiently perturbed in an intact 
animal, are expected to result in adverse health effects” (NRC, 2007). An example pathway 
perturbation is the response of cells to oxidative stress caused by exposure to diesel exhaust 
particles (DEP) within a cellular response network. In vitro exposures to DEP lead to dose-
related activation of a set of biological pathways. DEPs activate normal adaptive signaling 
pathways associated with maintaining homeostasis; however, when oxidant exposure is 
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sufficient to overwhelm these adaptive processes, these toxicity pathways then lead to adverse 
health effects (NRC, 2007). Thus, the NRC report describes testing these pathways through in 
vitro assays that measure “critical mechanistic end points involved in the induction of overt toxic 
effects rather than the effects themselves” (as cited in Ankley et al., 2010).  
In vitro assays, or experiments, can be adapted for high-throughput, the primary analysis 
method for drug discovery. Once an assay has been adapted to a fully automated system, 10,000 
chemicals per week can be screened (Attene-Ramos et al., 2013).  Assays test the effect of a 
perturbing agent in a biological system, measuring effects of the agent translating the 
perturbation into a detectable signal to arrive at endpoint(s) that quantify the extent of the 
perturbation (Abeyruwan et al., 2014). Typical drug discovery methods test compounds at one 
concentration between 2 and 10 uM, which can lead to high rates of false negatives. Newer 
methods test all compounds at as many as fifteen concentrations, from ~5 nm to ~100 uM, to 
generate a concentration-response curve.  This approach produces lower false positive and false 
negative results (Collins et al., 2008). HTS of a large set of chemicals can be used to prioritize 
chemicals for further testing, by comparing the profile of positive assay results for a test 
chemical with known toxicity “signatures” based on reference chemicals of known toxicity.  U.S. 
EPA’s ToxCast project has assessed nearly 2,000 chemicals in 700 assays covering a range of 
endpoints to prioritize chemicals for further testing (USEPA, 2013), with the eventual goal of 
screening thousands of environmental chemicals.   
Current toxicity databases vary in breadth and depth of information, with many structure-
searchable chemical databases existing and a lack of uniform guidelines regarding their content 
and outputs.  PubChem contains information on chemical structure and HTS assay endpoints for 
more than 10 million unique compounds, and represents a compilation of multiple data sources 
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(Judson et al., 2008).  EPA structure-searchable databases include DSSTox, ToxRefDB, and 
ACToR. ToxRefDB houses screening data from the ToxCast effort (Dix et al., 
2007). Aggregated Computational Toxicology Resource (ACToR) is a database and set of 
software applications from multiple sources including in vitro and in vivo assay results to support 
the ToxCast effort (Judson et al., 2008). ToxCast chemical data is publicly available through the 
interactive Chemical Safety for Sustainability Dashboards (iCSS) (USEPA, 2013).  Additional 
informatics tools such as DSS Tox (Distributed Structure Searchable Toxicity), located at 
www.epa.gov/ncct/dsstox/ provide a structure-searchable database of chemicals linked to 
physicochemical and toxicological data, facilitating linking HTS data to historical toxicological 
test results (Collins et al., 2008). Systems such as ToxNET store literature citations and summary 
toxicity information (Martin, 2008). 
Computational approaches to assessing priority environmental chemicals might be used 
to predict chemical properties, estimate biological activity and potency, and build quantitative 
structure activity relationship (QSAR) models that predict biological activity from molecular 
structure (Krewski et al., 2010). Physiologically based pharmacokinetic (PBPK) models allow 
dose extrapolation from in vitro conditions to projected in vivo exposure to provide a quantitative 
model for humans and animals (Krewski et al., 2010).  Dose response and extrapolation 
modelling integrate mechanistic and dosimetric information about toxicity into mathematical 
terms, resulting in a quantitative model allowing for dose and interspecies extrapolation 
(Conolly, 2002).  
Collins et al. describes several initiatives that are transforming toxicology (2008). 
Progress has been made in several areas including the examination of genetic diversity of human 
and animal responses to known toxicants, such as the International HapMap project 
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(http://www.hapmap.org/) to evaluate differential sensitivity of human cell lines. The Host 
Susceptibility Program tests for the genetic basis for differences in disease response in various 
mouse models. Cell lines from these models will be evaluated for differential sensitivity to 
HapMap compounds, with an ultimate goal of establishing in vitro signatures of in vivo rodent 
and human toxicity tests (2008).  Virtual tissue models such as the v-Liver project use 
computational models to simulate how chemicals may affect human development, reducing the 
use of animal models (Shah & Corton, 2010). 
The NRC report envisions that traditional in vivo tests will most likely continue to be 
used to evaluate the formation of metabolites and for some mechanistic aspects of target-organ 
responses to environmental agents (Krewski et al., 2010). In vitro tests will comprise the bulk of 
toxicity tests and may be conducted using human cell lines, animal cell lines transfected to 
express human genes and proteins, and metabolic screens with human enzymes (Krewski et al., 
2010).  In order to support HTS and other emerging alternatives to animal testing, a framework is 
needed to organize disparate information from these information sources. The adverse outcome 
pathway (AOP) framework provides a way to connect perturbations of biological processes at 
the molecular and cellular levels with apical endpoints useful in regulatory decision-making 
(Ankley et al., 2010). 
The Adverse Outcome Pathway Framework  
In the context of the alternative testing methods described and changes in the way that 
toxicity pathways are evaluated, Ankley, et al. proposed the Adverse Outcome Pathway (AOP) 
framework as a conceptual construct that portrays existing knowledge concerning the linkage 
between a direct molecular initiating event, the molecular interaction between a xenobiotic and a 
specific biomolecule, and an adverse outcome at a biological level of organization relevant to 
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risk assessment (2010). While toxicity pathways focus on molecular-level initating events and 
the resulting cellular responses that can be monitored in vitro, the AOP framework is intended to 
connect these events to an adverse outcome relevant to regulatory assessment (Ankley et al., 
2010). This can then provide the mechanistic context for defining the toxicity signatures used to 
identify chemical toxicities from HTS results and links those toxicity signatures to a defined 
regulatory endpoint. 
The AOP definition is also distinct from similar pathway-based concepts in the field of 
predictive toxicology, mechanism of action and mode of action. Mechanism of action is defined 
as “a complete and detailed understanding of each and every step in the sequence of events that 
leads to a toxic outcome” (ECETOC, 2007). Mode of action (MOA) describes a “biologically 
plausible series of key events leading to” an adverse effect (Meek et al., 2014).The AOP differs 
from these concepts in that it is chemical agnostic and is focused more on the interpretation of 
the in vitro and in silico toxicity predictions than assembly of mechanistic information for a 
specific chemical (OECD, 2013a). Villeneuve et al. outline a number of core principles 
underlying AOP development intended to address uncertainties and foster consistency (2014a, 
2014b). 
The AOP Development Programme was launched in 2012 and defines a workflow for 
developing, reviewing, and publishing an AOP. A project for development is proposed at OECD, 
reviewed by the Extended Advisory Group for Molecular Screening and Toxicogenomics 
(EAGMST), and, if approved, included in a workplan for development.  Upon development of 
draft AOP’s, the AOP’s then return to OECD for revisions and consultation.  The final document 
is submitted to the WNT (National Coordinators Test Guidelines) and the TFHA (Task Force 
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Hazard Assessment) for endorsement.  The final endorsed document is declassified and 
published as an OECD report (OECD, 2013a).  
A Users’ Handbook Supplement by the OECD EAGMST provides guidance for the 
systematic development and assessment of AOP’s (OECD, 2013b). The molecular initiating 
event explains how the chemical being assessed interacts with a biological target. Identifying the 
final adverse event, or “adverse outcome”, involves determining the most relevant mechanistic 
information and is often associated with in vivo toxicological test endpoints. Strategies for AOP 
development can either be top-down beginning with the AO, bottom up beginning with the MIE, 
or start with a middle entity in the AOP depending on the use case (Villeneuve et al., 2014a). 
Data from in vitro and test methods can be used here to identify key events and provide scientific 
evidence supporting the AOP. Scientific evidence could include: structural alerts for chemicals 
involved in the initiating event, in chemico methods measuring chemical-biological interactions, 
in vitro assays for cellular response, ex vivo and in vivo mechanistic tests and in vivo tests that 
measure endpoints directly relevant to the adverse outcome of interest (Figure 1).  AOP 
integrates events at different levels of biological organization: molecular, cellular, tissue, organ, 
organism, and population-level effect (OECD, 2013b). 
 
Figure 1. Framework of an AOP beginning at the MIE and ending at the AO, showing KE’s at levels of 
biological organization from Macromolecular to Population, connected by KER’s. HTS Assays, 
Bioindicators, and Adverse Outcomes represent attaching scientific evidence to KE’s. (Source: Stephen 
Edwards). 
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A molecular initiating event describes the perturbation resulting from interaction of a 
chemical or non-chemical stressor with a biological target (OECD, 2013a; Villeneuve et al., 
2014a). Many MIE’s are defined in terms of covalent binding to protein or DNA. In contrast to 
this electrochemical interaction, enzyme-receptor binding is usually a non-covalent interaction 
based on affinity for the target. Understanding of how the properties of the drug or chemical, 
such as bioavailability, structural requirements, and metabolic transformation affect affinity for 
the target helps define this interaction. Often, a list of known “chemical initiators” (OECD, 
2013a; Villeneuve et al., 2014a) will be supplied to provide evidence for the initiating event. For 
example, 17a- ethynyl estradiol is a prototypical ER agonist. Groups of chemicals with structural 
features known to trigger the MIE could be supplied as well. A single MIE can trigger multiple 
different AOPs. For example, binding of estrogen-like compounds to the estrogen receptor can 
result in several different AOs driven by multiple AOPs. Endogenous estrogen binding to the 
estrogen receptor also represents an intermediate key event in several AOPs that are initiated by 
perturbations in estrogen synthesis or regulation. A single molecular target may be active at 
different sites and therefore represent multiple separate MIEs. An example of this is covalent 
protein binding, which can result in skin sensitization or liver fibrosis depending on whether it 
occurs in keratinocytes or hepatocytes.  
The adverse outcome usually represents an outcome relevant to regulatory decision-
making, either an accepted protection goal or a common apical endpoint in an established study 
(OECD, 2013b; Villeneuve et al., 2014a).  The AO may include long term health endpoints, such 
as cancer, and short term, local effects such as skin sensitization. Associated with an AO are 
descriptions of its biological state, how it can be measured, and its taxonomic applicability 
(OECD, 2013b; Villeneuve et al., 2014a). 
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 A key event describes a change in biological state that is both measurable and essential 
to the progression of a defined biological perturbation leading to a specific adverse outcome 
(OECD, 2013b; Villeneuve et al., 2014a).  KE’s represent points along the pathway that can be 
used for monitoring the progression along the AOP.  KE’s are defined in terms of their biological 
context (tissue, taxa, or life stage), are specific, and are measurable (OECD, 2013b; Villeneuve 
et al., 2014b).  This may include citation of methods used in their detection and the level of 
confidence in those measurements.  
KE’s are connected to one another through key event relationships (KERs), a directed 
relationship between an upstream and a downstream KE (2013b; Villeneuve et al., 2014a). The 
definition facilitates extrapolation from the known state of the upstream event to the predicted 
state of the downstream event. Scientific evidence supporting the KER is described with respect 
to qualitative and quantitative supporting evidence.  The biological rationale or “biological 
plausibility” for a relationship between two KE’s may be referenced. Empirical support, specific 
evidence for the relationship, should be cited, as well as uncertainties or inconsistencies in the 
relationship. Finally, quantitative relationships between KE’s may be defined in terms of 
correlations, response-response relationships, or dose dependent relationships (OECD, 2013b; 
Villeneuve et al., 2014b).   
The utility of the AOP Framework in hazard assessment is that the AOP framework 
provides the biological context and supporting weight of evidence (WoE) to facilitate the 
interpretation of data from in vitro and alternative testing methods (Becker et al., 2015, OECD, 
2013b). The evaluation process for assessing confidence in supporting information as a basis for 
regulatory application of AOP’s includes explicit evaluation of the evidence supporting each key 
event relationship and defining the domain of applicability for the AOP in terms of sex, life-
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stage, taxa, and other aspects of biological context.  The relative level of confidence for each key 
event relationship in the AOP is assessed based on biological plausibility, empirical support, and 
quantitative understanding. Level of confidence can be high, moderate or low weight of evidence 
based on extent of available experimental data. The extent of support for biological plausibility 
based on a mechanistic (structural or functional) relationships between the upstream KE and 
downstream KE for each KER should be considered.  In addition, the extent of support for 
essentiality of each of the KEs is based on direct evidence from experimental studies.  A defining 
question is, “Are downstream KEs or the AO prevented if an upstream KE is blocked?” Extent 
of empirical support for each of the KERS and the overall AOP, as related to concordance of 
dose response relationships between upstream and downstream KEs. Finally, the degree of 
quantitative understanding for each KER in the overall AOP is assessed as weak, moderate, or 
strong (OECD, 2013b). 
An AOP represents a pragmatic unit of development and evaluation, and considering 
AOPs as a common network connected by shared KEs provides the basis for regulatory decision 
making (OECD, 2013b). The ultimate objective of AOP development is to support inference or 
extrapolation of information from one KE to another, allowing the creation of an AOP network 
based on multiple interacting AOPs sharing KEs or KERs.  Assessment of supporting 
information for the overall hypothesized AOP in the Network View represents the degree of 
confidence in weight of evidence for both essentialities of the KEs and biological plausibility and 
empirical support for KERs (OECD, 2013b). These AOP networks act as functional units of 
prediction representing the interaction in response to mixtures or toxicants with multiple 
biological responses (Villeneuve et al., 2014a). Such a network, based on confidence in 
qualitative and quantitative elements of the AOP, could be applied to development or refinement 
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of test guidelines, development of Integrated Approaches to Testing and Assessment (IATA), 
which integrate and weigh data from different test methods for hazard identification and 
assessment of chemicals and address data gaps (Tollefsen et al., 2014), development of 
Quantified Structure Activity Relationships (QSARs), and screening level hazard assessments or 
risk assessments (OECD, 2013a). 
The first AOP endorsed by the OECD was the AOP for Skin Sensitization Initiated by 
Covalent Binding to Proteins, which describes the regulatory hazards known as human allergic 
contact dermatitis or rodent contact hypersensitivity, a well-studied adverse outcome (2012). 
According to Landesmann, the MIE is covalent interaction of a target chemical or metabolite 
with cysteine or lysine residues (Landesmann, 2016). The second KE, taking place in the 
keratinocyte, includes inflammatory responses as well as gene expression associated with 
particular cell signaling pathways. The third KE is activation of dendritic cells, assessed by 
expression of specific cell surface markers, chemokines and cytokines. Dendritic cells 
subsequently mature and migrate out of the epidermis to the local lymph node where they 
display major histocompatibility complex molecules, which include part of the hapten-protein 
complex to naïve T-cells. This induces the fourth KE, T-cell proliferation, as measured in the 
current most applied in vivo test for skin sensitization, the murine Local Lymph Node Assay. 
The adverse outcome at the organ level is the acquisition of sensitization (Landesmann, 2016).    
This AOP resulted in OECD Test Guidelines based on non-animal methods for skin irritation. 
This AOP also forms the mechanistic basis for development of IATA for chemicals potentially 
causing skin sensitization (Landesmann, 2016). 
Due to the shift from in vivo toxicity testing to rapid in vitro methods, there is an 
increased need to efficiently identify and develop new AOP’s (Oki et al., 2016). A centralized 
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resource easily accessible to regulatory decision-makers is needed to provide structured 
information supporting AOP’s. To meet these needs, the AOP knowledgebase (AOP-KB) 
(https://aopkb.org/) provides the repository for AOPs developed under the OECD program (Oki 
et al, 2016). The AOP-KB represents a joint collaboration between the OECD, the US 
Environmental Protection Agency (USEPA), the European Commission’s Joint Research Centre 
(JRC), and the US Army Engineer Research & Development Center (ERDC). A resource for the 
scientific community to share, develop, and discuss AOP’s, the project consists of four 
independently developed platforms- AOP-Wiki, Effectopedia, AOPXplorer, and Intermediate 
Effects Database (AOP-KB, 2016). The AOP-Wiki supports collaborative development of AOP 
descriptions, in an encyclopedia-style text format, and captures the evidence supporting AOP’s 
(https://aopwiki.org). Stakeholders can build AOP’s by entering them with linked information 
regarding MIE’s, KE’s, AO’s, and Chemical Initiators. The Effectopedia provides detailed 
development of structured and computational AOP’s via a graphical interface, including the 
ability to store quantitative models (http://effectopedia.org/). The AOPXplorer provides for 
visualization of attribute networks to discover and explore AOPs in a broader context 
(http://aopxplorer.org/). The Intermediate Effects Database puts chemical-related AOP 
components in a regulatory context, connecting AOP’s to chemical-specific information 
(Edwards et al., 2016). AOP-KB additionally will support third party applications and plugins 
(AOP-KB, 2016).  
AOP-KB supports all stages of AOP development. Information needs vary for AOP’s in 
terms of data needs and confidence required, depending on the level of detail needed for a given 
AOP (Edwards et al., 2016). AOP-KB provides knowledge management for AOP’s, including 
identifying data in a computable standardized format, thus facilitating data integration and 
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information sharing, including evidence integration (Oki et al., 2016). Current challenges for the 
AOP-KB are the need to exchange information among modules, standardize naming of KE’s in 
support of AOP networks, develop computational methods to define AOP’s accelerating AOP 
development, build models from AOP’s, and provide the ability to attach evidence in support of 
the AOP, thus supporting data aggregation from HTS assays and experiments. 
Objectives 
The generation of vast amounts of toxicity data and the need to organize these data in a 
manner useful for risk assessors’ efforts at prioritizing decision making regarding particular 
chemicals, has resulted in data management projects for the structured organization of these data 
for improved machine-readability and contribution to the knowledgebase for AOP development; 
for example, the annotation of HTS assay data from EPA’s ToxCast (Phuong, 2014).  As such, 
the AOP framework provides a scaffold onto which this data can be organized. Current 
challenges for AOP development include the need to support data at different levels of 
granularity from the molecular level up to the organism and population levels. Tying AOP 
components to existing biological ontologies and controlled vocabularies, will contribute to the 
body of knowledge for AOP development. Providing the ability for machine-learning to these 
components will assist developers of tools and software for browsing and querying AOP 
information.  
The objective of this research is two-fold: 1) To provide data to support the AOP 
Framework at the higher levels of biological organization, by promoting a structured 
understanding of the supporting biological data and filling data gaps in the framework and 2) 
Using the resulting data model and approach to provide data from existing ontologies and 
controlled vocabularies for annotating a group of  AOP’s under development from EPA’s 
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National Center for Environmental Assessment (NCEA), forming the basis of an Integrated Risk 
Information System (IRIS) assessment. One of these AOP’s, a case example of an AOP for metal 
exposure culminating in adverse pregnancy outcomes, will demonstrate the formal AOP 
development process for a reproductive AOP that incorporates this standardized terminology.  
1) To provide data to support the AOP Framework at the higher levels of biological 
organization, by promoting a structured understanding of the supporting biological data 
and filling data gaps in the framework.  An ontology describes “a formal representation 
of a set of concepts within a knowledge domain and the relationships between those 
concepts” (Hardy, 2012b). Biological ontologies are developed in order to analyze 
domain knowledge and to provide consistent descriptions and machine-readability across 
the domain. AOP’s at the tissue, organ, individual, and population level will be examined 
using existing biological ontologies, including Gene Ontology (GO), Mammalian 
Phenotype Ontology (MPO), and Uberon; and non-ontologies including controlled 
vocabularies like Medical Subject Headings (MESH).  
Literature review of a formal sub-set of ontologies will be conducted in order to 
select the most fitting vocabularies by their characteristics at the molecular, cellular, 
tissue, organ, organism, and population levels and to fit the data needs of existing AOP’s. 
Once the ontologies are selected, literature review of priority existing AOP’s in the AOP-
Wiki (https://aopwiki.org/) will be conducted, and KE’s matched to their supporting 
ontological entity for seventeen priority AOPs.  For instance, a KE of reduced 
testosterone synthesis by steroidogenic tissue would be referenced to a specific ontology 
containing steroid hormone diseases related to testosterone.  A data model will be chosen 
to best represent this data, the output being a table mapping AOP entities to ontology 
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entities (classes).  Mapping KE terms from individual AOP’s to controlled vocabularies 
and ontologies will result in the formation of a network of interconnected AOP’s based 
on overlapping KE’s or nodes as individual AOPs are entered into the AOP-KB. A 
review of case studies or specific AOP’s will be conducted, to consider how ontological 
data in these AOP’s provide support for the key events in the AOP and to show how the 
resulting data model works in representing this information.  
2) Using the resulting data model and approach to provide terms from existing ontologies 
and controlled vocabularies for annotating a group of AOP’s under development from 
EPA’s National Center for Environmental Assessment (NCEA), forming the basis of an 
IRIS assessment. Using the data model formulated in the first part, entities from the 
selected ontologies and controlled vocabularies will be mapped to KE’s in hypothesized 
AOP’s for an IRIS assessment for inorganic Arsenic for NCEA. A case study of 
developing an AOP for environmental exposure will utilize the AOP-Wiki development 
tool to develop an AOP for metal exposure leading to adverse pregnancy outcomes as 
part of the IRIS assessment.  
Hypotheses 
1) Mapping AOP components to ontology classes provides a common syntax for AOP 
components, generating a data structure that promotes machine readability and use by 
software applications.  Additionally, mapping these components furthers development of 
computationally predicted AOP’s (cpAOP’s) and development of the AOPKB by 
addressing ontological data gaps at the higher levels of biological organization.  
2) The AOP framework describes mechanistic knowledge concerning the characterization of 
developmental effects resulting from metal exposure, furthering risk assessment for 
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metals with potential environmental health effects. Applying the resulting ontological 
framework from the first part of the project, will provide ontological data for the NCEA 
AOP’s to support integrated risk assessment. 
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CHAPTER 2: THE USE OF ONTOLOGIES IN PREDICTIVE TOXICOLOGY AND 
LITERATURE REVIEW OF SELECTED ONTOLOGIES 
 
The Use of Ontologies in Predictive Toxicology 
According to Hardy, predictive toxicology requires the development of a framework of 
open, public, computable, standardized ontologies and vocabularies to support applications 
required by in silico, in vitro, and in vivo toxicology methods (2012a). An ontology is a formal 
representation of a set of concepts within a knowledge domain, and the relationships between 
those concepts (2012b).  It represents a shared vocabulary in any domain, be it biomedical 
sciences, library science, or philosophy.  The vocabulary might include terms used for 
categorizing content, building labeling systems, or creating a database schema (2012b).  It is 
different from a controlled vocabulary, in that a controlled vocabulary provides a set of terms, 
while an ontology may include a controlled vocabulary and define the properties and 
relationships of those terms (2012b). In informatics, a database schema is an “ontology” for a 
database; in that it provides a description of the structure of the data. Using controlled 
vocabularies and ontologies in the domain of toxicology allows data to be organized and 
combined with metadata and vocabularies for study terms and experimental protocols (2012b).  
In this context, development of ontologies applicable for specific uses requires an 
understanding of computer organization and retrieval systems.  According to Robinson & Bauer, 
the elements required for computer reasoning include a formal knowledge representation 
language, a means for reasoning in the language, and a set of representations about a domain 
expressed in the language (2011). A formal language consists of a syntax, or rules for 
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constructing sentences; and semantics, or a specification for how the sentences relate to the 
domain (2011). One example application is Biological Expression Language (BEL), which 
represents scientific findings in a computable format by capturing causal and correlative 
relationships in the context of the system in which relationships were observed, the supporting 
publications cited, and the process of curation (Hourani, 2012).  BEL is intended as a knowledge 
capture and interchange medium, with a use-neutral language facilitating knowledge assembly 
by applications (Hourani, 2012).    
A second example is the use of web-based systems for the organization and retrieval of 
biological data (Baclawski & Niu, 2006). Development of the Semantic Web in 1999 enabled a 
framework in which computers are capable of acting as intelligent agents, analyzing the meaning 
or ‘semantic content’ of data on the web (Robinson & Bauer, 2011). A layer above the World 
Wide Web, which represents data as HTML pages referenced by hyperlinks, sites on the 
Semantic Web function as collections of semantically defined data which can be either read by 
other servers or used to generate Web pages for users (Robinson & Bauer, 2011). The Semantic 
Web provides reasoning and retrieval abilities, enabling automated processing, and annotates 
resources allowing the integration of different data sources (Baclawski & Niu, 2006). As an 
example, information available via the semantic web could be used for the prediction of protein 
function or for sequence similarity analysis (Baclawski & Niu, 2006). 
Ontologies available via the Semantic web can be used for the functional analysis of 
microarray data, network modeling, and semantic similarity analysis and clinical diagnostics 
(Robinson & Bauer, 2011). Hardy envisions a “toxicology ontology roadmap” for the 
development of an integrated toxicology ontology (2012a). In order to support alternative in vitro 
and computational methods to traditional animal testing, and make available the largest possible 
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knowledge base of previous toxicology findings, development of such an ontology will support 
data management, model building, integrated analysis, validation and reporting to support 
applications. The roadmap includes the promise of universal access to high quality experimental 
data, improved storage, exchange and use of information from experiments, integrated use of 
physical, biological, and chemical techniques and data, integration of interdisciplinary and 
translational concepts, standardized ontologies, computational research and prediction, and 
stepwise testing strategies and integrated testing schemes (2012a). The uses of ontology in 
predictive toxicology are in standardizing and organizing data for use cases (Hardy, 2012b).  
According to Hardy, “ontology and controlled vocabulary may be used to define biological 
effects and entities, systems and their components and interactions, algorithms and models, 
pathways, and other useful conceptual entities for supporting complex reasoning about concepts, 
questions, and data” (2012b). In the context of predictive toxicology, the applications of 
ontology include integration of in vivo and in vitro data from diverse sources, Quantitative 
Structure Activity Relationship (QSAR), and regulatory purposes such as REACH or 
classification and labeling (CLP) (Hardy, 2012b). Toxicology ontology should represent animal 
traditional experimental data as evidence, and may represent study terms and experimental 
protocols (Hardy, 2012b). 
Ontology makes information readily available for search and algorithmic processing. 
With the advent of the World Wide Web and increasing amounts of publicly available data 
generated by high-throughput methods, came the development of multiple biological ontologies; 
one of the first and best-known efforts is the Gene Ontology (GO), which contains “annotations” 
or links between data and structured vocabularies for human and model organism genomes 
(Robinson & Bauer, 2011). GO terms are manually curated and verified on the basis of published 
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experimental results (Robinson & Bauer, 2011).   
An example use of the Gene Ontology is for the functional annotation of gene expression 
microarray data. Expression microarray experiments can be annotated with GO terms, and 
clustered expression patterns for GO terms can be viewed for correlation of biological process, 
molecular function, and cellular component to a particular gene or gene product (Ashburner et 
al., 2000). GO also can be used to examine sequence and functional conservation for orthologous 
genes through the transfer of annotations from experimentally tractable model organisms to less 
tractable organisms based on gene and protein sequence similarity (Ashburner et al., 2000). 
The success of GO was based in large part on its adherence to a set of key principles. In 
an effort to answer the question of how to best represent biomedical data and information in a 
format commonly accessible to biologists, in 2001 Michael Ashburner and Suzanna Lewis 
developed the OBO Foundry, a central repository of life-science ontologies (Smith et al., 2007). 
OBO ontologies must be open, developed in a collaborative effort, use unambiguously defined 
common relations, and provide clear delineation of scope and mutual reuse (Smith et al., 2007). 
As of 2011, the library consisted of 99 ontologies covering the domains of biological process and 
molecular function, chemical entities, experimental investigations, anatomy, and disease (Hardy, 
2012b).  
Another use of ontology in predictive toxicology is the annotation of experimental data, 
such as use of ontologies and controlled vocabularies for the annotation of assay data from 
EPA’s ToxCast effort (Phuong, 2014). Launched in 2007, ToxCast uses automated chemical 
screening technologies, or high throughput-screening assays, to screen cells for biological 
activity with potential toxic health effects (USEPA, 2013).  Previous efforts have used the 
BioAssay Ontology (BAO) to annotate ToxCast assay endpoints for assays stored in PubChem, 
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enabling analysis of trends among annotated assays and observation of variances among 
screening data (Schurer et al., 2011; Vempati et al., 2014).  
Use of ontology for information access, organization, and retrieval requires the use of 
logic and semantics, enabling automated reasoning. Ontology construction involves selection of 
the entities or objects to be included, definition of a controlled vocabulary, and recognition of 
relationships, interactions, and hierarchies (Bard, 2005). Ontology solves some of the difficulties 
in representing knowledge hierarchies using relational databases; by enabling recursive searching 
or searches within the data itself, and by representing information as a set of structured links with 
rules that apply up or down the hierarchy.  Ontologies connect terms, usually represented as 
nodes, with a relationship or edge in an assertion.  For example, an IS-A relationship would be 
represented as ‘the cardiovascular system IS A MEMBER OF THE CLASS OF organ systems’. 
Relationships can be directed (one-way), or undirected (reciprocal).  The set of relationships 
represented graphically is a hierarchical tree or graph. Directed relationships are often used to 
generate directed acyclic graphs (DAGs), in which nodes have more than one ‘parent’ node. 
These relationships allow inferences to be made either by a user or computationally (Bard, 
2005).  
Construction of a bioinformatics ontology involves design dependent on envisioning its 
purpose; identifying what it will be used for, its scope, its user community, the length of time it 
will be used and what domain it will cover (Baclawski & Niu, 2006). Construction begins with 
choice of relationships to be used, assembly of terms, and then building the ontology using a 
computer program with a compiler, beginning with the root term and adding subordinate terms 
with connecting relationships (Bard, 2005). Subsequently, a language that will work with the 
chosen compiler program should be chosen. The major ontology languages used today can be 
  
 
22 
classified as basic XML, XML topic maps, and Semantic Web languages including RDF and 
OWL depending on the intended use. While some languages are preferable for expressing 
information as logical statements, others present data in an organized structure either in the form 
of frames or graphs (Baclawski & Niu, 2006). XML is the most basic and widely supported 
language, while OWL supports the Semantic Web and offers the most flexibility but is the least 
supported by applications (Robinson & Bauer, 2011). Resource Description Framework (RDF) is 
the data model on which OWL and the Semantic Web are based (Robinson & Bauer, 2011). RDF 
describes resources in triples, providing a common framework for integration of web data 
(Robinson & Bauer, 2011). Uniform Resource Identifiers (URIs) link information about RDF 
resources to other resources, enabling web representation (Baclawski & Niu, 2006). RDF data 
can be represented in a graph-based mode, enabling data integration (Robinson & Bauer, 2011). 
Protein databases, such as UniProtKB, commonly use RDF/XML in which RDF data is 
represented in an XML file format (Robinson & Bauer, 2011). Web Ontology Language (OWL), 
extends the use of RDFs with more powerful capabilities for constructs and inference rules 
(Robinson & Bauer, 2011). While most OBO Foundry member ontologies are developed for the 
biomedical domain, the OWL (Web Ontology Language), was developed as a way to define 
structured ontologies for web-based interoperability in any domain (Robinson & Bauer, 2011). 
Conversion between one language and another represents a challenge requiring special computer 
programs for transformation (Baclawski & Niu, 2006). 
According to Robinson and Bauer, the predominant language among bio-ontologies is the 
OBO format, developed by the Gene Ontology Consortium and used by the OBO Foundry as a 
standard language among ontologies (2011). OBO format ontologies are compact, easy to read 
and easy to parse (2011). The OBO format begins with headers containing general information, 
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then a list of stanzas; each begins with a keyword and contains key value lines containing 
specific information such as the GO id, name, and definitions; one file can contain 30,000 
stanzas: 
[Term] 
id: GO:0000031 
name: mannosylphosphate transferase activity 
namespace: molecular_function 
def: “Catalysis of the transfer of a mannosylphosphate group from one compound to another.” 
[GOC:jl] 
is_a: GO:0016740 ! transferase activity 
 
Each tag-labeled pair contains a name, a colon, and a value.  For the above example, the 
name id contains the value “GO:000031”; id is the unique identifier of the entity of a nucleotide 
sequence accessible through GenBank. Terms may also contain relations such as is_a; in the 
above example GO:0000031 is_a subclass of GO:0016740 ! transferase activity (2011).  
Several free and open-source programs are available for building and editing ontologies, 
the most common of which is the program Protégé developed by Stanford University (Robinson 
& Bauer, 2011). Choice of an editor involves choosing which language the program supports. 
Other notable tools such as the EMBL-EBI Open Lookup Service (OLS) provide a web interface 
for browsing, searching, and accessing OBO file content (Mayer et al., 2014).  Additionally 
publicly available browsers that aggregate terms from multiple ontologies and make their 
information available on the Web include Ontobee (http://www.ontobee.org/) and NCBO 
Bioportal (http://bioportal.bioontology.org/), while specific ontologies may have their own 
search tools, such as GO’s AMIGO2 (Ashburner et al., 2000). 
Review of Selected Ontologies 
OBO Foundry Ontologies 
Several of the most common OBO Foundry member ontologies were chosen for review 
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for their domain, content, and level of biological resolution (OBO Foundry, 2016a). Emphasis 
was placed on OBO Foundry ontologies for their uniformity and consistency of use. Several non-
Foundry ontologies and controlled vocabularies were also reviewed.  
OBO Foundry candidate ontologies are built on a common top-level ontology, the Basic 
Formal Ontology (BFO) and use a common set of relations defined in the Relation Ontology 
(RO) (Zheng et al., 2013). The BFO doesn’t contain domain terms from the sciences, but 
provides concepts to support domain ontologies for information retrieval, analysis, and 
integration for scientific research (IFOMIS, 2015). BFO provides a hierarchy of upper-level 
abstract classes, from which classes in domain-specific ontologies can inherit, linking together 
independently developed ontologies within the OBO Foundry (Mungall et al., 2011). The BFO 
divides entities into objects and processes, called “continuants” and “occurrents” respectively 
(Robinson & Bauer, 2011). Continuants represent entities that continue to exist over time and 
preserve their identity despite change; for example, an organism or cell; while occurrents 
happen, unfold or develop through time, for example, the process of meiosis (Robinson & Bauer, 
2011).  
The Relation Ontology (RO) provides a set of relations for standardization across OBO 
Foundry ontologies and ontologies in the wider OBO library (OBO Foundry, 2016e).  Several 
other upper-level or application ontologies are the Experimental Factor Ontology (EFO), Brenda 
Tissue Ontology (BTO) and Eagle-I Resource Ontology (ERO) concerned respectively with the 
domains of experiments, anatomy, and research resources (OBO Foundry, 2016a). The BTO 
(http://www.BTO.brenda-enzymes.org) provides a standardized representation of all tissue terms 
from taxonomic groups covering animals, plants, fungi and prokaryotes connecting to the 
BRENDA enzyme database (Gremse et al., 2010). The BTO contains more than 4600 different 
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anatomical structures, tissues, cell types and cell lines classified according to the format of the 
Gene Ontology Consortium and organized as a directed acyclic graph (DAG) (Gremse et al., 
2010). The EFO provides a systematic description of experimental variables in the European 
Bioinformatics Institute (EBI) databases; facilitating consistent annotations and pulling together 
classes from multiple reference ontologies including disease, cell line, cell type and anatomy 
(NCBO Bioportal, 2016b). 
Gene Ontology 
The purpose of the Gene Ontology (GO) project is to produce a dynamic, controlled 
vocabulary that can be applied to all eukaryotes in a species-independent manner (Ashburner et 
al., 2000). GO consists of ontologies or defined terms and structural relationships, and 
annotations or associations between gene products and terms (2000). GO genes and gene 
products are assigned to three independent ontologies: molecular function, biological process, 
and cellular component or location (Ashburner et al., 2000). Within the three ontologies, GO 
terms are related by formally defined is_a and part_of relationships (Baclawski & Niu, 2006). 
According to Ashburner et al., the complete sequencing of several model organism 
systems including the budding yeast, nematode, and fruit fly, have accelerated the availability of 
genomic information (2000).  Although molecular sequences are more readily available for more 
species, the way in which biologists conceptualize shared biological elements hasn’t kept pace 
with sequencing.   Current systems of nomenclature for genes and their products remain 
divergent, even when there are underlying similarities. Functional conservation of genes and 
gene products requires a common language for comparison between species. A comparison 
between the complete genomes of the budding yeast and worm revealed a large fraction of genes 
displaying orthology; with approximately 12% (~18,000) of worm genes encoding proteins 
  
 
26 
whose biological roles could be inferred from their similarity to orthologs in yeast, comprising 
approximately 27% (~5,700) of yeast genes. 
Annotations, or descriptions supported by evidence, associate a specific gene with a term 
in the ontology, and are either manually curated or generated through predictive methods 
(Robinson & Bauer, 2011). A ‘GO annotation’ describes the association between an ontological 
class and a gene product, including references to evidence in literature supporting the association 
(Ashburner et al., 2000).  Evidence-supported annotations may describe the biological roles of 
individual genomic products such as genes, proteins, RNA, and complexes) by tying them to 
ontologies (Ashburner et al., 2000).  Annotations are useful for functional prediction based on 
patterns of annotation, in that if annotations for two attributes occur together in a database, a 
gene holding one attribute is likely to hold the other attribute too (King et al. 2003). 
According to Ashburner et al., GO provides information on genes for over 460,000 
eukaryotic species (2000). The information in Gene Ontology derives from three model 
organism databases: FlyBase, MouseGenome Informatics (MGI), and the Saccharomyces 
Genome Database (SGD).  Each term or ‘node’ in GO is linked to other information, such as 
gene and protein databases.  The utility of GO is the ability to organize, describe, query, and 
visualize biological knowledge despite changes and updates. 
According to Ashburner et al., the biological process ontology describes “the biological 
objective to which a gene or gene product contributes” (2000).  A biological process consists of 
an ordered assembly of molecular functions, often involving a chemical or physical 
transformation, for example, ‘cell growth and maintenance’ or ‘translation’.  Molecular function 
ontology describes the biochemical activity of a gene product, including specific binding to 
ligands or structures; example functional terms include ‘enzyme’ or ‘adenylate cyclase’.  
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Cellular component ontology describes the location in the cell where a gene product is active; 
such as ‘ribosome’ or ‘proteasome.’  Biological process, molecular function, and cellular 
component comprise attributes of genes and gene products, reflecting a one-to-many relationship 
such that one gene or protein may play a role in multiple pathways, processes, or interact with 
multiple cell components and locations (Ashburner et al., 2000).   
An example of a GO annotation is the term ‘DNA metabolism’.  Metabolism is a 
biological process carried out by mostly shared elements in eukaryotes (Ashburner et al., 2000).  
The biological process ontology pertaining to DNA metabolism contains nodes or terms that can 
have multiple parents, for instance, the term ‘DNA ligation’ has parent terms of ‘DNA-
dependent DNA replication’, ‘DNA repair’ and ‘DNA recombination’ (Ashburner et al., 2000).   
According to the Gene Ontology Consortium, GO ontologies and annotations are publicly 
available through http://www.geneontology.org (2014).  Through AMIGO2, an open-source set 
of tools for querying and browsing GO data, users can perform GO enrichment analysis, search 
for GO terms, annotations, and metadata across species.  The site also includes documentation 
for generating ontology terms and use of logical definitions.  GO is available for download in the 
OBO flat file format, RDF-XML format, and GO annotation file formats (Gene Ontology 
Consortium, 2015a). Additionally, many programs have been developed for profiling gene 
function based on the GO, such as the DAG-Edit, GenMAPP, GoMiner, and DAVID tools 
(Baclawski & Niu, 2006). 
Chemical Entities of Biological Interest (ChEBI) 
According to Hastings et al., ChEBI (Chemical Entities of Biological Interest) accessible 
at http://www.ebi.ac.uk/chebi is a database and ontology of low molecular weight chemical 
entities of biological interest (2013). Molecules encoded by the genome; nucleic acids, proteins 
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and peptides derived from protein, are not included. Annotations emphasize immunology, natural 
products and metabolites in many species.  High quality chemical reference data are needed for 
computer modeling in fields of predictive toxicology, metabolic modeling and the search for 
disease biomarkers, and ontologies such as ChEBI make the semantics of such information 
available and computable.  
According to EMBL-EBI, ChEBI specifies relationships between molecular entities or 
classes of entities, and their parents or children (2016). ChEBI uses terminology from the 
International Union of Pure and Applied Chemistry (IUPAC) and nomenclature from the 
International Union of Biochemistry and Molecular Biology. Data are drawn from four sources: 
The Integrated relational Enzyme database of the EBI (IntEnz), Kyoto Encyclopedia of Genes 
and Genomes (KEGG) Compound, PDBeChem database, and ChEMBL database. A ChEBI 
page contains the following data fields: ChEBI Identifier, ChEBI Name, ChEBI ASCII Name, 
star rating, structure, formula, charge, average mass, ChEBI Ontology, IUPAC name, 
International Nonproprietary Name (INN), synonyms, brand name, database links, registry 
number such as CAS, citations, and cross-references to biological and chemical databases.  
Database entries are manually annotated, with links to external databases such as Rhea 
and Reactome which use ChEBI identifiers to refer to chemicals in biological context.  Where 
possible, a molecular graph is provided accompanied by chemical structural graphs in InChI, 
InChIKey, and SMILES (Robinson & Bauer, 2011). ChEBI is also cross-referenced to PubChem 
(Hastings et al., 2013).  The database is aligned with other chemical involving processes in 
ontologies, such as the Open Biomedical Ontologies (OBO) Foundry and Gene Ontology 
(Hastings et al., 2013). Of special interest is annotation of compounds deemed ‘natural products’, 
or secondary metabolites, relevant in drug discovery and metabolism research (Hastings et al., 
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2013). Data have been drawn from primary literature sources; publications identifying a 
particular metabolite in a given species (Hastings et al., 2013). 
Using the ChEBI website, data is open and freely available for download (Robinson 
&Bauer, 2011). Users may search by substructure or similarity of compounds (Hastings et al., 
2013).  The ChEBI ontology may be displayed in ‘tree view’ in an interactive graph-based 
visualization beginning with the chemical entity up to the root of the ontology (Hastings et al., 
2013).  Roles and structural relationships are displayed separately from the graph-based browser 
(Hastings et al., 2013). The graph visualization is based on the JavaScript InfoVis toolkit 
(http://thejit.org/) and mapped to other ontologies available as an OWL file (Hastings et al., 
2013).  
An example of a natural product in ChEBI would be caffeine (Robinson & Bauer, 2011): 
 
[Term] 
id: CHEBI: 27732 
name: caffeine 
synonym: “C8H10N4O2” RELATED FORMULA [KEGG COMPOUND:] 
synonym: “Cn1cnc2nc(C)c(=O)n(C)c(=O)c12” RELATED SMILES [ChEBI:] 
is_a: CHEBI:27134 ! trimethylxanthine 
relationship: has_role CHEBI:25435 ! mutagen 
relationship: has_role CHEBI:35337 ! central nervous system stimulant 
relationship: has_role CHEBI:38809 ! ryanodine receptor modulator 
 
Caffeine is one of the superclass, trimethylxanthine. Synonyms describe the molecular formula 
and SMILES representation of caffeine. 
Ontology for Biomedical Investigations (OBI) 
According to Brinkman et al., Ontology for Biomedical Investigations (OBI), available at 
(http://purl.obolibrary.org/obo/obi/2009-11-02/obi.owl) addresses the need for a standardized 
terminology for descriptions of biological and clinical investigations (2010). It is developed 
collaboratively by representatives of 19 global biomedical communities and is an OBO- Foundry 
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member ontology. Biomedical experimental descriptions are usually stored as free text without a 
standardized terminology, creating challenges in comparison, reproduction, and analysis. 
Application of OBI to biomedical investigations facilitates interpretation of the experimental 
process, as well as increasing computational processing and integration with the Semantic Web. 
OBI represents all phases of experimental processes and the entities involved in preparing for, 
executing, and interpreting those processes. OBI terms span biomedical and technological 
domains, representing all phases of experimental processes, and the entities involved in those 
processes, such as study designs, protocols, instrumentation, and analyses regardless of the field 
of study. It also represents roles and functions used in biomedical investigations. 
OBI is written in OWL and an example OBI class describes culturing cells that do not 
express the CD8 cell surface receptor using the ‘owl:complementOf:’  keyword to restrict the 
properties of the class representing cells that are the complement of cells that express the CD8 
receptor (Robinson & Bauer, 2011): 
 
<owl:intersectionOf rdf:parseType=”Collection”> 
  <owl:Class rdf:about=”CL:cell”/> 
  <owl:Class> 
    <owl:complementOf> 
      <owl:Restriction> 
        <owl:someValuesFrom> 
         <owl:Class rdf:about=”#CD8 receptor”/> 
        </owl:someValuesFrom> 
        <owl:onProperty> 
          <owl:TransitiveProperty rdf:about=”#has_part”/> 
        </owl:onProperty> 
      </owl:Restriction> 
    </owl:complementOf> 
  </owl:Class> 
</owl:intersectionOf> 
 
 
  Brinkman et al. describes a vaccine protection investigation use case, demonstrating how 
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entities and relations involved in experimental processes can be modeled in a biomedical domain 
using OBI (2010). A vaccine protection investigation describes an experiment that examines how 
efficiently a vaccine induces protection against a virulent pathogen. Upper-level classes in OBI 
describe experimental processes, material entities, roles, and inputs and outputs regarding the 
investigation. For example, the class ‘administering substance in vivo’ describes experimental 
processes. Subtypes of this parent class include ‘vaccination’ and ‘pathogen challenge’, 
describing the type of experiment being conducted.  The definitions of classes in this use case 
help validate OBI’s design and granularity extending from the molecular to higher level 
biomedical investigations.  
Protein Ontology (PRO) 
Increasingly, journals require that the data underlying a proteomics study should be made 
public through journal websites or publicly available repositories for MS (mass spectrometry)-
based proteomics data (Mayer et al., 2014). The use of a standardized format in proteomics eases 
the comparison of data from different sources and reproducibility of results (Mayer et al., 2014). 
Ontologies in proteomics support flexible definition of semantics of the represented data, making 
the data computer-readable and accessible for analysis and data mining using software tools 
(Mayer et al., 2014). The most important ontologies in the proteomics domain are used by the 
XML-based proteomics standards defined by the HUPO PSI working groups (Mayer et al., 
2014). The Protein Ontology (PRO; http://proconsortium.org), formally defines protein entities, 
complexes, and interrelations (Natale et al., 2014). Protein entities corresponding to single amino 
acid chains are categorized into family, gene, sequence and modification metaclasses (Natale et 
al., 2014). Entities may be defined as either organism-agnostic or organism-specific metaclasses 
(Natale et al., 2014). Members of orthologous genes are recognized on the basis of similarity in 
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protein sequences, allowing the grouping of genes that are evolutionarily conserved (Robinson & 
Bauer, 2011). According to Natale et al., some of the uses of PRO include “to define dendritic 
and hematopoietic cell types, describing biological processes, flagging protein entities mentioned 
in literature, and capturing information isolated from literature in text mining workflows” (2013). 
PRO is an OBO Foundry ontology, using the standardized definitions and relationships 
from BFO and RO, and it is interoperable with other resources such as UniProtKB and GO. As 
of 2013, PRO mappings covered 12 GO reference organisms (Natale et al., 2014). PRO is 
available for download in the OBO file format (Natale et al., 2014). 
Sequence Ontology (SO) 
Sequence Ontology, located at https://github.com/The-Sequence-Ontology/SO-
Ontologies defines sequence features used in biological sequence annotation. Annotating a 
genome provides information about the genomic sequence and the sequence of molecules 
derived from the genome to coordinates on biological sequence (Mungall et al., 2011). The 
Sequence Ontology provides “a structured controlled vocabulary for sequence annotation, for the 
exchange of annotation data and the description of sequence objects in databases” (The OBO 
Foundry, 2016). 
SO describes the features of biological sequence for both genomic and derived sequences 
(Mungall et al., 2011). Genome annotation locates genomic sequence information to a linear 
representation of a chromosome, using coordinates to capture the sequence of information 
(Mungall et al., 2011). Examples of SO classes include biological features, such as ‘binding_site’ 
and ‘exon’ (Sequence Ontology, 2009). Biomaterial features are intended for experimental use, 
such as ‘aptamer’ and ‘PCR_product’ (Sequence Ontology, 2009). Experimental features 
describe the results of an experiment (Sequence Ontology, 2009).  
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SO describes how sequences change over the course of genomic and post-genomic 
processes (Mungall et al., 2011). SO increases the interoperability of model organism databases, 
providing a standardized set of terms and relationships with which to describe genomic 
annotations and enable automated reasoning (Robinson & Bauer, 2011). One use of the SO to the 
biological community is in providing a structured vocabulary for describing nucleic acid 
sequence; for example, the BioDAS server for sharing biological data the description of primary 
annotations of nucleic acid sequence; for example, the annotations shared by a DAS server 
(Sequence Ontology, 2009). 
The SO is an OBO Foundry ontology and its classes have been aligned with the BFO to 
allow for computable definitions and interoperability with other Foundry ontologies (Robinson 
& Bauer, 2011). Contributors to SO include the GMOD community, model organism databases 
such as WormBase, FlyBase, and Mouse Genome Informatics, and institutes such as the Sanger 
Institute and EBI (NCBO, 2016c).  It currently contains 2301 classes.  SO is available in the 
OWL format (NCBO, 2016c).  
Cell Ontology (CL) 
The cell ontology, located at http://cellontology.org, was developed as a controlled, 
structured vocabulary for cell type that is non-organism specific, covering cell types from the 
prokaryotic, fungal, and animal kingdoms (Robinson & Bauer, 2011). Model organisms included 
in CL are: human, mouse, Drosophila, Caenorhabditis, zebrafish, Dictyostelium discoideum, 
Arabidopsis, fungi, and prokaryotes (Robinson & Bauer, 2011). CL is linked to anatomical 
structures in Uberon, biological processes in GO, and other entities in ChEBI, PR, and PATO; in 
turn multiple ontologies provide logical definitions for CL terms (The OBO Foundry, 2016a). 
Uses of the CL include providing a common reference framework for annotating experimental 
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metadata from functional genomics studies such as the ENCODE project (The OBO Foundry, 
2016a) and gene expression databases such as Array Express (Robinson & Bauer, 2011).  CL is 
also used in Library of Integrated Network-based Cellular Signatures (LINCS), a project to 
generate multidimensional data sets including biochemical, genome-wide transcriptional, and 
phenotypic cellular response signatures to a variety of small molecule and genetic perturbations 
to create a widely applicable systems biology resource (Schurer, 2011).  
CL is an OBO Foundry member ontology with files provided in OWL and OBO formats 
(The OBO Foundry, 2016a). An example class in CL would be the relationship of ‘B cell’ with 
its subsuming parent term ‘lymphocyte of B lineage’ through is_a relationships; while a ‘pro-B 
cell’ is related to the parent class ‘B cell’ through a develops_from relationship (Robinson & 
Bauer, 2011, p.161). 
Foundational Model of Anatomy (FMA) 
Foundational Model of Anatomy is located at 
http://sig.biostr.washington.edu/projects/fm/. According to the Structural Informatics Group at 
the University of Washington, FMA provides a reference ontology representative of the “types 
and relationships necessary for the symbolic representation of the phenotypic structure of the 
human body in a form that is understandable to humans and is also navigable, parseable, and 
interpretable by machine-based systems” (2007).  The lack of a generalizable, computable 
representation of anatomy led to ontology developers creating divergent controlled vocabularies 
and ontologies from their own viewpoints (Rosse & Mejino, 2007). FMA differs from other 
anatomical domain ontologies and vocabularies in that it provides anatomical information 
designed to serve the needs of any user group, and to be reused by any application (Rosse & 
Mejino, 2007). Additionally, FMA encodes anatomical knowledge in a way that supports 
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computational analysis and the development of anatomy applications targeting specific user 
groups. These user groups may include knowledge modelers and developers of applications for 
education, clinical medicine, electronic health records, biomedical research, and health care 
delivery and management (Rosse & Mejino, 2007). 
One of the largest computer-based knowledge sources in the biomedical sciences, FMA 
comprises 75,000 classes and over 120,000 terms, as well as over 2.1 million relationship 
instances from 168 relationship types (University of Washington Structural Informatics Group, 
2007). The anatomy taxonomy (At) comprises the dominant class, containing types of biological 
macromolecules, cells and their parts, tissue portions, organs and organ parts, organ systems, and 
body regions (University of Washington Structural Informatics Group, 2007). Other components 
include the Anatomical Structural Abstraction (ASA), the Anatomical Transformation 
Abstraction (ATA), and the Metaknowledge (Mk) components (University of Washington 
Structural Informatics Group, 2007). Anatomical structures are defined in terms of a genus or 
‘material anatomical entity’ and subsequent assertions are differentiae (University of Washington 
Structural Informatics Group, 2007).  An example annotation in FMA is the definition of the 
organ, “Heart” as “Organ with cavitated organ parts, which is continuous with the systemic and 
pulmonary arterial and venous trees” (Robinson & Bauer, 2011). 
FMA is an OBO Foundry member ontology. It is a frame-based ontology, where each 
frame stores all the information about a named type viewable with the Protégé ontology editor 
(Robinson & Bauer, 2011). It has also downloadable files available in the OWL and OBO 
formats (Robinson & Bauer, 2011).  
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Uberon 
Located at http://uberon.org, the Uber Anatomy Ontology (Uberon) facilitates the 
unification of multiple anatomy ontologies into a multi-species ontology for anatomics (Haendel 
et al., 2014).Anatomics describes the analysis, computer formulation and use of the anatome, or 
the complete set of tissues and organs in a model organism.  There are about 15 anatomical 
ontologies currently available for a range of model organisms, including the mouse, Drosophila, 
C. elegans, and zebrafish (Bard, 2005). Databases for human adult and developmental anatomies 
are available but there is as yet no central resource for human data (Bard, 2005). Phenomics, or 
phenotype-based analyses, play an important role in understanding gene function and the genetic 
and epigenetic contributions to developmental, behavioral, evolutionary and morphological 
variation (Haendel et al., 2014). Model organism databases (MODs) aggregate genetics and 
genomics information from specific model organisms (Haendel et al., 2014).  Single-species 
model organism anatomy ontologies have been developed to annotate and query these gene 
expression and phenotype data for specific organisms and multi-species anatomy ontologies have 
been developed for multiple taxons (Haendel et al., 2014). Such single-species ontologies 
include the adult mouse anatomy ontology (MA), adult human ontology (FMA), zebrafish 
ontology (ZFA) and Xenopus anatomy ontology (XAO) (Haendel et al., 2014). However, each of 
these model organism anatomies is categorized into an individual ontology with no connection 
between ontologies, making querying and searching challenging (Mungall et al., 2012). Uber 
Anatomy Ontology (Uberon) is a metazoan, multi-species anatomy ontology that aims to 
integrate multiple taxon specific vertebrate ontologies (Haendel et al., 2014). 
According to Bard, anatomics is challenging to format in a computer-comprehensible 
manner because of the complexity of relationships between tissues in an organism (2005). 
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Precision concerning the actual number of tissues and organs in an organism presents a 
challenge. Specifying anatomical relationships such as part of, develops from, and is-a requires 
being explicit as to the knowledge that relationships contain, and preventing errors of inference. 
As of 2014, Uberon contained 12241 classes representing high level categories from the 
Common Anatomy Reference Ontology (CARO) (Haendel et al., 2014). Classes include 
anatomical systems such as ‘nervous system’, organs such as ‘heart’, tissues such as ‘adipose 
tissue’ and appendages such as ‘pelvic girdle’ (Mungall et al., 2012).  Ontology entities are 
referred to by classes and relations, referred to as axioms (Mungall et al., 2012). Relationships 
were implemented by applying a common set of design and modeling patterns in Uberon for how 
anatomy parts relate, such as the representation of the ‘quadrate-articular joint’ as connected_to 
the ‘quadrate’ and ‘articular’ classes (Haendel et al., 2014). 
Uberon files are available in Open Biomedical Ontologies (OBO) format and OWL.  
Annotations from source ontologies were manually curated (Haendel et al., 2014). An example 
would be the Uberon class ‘lung’ and its relation to ontologies outside of Uberon. ‘Lung’ is 
present in Uberon as a superclass including lung classes from mouse and human anatomy 
ontologies (Mungall et al., 2012). The Uberon term ‘alveolus of lung’ is_a ‘alveolus’ part_of  
‘lung’ (Mungall et al., 2012).  
Mammalian Phenotype (MP) 
The Mammalian Phenotype (MP) ontology, located at 
http://www.informatics.jax.org/searches/MP_form.shtml is used in the annotation of phenotype 
data from high-throughput screens (Smith & Eppig, 2015). Information from these screens can 
be applied to human disease by relating data from mouse phenotype to human phenotype 
(Robinson & Bauer, 2011). The International Mouse Phenotyping Consortium (IMPC) is using 
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MP in the annotation of data from large scale high-throughput mouse knockout phenotyping 
projects (Smith & Eppig, 2015).   Many screens look for deviants in specific phenotype areas and 
map these phenodeviants to molecular mutations (Smith & Eppig, 2015). The phenotype data 
can be used to infer information about gene function, expression and biological pathways (Smith 
& Eppig, 2015).  
According to Smith & Eppig, MP is manually curated with data from large-scale 
phenotype datasets and from published literature (2015).  MP files are in OWL format and 
converted OBO format and edited using Protégé-4.3 software.  
MP has been expanded to be used as the common data standard for annotation of large 
scale mouse phenotype data sets and data import to MGI without curation (Smith & Eppig, 
2015). MP terms are assigned to IMPC parameters by anatomical system, ‘Cardiovascular 
system’ and ontology terms captured in IMPReSS, a database and web portal used to track 
phenotyping procedures used by IMPC. For example, test results for Heart Weight 
[IMPC_HWT_001] are captured by MP terms ‘abnormal heart weight’ [MP:0004857], 
‘increased heart weight’ [MP:0002833] and ‘decreased heart weight’ [MP:0002834]. 
Relationships such as is-a or part-of are denoted; for example, ‘abnormal cardiovascular system 
morphology’ is-a ‘cardiovascular system phenotype’ (Mouse Genome Database, 2016). IMPC 
provides a RESTful, or web-browser accessible, interface to mouse alleles, experimental results 
and genotype-phenotype associations (Smith and Eppig, 2015). According to Smith & Eppig, 
“MGI will remain the source of global mouse phenotype data integration from large and small 
scale data sets, contributions and literature” (2015). Since most human diseases are caused by 
other functional mutations, information imported from MGI contains information on other type 
of mutations than those caused by knockouts (Smith and Eppig, 2015). MGI data also contain 
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data on knockout alleles exhibiting a prenatal or perinatal lethal phenotype; processes driving 
prenatal growth and differentiation that may help identify origins of developmental disease and 
congenital defects (Smith and Eppig, 2015). 
Human Phenotype Ontology 
Human Phenotype Ontology (HPO) is publicly available at http://human-phenotype-
ontology.github.io/. Created in 2007 (Köhler et al., 2014), its purpose is “to provide a 
standardized vocabulary of phenotypic abnormalities encountered in human disease” (Human 
Phenotype Ontology, 2016a). The human phenome describes phenotypic features found in 
disease; abnormalities describing the signs, symptoms, and manifestations of disease (Robinson 
& Bauer, 2011). In the past, databases have offered an incomplete representation of the human 
phenome; by either focusing on genetic mutations (Robinson & Bauer, 2011), or failing to agree 
on common semantics for phenotype data (Köhler et al., 2014). HPO addresses these issues by 
providing a set of terms or annotations and relations derived from the medical literature and 
external databases (Human Phenotype Ontology, 2016a).   
Providing computable definitions for phenotypic abnormalities can prove useful for 
differential diagnosis in the clinical setting. Identifying the same disease phenotype in multiple 
affected patients, can aid in discovering genetically-linked diseases (Köhler et al., 2014). In this 
way, queries can search the relationships between ontology terms to return diseases related to the 
term (Robinson & Bauer, 2011, p. 251).  
The current content of HPO is 11,000 terms and 115,000 annotations for hereditary 
diseases, and about 4000 annotations for common diseases (Human Phenotype Ontology, 
2016a). Individual terms describing phenotypic anomalies are connected by is-a relationships in 
a Directed Acyclic Graph (DAG) format, in which one term can have multiple parents (Human 
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Phenotype Ontology, 2016a). Terms have a unique ID, label, and textual definition (Human 
Phenotype Ontology, 2016b). 
For example, the entry for “Epibulbar dermoids” has the unique ID [HP:0001140] and 
text definition, “An epibulbar dermoid is a benign tumor typically found at the junction of the 
cornea and sclera(limbal epibullar dermoid)” (Human Phenotype Ontology, 2016b).Terms are 
respectively mapped to four ontologies: phenotypic abnormality, clinical modifier, 
mortality/aging, and mode of inheritance (Human Phenotype Ontology, 2016b).  HPO classes are 
interoperable with other model organism databases. Human diseases are cross-listed to terms in 
OMIM, Orphanet, and DECIPHER (Human Phenotype Ontology, 2016b). HPO is cross-
referenced with external ontologies and vocabularies including MESH and International 
Classfication of Diseases (ICD) (Köhler et al., 2014). 
HPO is available in OBO and OWL-formats as generated by the Oort, the OBO ontology 
release tool (Köhler et al., 2014). HPO maintains an integration system for managing releases 
(Köhler et al., 2014). HPO is linked to external databases and model organism databases (Köhler 
et al., 2014); providing annotations to clinical descriptions in Online Mendelian Inheritance in 
Man (OMIM), Orphanet, and DECIPHER  (Human Phenotype Ontology, 2016b). The 
Phenomizer, https://compbio.charite.de/phenomizer/, uses HPO for clinical diagnostics (Human 
Phenotype Ontology, 2016a). HPO also has a web browser located at 
http://compbio.charite.de/hpoweb/showterm?id=HP:0001197. (Human Phenotype Ontology, 
2016a). 
An example annotation defines the HPO term “Hypoglycemia”. The disease class is 
linked to terms from PATO and FMA (Köhler et al., 2014): 
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Class: Hypoglycemia 
EquivalentTo: 
 ‘decreased concentration’ 
and towards some ‘glucose’ 
and inheres_in some ‘portion of blood’ 
and qualifier some ‘abnormal’ 
 
PATO 
The Phenotype and Trait Ontology (https://github.com/pato-ontology/pato/) is an 
ontology of descriptive terms for use in phenotype annotation (OBO Foundry, 2016d).  PATO 
links “phenotypic abnormalities in humans and model organisms to ontologies for anatomy, 
biochemistry, cell type and components, pathology, as well as molecular functions and processes 
in a way that would enable an integrative computational analysis of phenotypic abnormalities 
and disease” (Robinson & Bauer, 2011). One of the uses of PATO is in the gene driven approach 
to model organism discovery; determining the relationships between mouse phenotype and 
human disease and looking for common elements across both species to understand the disease 
manifestation in humans (Robinson & Bauer, 2011).  
According to Robinson & Bauer, PATO is constructed as a single hierarchy of 
phenotypic qualities with 22090 terms (2011). It’s used with other ontologies of ‘quality-bearing 
entities’ including FMA, GO, and CL. A PATO annotation consists of a combination of PATO 
terms with terms from these ontologies. For instance, a PATO annotation usually consists of a 
combination of a quality-bearing entity and a quality. The PATO annotation to describe a “red-
eye” phenotype in Drosophila combines the PATO quality term red with the existing Drosophila 
gross anatomy entity term eye from Mouse Anatomy ontology (2011): 
 
E=FBbt:eye   Q= PATO:red 
 
PATO is written independently of a database schema or format; annotations are in pheno-
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syntax or pheno-xml (OBO Foundry, 2016d). PATO is an OBO Foundry ontology with files 
available in OWL and OBO formats (OBO Foundry, 2016d). 
PCO 
According to PCO, Population and Community Ontology (PCO) 
(https://github.com/PopulationAndCommunityOntology/pco), “describes material entities, 
qualities, and processes related to collections of interacting organisms such as populations and 
communities” (2016). It’s applicable in the fields of behavioral studies and ecology.  An OBO 
Foundry ontology, it communicates with the Basic Formal Ontology (BFO) and is compatible 
with GO, PATO, RO, and NCBITaxon.  PCO classes describe evolutionary processes, 
organismal interactions, and ecology experiments. It is available in an OWL format file. 
NCBI Taxon 
According to Federhen, the purpose of the NCBI Taxonomy, located at  
http://www.ncbi.nlm.nih.gov/taxonomy is indexing the domain of sequences for all of the 
organisms in the publicly available databases of the International Nucleotide Sequence Database 
Collaboration (INSDC) (2012).  The NCBI Taxonomy Project began in 1991 with the design of 
the Entrez information retrieval system, the first database to link nucleotide sequences and 
protein sequences together with relevant literature in a single resource. The partnership known as 
International Nucleotide Sequence Database Collaboration (INSDC) contained the nucleotide 
sequence databases GenBank, EMBL and DDBJ. NCBI Taxonomy evolved out of an agreement 
among INSDC members to resolve issues of taxonomic nomenclature and classification before 
the release of new sequence data.  
The current NCBI Taxonomy provides a set of names and classifications in the structure 
of a phylogenetic taxonomy, representing the evolutionary relationships in the evolutionary life 
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history tree (Federhen, 2002). The taxonomy includes monophyletic groups only, in which group 
members are closely related (Federhen, 2012). An NCBI Taxonomy entry includes the primary 
or “scientific name” and associated secondary names (Federhen, 2012). As of 2011, the 
taxonomy database contained 234,991 species with formal names, 405,546 with informal names 
(Federhen, 2012). The database contains 111110 prokaryotic species, 221,263 eukaryotic 
species, and 95 extinct species with formal scientific names (Federhen, 2012). Within the 
taxonomy database, three nomenclature codes describe animals (ICZN); plants, algae and fungi 
(ICN); and prokaryotes (ICNB). An additional fourth code describes viruses, and each code has a 
set of rules for publication of new taxonomic names (Federhen, 2012). The taxonomy database 
serves as an entry point to Entrez, a system to link nucleotide and protein sequences with 
abstracts from published literature (Federhen, 2012).  
NCBI Taxonomy database is stored in TAXON, a SyBase relational database (Federhen, 
2002). Database entries are “taxons” represented by nodes (Handbook). Taxons are represented 
by unique “taxids”, or identifiers (Federhen, 2002). Taxids are stable and persistent; they can be 
deleted and merged but not reused (Federhen, 2012).  The path from the root node to a taxon 
within the tree is a taxon’s “lineage,” while the “subtree” represents the collection of nodes 
below a taxon (Federhen, 2002). The database is publicly available through three resources: 
Taxonomy Browser http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi, Taxonomy 
domain of Entrez http://www.ncbi.nlm.nih.gov/taxonomy and the Taxonomy ftp site 
ftp://ftp.ncbi.nlm.nih.gov/pub/taxonomy/  (Federhen, 2012). The TaxBrowser “provides a 
hierarchical view of the classification from any particular place in the taxonomy” (Federhen, 
2002). The Browser provides information about publicly-available sequence entries; excluding 
those entries that have not yet been released (Federhen, 2002).   
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For example, the taxonomy browser taxon-specific display page for the entry 
‘Mammalia’ contains the fields: Name, Taxonomy ID, GenBank common name, Inherited blast 
name, Rank, Genetic code, other names, full lineage; links to other Entrez records; and a 
Comments and References section containing links out to other resources (Federhen, 2012).  An 
example use of NCBI Taxon would be using the NCBI Taxonomy browser to view the 
hierarchical display for the family ‘Hominidae’, consisting of four genera: ‘Gorilla’, ‘Homo’, 
‘Pan’, and ‘Pongo’ with six species-level names (Gorilla gorilla, Homo sapiens, Pan paniscus, 
Pan troglodytes, Pongo pygmaeus, and Pongo sp.) and 2 subspecies (Federhen, 2002). The 
browser shows a taxon-specific display for ‘Hominidae’ with the ability to view lineage above 
and below ‘Hominidae’ as well as links to information in related databases (Federhen, 2002). 
The ontology representation of NCBI taxon is the NCBI taxonomy database translated 
into OBO/OWL format, available at https://github.com/obophenotype/ncbitaxon (The OBO 
Foundry, 2016c). Each taxon is taken as an OBO/OWL class with individual organisms forming 
instances of the class (The OBO Foundry, 2016c).  
Controlled Vocabularies 
These represent vocabularies and ontologies that are not currently members of the OBO 
Foundry.  
MESH/UMLS 
Medical Subject Headings (MeSH), located at https://www.nlm.nih.gov/mesh, is one of 
the oldest controlled vocabularies for the domain of medical informatics, providing the 
controlled vocabulary thesaurus for the National Library of Medicine (NLM) (USNLM, 2015).   
Common terminology is important in clinical practice, and a problem facing medical informatics 
is the consistent representation of patients, treatments, and outcomes (Nelson, 2009). In 1986, the 
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NLM began a project to build the Unified Medical Language System (UMLS), a repository 
integrating biomedical vocabularies from various sources, in order to integrate medical literature 
in a computer-accessible format (USNLM, 2015). The UMLS integrates names, concepts, and 
relations from more than 100 biomedical vocabularies, including NCBI, GO, and MeSH 
(Baclawski & Niu, 2006). The MESH browser consists of a set of terms that assist in locating 
descriptors in a hierarchical structure (Baclawski & Niu, 2006).  Today, MESH contains 13 
levels, 27,883 descriptors, with more than 87,000 entry terms, 232,000 supplementary concept 
records (SCRs), indexing articles from 5400 biomedical journals (USNLM, 2015).   Descriptors 
help locate MESH headings, which are assigned to a citation from medical literature including 
Medline and PubMed (Nelson, 2009).    Examples of broad headings in MeSH are "Anatomy" 
and "Mental Disorders,” while more specific headings at narrow levels of hierarchy, are "Ankle" 
and "Conduct Disorder” (USNLM, 2015).   “Vitamin C” is an entry term to the heading 
“Ascorbic Acid” (USNLM, 2015).   SCRs are specific chemicals, diseases, and drug protocols 
assigned to descriptors connected to citations to enable user queries tied to the descriptor 
(USNLM, 2015).   The MeSH thesaurus is small in relation to the entirety of UMLS terms, 
which has browsers independent of MeSH (Baclawski & Niu, 2006).  
One use of MeSH is for formulating queries for keyword search or for generating 
knowledge representations (Baclawski & Niu, 2006). MeSH is organized according to a user 
model, based on bibliographic retrieval, and an information model in which headings are 
assigned to citations (Nelson, 2009). Representational integrity means that a single term can be 
represented in only one way (Nelson, 2009). According to Nelson, “MeSH is successful due to 
the careful examination of the scope of its use, demanding of itself a clear statement of its 
mission, regular examination of feedback from its user group, and conscious conceptual 
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evolution in response to the use environment” (2009). Additionally, indexing procedures ensure 
that MeSH terminology is kept up-to-date (Nelson, 2009). MeSH is available in XML format 
from the site https://www.nlm.nih.gov/mesh/filelist.html and in Research Description 
Framework (RDF) format at https://id.nlm.nih.gov/mesh/ (USNLM, 2015).    
OpenTox 
The OpenTox Framework, located at http://www.opentox.org, aims to promote data 
integration and machine accessibility to toxicity data by standardizing chemical and toxicity 
databases, improving interoperability between toxicity resources, and providing a representation 
suitable for modeling algorithms (Tcheremenskaia et al., 2012). The project was funded by the 
EU Seventh Framework Program for predictive toxicology modeling and application 
development (Tcheremenskaia et al., 2012). OpenTox provides toxicity information regarding 
endpoints considered by Registration Evaluation and Authorization of Chemicals (REACH) 
legislation, outlining alternative methods to animal models for chemical testing (Hardy et al., 
2010).  
Data organization and retrieval consists of selection of toxicological endpoints to be 
included, and definition of the type and extent of information for each endpoint and their 
relationships and hierarchies (Hardy et al., 2012b). OpenTox provides a set of ontologies 
available through REST web services that support tools and APIs (Tcheremenskaia et al., 2012). 
Within OpenTox, the included ontologies are a)Toxicological ontology –toxicological endpoints; 
b) Organs system and Effects ontology – addressing organs, targets/examinations in in vivo 
studies; c) ToxML ontology –conversion of the ToxML schema to ontology format; d) ToxLink–
ToxCast assays ontology e) OpenTox ontology– representation of OpenTox framework 
components e) Algorithms ontology and  f) OpenToxipedia- collaborative resource for entry and 
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editing of toxicology terms (Hardy et al., 2012b). The Toxicological ontology is the main 
ontology, available in OWL format, containing the study types which can be mapped to toxicity 
datasets: carcinogenicity, in vitro bacterial mutagenesis, in vivo micronucleus, repeated dose 
toxicity, and aquatic toxicity (Hardy et al., 2012b). The organs system ontology provides non-
endpoint specific diagnostic features for 12 organ systems for rodent in vivo studies (Hardy, 
2012b). OpenTox ontology provides an OWL representation for the core components- the 
datasets, features, tasks, algorithms, models, and validation- of OpenTox (Tcheremenskaia et al, 
2012). OpenTox is constructed using OBO Foundry principles and using the OWL DL language 
edited by Protégé OWL editor (Hardy et al., 2012b). 
OpenTox components are made available through standardized REST web services, in 
which compounds, data sets, and predictive methods have a unique URI used to retrieve its 
associated Resource Description Framework (RDF) representation (Tcheremenskaia et al., 
2012). OpenTox is available at three levels aimed at different use cases: a user interface for 
access to predictions, data, and models; an interface for new model development; and the public 
OpenTox API for new model development and integration (Hardy et al., 2010).  APIs support the 
integration of chemical and toxicity data, and the development of end user-oriented tools (Hardy 
collaborative). One application of OpenTox is the support of data mining and cheminformatics 
applications for modelling Quantitative Structure Activity Relationships (QSARs) (Hardy et al., 
2010). Another is the development of distributed web services, two of which are ToxPredict, 
which given a chemical structure reports toxicities, and ToxCreate which, given a dataset 
predicts and validates a toxicity model (Hardy et al., 2010).  
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AOP-Ontology 
The adverse outcome pathway ontology (AOPO), located at 
https://github.com/DataSciBurgoon/aop-ontology, is specific to managing data for AOP’s 
(DataSciBurgoon, 2015a).  The purpose of the ontology is to provide: a) Semantic NoSQL way 
of accessing and managing Adverse Outcome Pathways (AOP) b) Ways and means to facilitate 
computation on data within the OECD AOP-KB c) Ways and means to standardize the lingua 
franca of the OECD AOP-KB d) The data framework to enable the development of artificial 
intelligence for predictive toxicology e) A central repository of toxicological knowledge to 
facilitate rapid and more efficient risk assessment.  
AOPO is “capable of performing first order logic inferences”, coupling “key events to 
assays to phenotypes” (DataSciBurgoon, 2015b). It enables queries; for instance, “At what 
concentration is chemical X likely to cause leukemia based on data from Tox 21 assays?” 
(DataSciBurgoon, 2015b). Other queries might identify chemicals associated with a disease, or 
develop a test battery for assays associated with disease (DataSciBurgoon, 2015b). The core 
AOPO is restricted to a formal description of the AOP and its components (key events and key 
event relationships). By design, it doesn’t include any biological information.  The biological 
information is inherited from previously established ontologies such as ChEBI, Human 
Phenotype Ontology, and Bioassay Ontology. This structure makes the long-term management 
of the AOPO relatively straightforward as the AOP components are static and the biological 
information will be maintained separately by the outside ontology efforts. 
The ontology consists of an OWL file to facilitate use in semantic web and web data 
(DataSciBurgoon, 2015a). Ultimately, AOP-Ontology will contribute to the AOP-
Knowledgebase by providing a unified controlled vocabulary for AOP components.  
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CHAPTER 3: CREATING AND APPLYING A DATA MODEL TO ANNOTATE 
ADVERSE OUTCOME PATHWAYS (AOP’S) 
 
Introduction 
With the advent of alternative approaches to traditional toxicological assessments of 
environmental chemicals, namely the use of high throughput (HTS) and high content (HCS) 
screening assays, came the generation of vast amounts of data and the need to organize such data 
to support regulatory decision-making. The AOP framework provides the biological context and 
supporting scientific evidence for organizing such alternative data. The objective of this chapter 
is to demonstrate the results and application of a common controlled vocabulary to address the 
data needs of the AOP-Knowledgebase, located at (http://aopkb.org). First, we review the data 
needs of currently approved AOP’s and AOP’s under development at levels of biological 
organization from molecular to population. Second, we define a data model to represent these 
needs. Third, we designate a common set of ontologies and controlled vocabularies at levels of 
biological organization relevant to the AOP, to annotate key terms from AOP entities. Finally, 
we conduct a cross-analysis applying ontology terms to AOP entities. Using the results of this 
mapping, we further define properties that apply to the data model. Case examples illustrate how 
the data model represents AOP entities at different levels of biological resolution. Future 
directions for application to the AOP-KB and AOP Framework as a whole are detailed.  
Data resources and retrieval tools publicly available on the World Wide Web provide 
biologists with access to a variety of information including genomic, chemoinformatic, 
biological pathway, phenomic, ontological, metabolomic and toxicogenomic data (Oki et al., 
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2016). While some sources are specific to one data type, others serve as aggregators or curators 
of information from disparate data sources (Oki et al., 2016). Publicly available data sources that 
may be used to drive AOP development include repositories storing multiple types of 
information. Macromolecular sequence databases, such as GenBank and SWISS-PROT, contain 
information about nucleotides or protein sequences and may be used in the discovery of novel 
genes, identification of homologous genes, and detection of polymorphisms (Pandey & Lewitter, 
1999).  Databases such as Gene Expression Omnibus (GEO) provide storage and retrieval of data 
sets from high throughput gene expression and genomic hybridization experiments (Edgar et al.,  
2002). Comparative Toxicogenomics Database (CTD) includes toxicogenomic connections 
relating chemicals/drugs, genes/proteins, diseases, taxa, phenotypes, GO annotations, pathways, 
and interaction modules (Davis et al., 2015). Model organism databases such as Mouse Genome 
Informatics (MGI), FlyBase, and Wormbase organize species-specific genomic information. 
Pathway resources include Kyoto Encyclopedia of Genes and Genomes (KEGG), “for 
understanding higher-order functional meanings and utilities of the cell or organism from its 
genome information” (Baclawski & Niu, 2006).  These data sources inform the different levels 
of biological organization (molecular, cellular, tissue, organ, organism, and population-level) 
that populate the AOP. 
AOP’s integrate diverse data types from in vitro, in vivo, in silico, and in chemico tests 
supporting KE’s at each level of biological organization of the AOP, providing a mechanistic 
understanding of a chain of biological events to inform regulatory decision-making regarding a 
chemical.  AOP developers should be concerned with identifying the data needs of AOP’s and 
how to integrate this information in a usable format.  According to Oki et al., the biological space 
covered by existing AOP’s is lacking, and the current process for AOP development is unable to 
  
 
51 
address this issue in an acceptable time frame (2016).  Computational approaches can speed up 
the process of AOP development by avoiding the rate-limiting step of expert derivation (Oki et 
al., 2016). One difficulty is that the incorporation of data from a variety of approaches has 
resulted in an assortment of diverse terms and definitions, leading to confusion among scientists 
and organizations.   
The OECD recommended development of a standardized set of terminologies to assist in 
the understanding of the AOP concept and in applying terms relevant to the AOP concept in 
developing QSAR’s and chemical categories to advance the use of predictive techniques in 
assessments (OECD, 2013a). Use of a common vocabulary providing a cohesive description of 
events happening across different datasets of interest will facilitate data integration and 
identification of pathways developed from different datasets (Oki et al., 2016).   Providing 
centralized databases for cross-reference of terms and other information, allowing for 
identification and aggregation of shared information, will contribute to further development of 
AOP’s in a network framework (Oki et al., 2016). Using a standardized set of ontologies and 
controlled vocabularies will improve the ability to attach evidence in support of the AOP, 
supporting aggregation of data from HTS assays and experiments (Edwards, personal 
communication, July 8, 2016). This will speed up the rate of AOP development by reducing the 
computational challenge of translating information across datasets in individual ontologies (Oki 
et al., 2016). 
The existing AOP-Ontology provides a set of terms and relationships with which to 
manage data on AOP’s and facilitate computation on data in the AOP-KB (DataSciBurgoon, 
2015a); however, it excludes text portions of AOP’s such as KE names, KE descriptions, level of 
biological organization, and the biological context in which a KE occurs. A data model to 
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provide structure for these entities external to AOP-Ontology, will provide computability for 
these components. 
 
Methods 
 
A review of OBO Foundry member ontologies obtained from the OBO Foundry website 
at http://www.obofoundry.org/ was conducted in order to choose a minimum list of ontologies 
and controlled vocabularies (Table 1) from which to draw ontology terms or “classes”.  
Table 1. Minimum list of ontologies selected from the review of all ontologies and controlled 
vocabularies, ordered by level of biological organization.   
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Figure 2. Review of ontologies and controlled vocabularies at each level of biological organization to 
select the minimum list. Numbers in () represent (ontologies reviewed at each level, ontologies selected at 
each level). Classes represents the total possible number of ontology classes or terms contained in the 
selected ontologies at that level of organization. The number of terms at each level was duplicated for 
ontologies representing more than one level of organization to ensure that the maximum number of 
possible terms was represented. 
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Figure 3. Ontology Lookup Service (OLS) output for a search on a GO term (signaling). Tree View of 
the GO term, its term info, and term relations are displayed. 
 
OBO Foundry ontologies were chosen as the most broadly accepted and syntactically 
uniform ontologies available when possible. Ontologies were reviewed based on published 
literature for their domain of study, their taxonomic applicability, syntax and available format for 
download, the level of biological organization that they cover from molecular to population, and 
whether the ontology imported or aggregated other data sources. The upper level Relations 
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Ontology (RO) and Basic Formal Ontology (BFO) were excluded, as it was assumed that they 
contain relations common to OBO Foundry member ontologies (Brinkman et al., 2010).  
An initial review was conducted of the OBO Foundry ontologies (Appendix A), a few 
ontologies that were not OBO Foundry members, as well as several controlled biomedical 
vocabularies from the literature. The final selection (Table 1) of ontologies and vocabularies was 
chosen based on literature review of those containing entities at a level of biological organization 
applicable to AOPs; as well as characteristics and chosen vocabularies used in projects involving 
construction of new frameworks drawing on existing ontologies, such as the Beta Cell Genomics 
project (Zheng et al., 2013) and PubChem RDF project (NCBI, 2015). This selection represented 
the minimum number of ontologies that could accurately represent the biological space of key 
events in the AOP Framework. 
After selection of ontologies, key event terms from AOP Wiki 
(https://aopwiki.org/wiki/index.php/Main_Page) were mapped to classes from the chosen 
ontologies. For 17 priority AOP’s in the categories “Currently under OECD EAGMST Review” 
and “Open for General Comments”, and for 6 AOP’s in the “EAGMST Approved” category, KE 
pages from the Wiki were manually reviewed for text query phrases. Query phrases 
representative of key events from these pages were entered into three ontology browser sites: 
Ontobee (http://www.ontobee.org/), NCBO Bioportal (http://bioportal.bioontology.org/), and the 
EMBL-EBI Ontology Lookup Service (http://www.ebi.ac.uk/ols/beta/index).  From the list of 
“hits” on the search browser output, matching ontology classes (entities) were reviewed for their 
match to query terms and the appropriate ontology class was chosen (Figure 3). When possible, 
the least specific class available to accurately portray the information was selected, to promote 
reusability of terms and minimize the number of classes chosen.  
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The AOPO (https://github.com/DataSciBurgoon/aop-ontology) was extended to include a 
data structure (Figure 4) that best captures the results of the matching process between ontology 
classes and KE terms. Ontology classes were aligned with a data model containing the fields: 
Process, Object, Action, and Context. Biological process was defined as a recognized series of 
events or molecular functions representing the key action happening in the event as defined by 
GO (Gene Ontology Consortium, 2015b). Object represents the biological object to which the 
process is occurring, a chemical entity or cellular component such as ‘vitellogenins’ or ‘hepatic 
stellate cell’. Action terms representing directionality were chosen from the following: Increased, 
Decreased, Altered, Delayed, Accelerated, or Unknown (Crofton, K., personal communication, 
April 8, 2016). KE’s occurring at the Molecular and Cellular level of biological organization 
were assigned a Cellular Context, and terms at the Tissue and Organ level were assigned an 
Organ Context based on either the cell or the organ where the event was applicable, and terms at 
the Individual or Population level were not assigned a context. The data fields of Process, Object, 
and Context were linked to terms from external ontologies. 
Results were compiled and analyzed using Excel. The choice of ontology terms used was 
validated through review by and consultation with experts and AOP authors (Burgoon, L., 
Edwards, S., Villeneuve, D., personal communication, April 8, 2016). 
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Figure 4. Schematic for how the data model extends the AOP Ontology. Components contained in the 
existing AOP-Ontology are in red. The data model provides Process, Object, Action, and Context (green), 
which are external but linked to AOP Ontology via the annotation of KE’s. Entities in blue are part of the 
AOP-Wiki application. Uberon, CL, and GO represent examples of ontologies that these data fields will 
import from. 
 
Results 
 A review was conducted of 64 ontologies and controlled vocabularies, 49 of them which 
were OBO Foundry member ontologies (Appendix A). From this, it was determined that a final 
list of 22 ontologies and vocabularies was the minimum necessary to represent key events at the 
molecular, cellular, tissue/organ, individual, and population levels (Table 1). The total number of 
possible terms at each level represents a subset of the total number of possible terms of all the 
ontologies reviewed (Figure 2) as calculated using estimates of number of classes from NCBO 
Bioportal and Ontobee (Burgoon, L., Edwards, S., Villeneuve, D., personal communication, 
April 8, 2016). Calculation of the possible number of total terms did not account for those 
ontologies that import terms from other ontologies, so may include overlap. Of the OBO 
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Foundry ontologies selected, two of these were OBO-Foundry application ontologies, BRENDA 
tissue/enzyme source (BTO) and Experimental Factor Ontology (EFO) and the remainder were 
OBO Foundry reference ontologies. One controlled vocabulary, Medical Subject Headings 
(MeSH), was selected due to its widespread use even though it is not a formal ontology. 
Ontologies were ordered by level of biological organization according to the minimum level of 
organization that they represent. For example, while GO includes entities at the cellular level, for 
the purposes of this review it was considered a molecular level ontology. Finally, in the domain 
of experiments, the Ontology for Biomedical Investigations (OBI), Protein-protein interaction 
(MI), and Experimental Factor Ontology (EFO) were included. 
 The AOPO forms the basis for incorporation of other ontologies as the resulting 
minimum list of ontologies (Table 1) extends the AOPO and the ontologies it currently inherits. 
The data model (Figure 4) capturing the results of the matching process between ontology 
classes and KE terms provides an organizational framework for mapping of KE terms to 
ontology classes from the minimum list.  As shown, the selected ontologies extend the currently 
existing components of the AOP-Ontology and the ontologies that it currently imports. 
 The resulting data model developed to extend AOPO provides representation for KE 
entities, including Events as represented by terms obtained from the selected ontology list (Table 
1). Using a text match approach mapping terms from KE’s to ontology classes from the selected 
list, and the data properties needed to represent this information, resulted in the data model.  
 You should include a paragraph here describing the AOP ontology and how it forms the 
basis for incorporating all the other ontologies.  You can use Figure 4 as the basis for this 
discussion. I would then discuss the data model again since not everyone reads the methods. That 
will set up the discussion below. 
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 Mapping the results of search queries for the 23 AOP’s to ontology classes from the 
selected list, resulted in a total of 173 key events, 155 of them unique, being mapped to 467 
ontology classes, 209 of them unique as defined from the selected ontology list. Three terms 
could not be matched to an ontology class or were undefined (Appendix B). This shows that 
more than half of ontology classes were duplicates, and that only a small part of each ontology 
was needed to accurately describe the chosen key events.  
For example, the KE “17beta-estradiol synthesis by ovarian granulosa cells, Reduction” 
can be condensed into the query terms “synthesis,” “17beta-estradiol,” and “ovarian granulosa 
cells” from the KE name and the text description on the wiki page for the event at 
https://aopwiki.org/wiki/index.php/Event: 3 (2016), resulting in a mapping to ontology classes 
as: 
Process: ‘biosynthetic process’ (GO: GO_0009058)  
Object: ‘17beta-estradiol’ (CHEBI: CHEBI_16469)  
Context: ‘granulosa cell’ (CL: CL_0000501)  
 Action: ‘Decreased.’ 
  
 Resulting from the mapping of key event terms to ontology classes, came to define 
properties for the data structure of Processes, Objects, Context, and Actions. The following 
properties were arrived at to better define requirements for each data field within the structure: 
(1) Multiple and blank fields 
One issue that arose was the necessity of using multiple ontology classes to define 
key events. It was decided that multiple classes would be allowed for Processes and 
Objects. Context was restricted to from 0 to 1 context entry; in other words, context is 
optional but cannot be multiple. Finally, blank fields are allowed for Objects and 
Contexts, but not for Processes and Actions.  
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(2) Excluded entities 
Based on the definition of an Event, it was decided that relationships, chemicals, and 
experiments or assays would be excluded from this mapping. These components are 
represented in AOP-Ontology (DataSciBurgoon), and this data structure was intended 
to be external to the AOP-Ontology. An exception was the representation of chemical 
entities; a chemical was included when it was an endogenous metabolite as opposed 
to exogenous. 
(3) Specificity of ontology class 
When a query resulted in multiple “hits,” it was determined that the least specific 
ontology class to accurately represent the Event should be selected. This allowed for 
maximal reuse of classes while accurately portraying the Event. 
(4) Consideration of taxonomic applicability 
Efforts were made to match the chosen ontologies based on taxonomic applicability 
as defined in the Event. When an Event included multiple taxons, an ontology that 
was minimally taxon-specific was chosen. 
(5) Restrictions on level of organization 
Some ontologies and vocabularies contain classes at multiple levels of biological 
organization. GO’s ‘biological_process’ sub-ontology, for example, contains classes 
describing processes at the tissue, organ, and organism levels (NCBO, 2016a). Where 
possible, we tried to restrict the choice of ontology based on the level of organization it 
represented. 
Further examples of these data properties are illustrated in the following case studies. 
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Case Example 1: Aromatase inhibition leading to reproductive dysfunction (in fish) 
 This AOP is one of three related AOP’s operating through the shared KE of impaired 
vitellogenesis, leading to reduced fecundity and declining population levels in fish (Ankley et al., 
2010). The MIEs for these AOP’s are: ER antagonism, aromatase inhibition, and AR agonism 
(Ankley et al., 2010). This AOP’s taxonomic applicability is the fathead minnow (Pimephales 
promelas), although the AOP is applicable to other oviparous vertebrates as well (Becker et al., 
2015). The MIE is inhibition of cytochrome p450 aromatase (cyp19a1), and associated KE1 is 
reduced 17beta-estradiol synthesis by ovarian granulosa cells. KE2 is a reduction in plasma 
17beta-estradiol concentrations; KE3, reduced transcription and translation of vitellogenin in the 
liver; KE4, reduced plasma vitellogenin concentrations; KE5, reduced vitellogenin accumulation 
into oocytes and oocyte growth/development; KE6, reduced cumulative fecundity and spawning; 
and the AO, declining population trajectory (Villeneuve, 2016). In ovarian granulosa cells, 
aromatase catalyzes the conversion of testosterone to 17beta-estradiol (E2), which stimulates 
production of vitellogenin in the liver. Hepatic vitellogenin is transported via circulation to the 
ovaries for uptake.  Vitellogenin is necessary for oocyte development, and aromatase inhibitors 
cause a reduction in egg production leading to population decline. There is strong biological 
plausibility, empirical support, and weight of evidence for the AOP as a whole, making it 
applicable for chemical assessment and regulatory purposes (Becker et al., 2015). 
 Applying the data structure for mapping key event terms to ontology classes, allows the 
visualization of how the data structure applies to key events at each level of biological 
organization (Figure 4). ‘AOP 25’ illustrates the data properties and discussion points regarding 
choice of the relevant class for each process, object, and context, and selection of the appropriate 
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Action term. Illustrating data property (1), the mapping for KE3 allows for multiple terms to 
describe the process field, accurately portraying the complexity of key events: 
Process: GO: ‘gene expression’ and GO: ‘translation’ 
Object: MESH: ‘vitellogenins’  
Context: CL: ‘hepatocyte’ and modified by  
Action: ‘Decreased.’ 
 
Secondly, for the KE6 and the AO, the Object and Context fields are blank.  Allowing a 
blank object is useful when a process fully captures the KE without need for an object; the 
context at the Organism and Population level is defined by the different applicability domains 
(species, sex, and life stage) that are captured for all KEs, so no separate Context term is needed. 
For KE6, 
Process: PATO: ‘fecundity’ 
Object: UBERON: ‘egg’  
Context: n/a 
Action: ‘Decreased.’ 
 
For the AO: 
Process: PCO: ‘population growth rate’ 
Object: n/a  
Context: n/a 
Action: ‘Decreased.’ 
 
 
 Illustrating property (2), for KE2, is the inclusion of the object ‘17beta-estradiol’ from 
ChEBI. Since E2 is an endogenous chemical entity produced by synthesis in granulosa cells, it 
was not excluded from the mapping: 
 
Process: GO: ‘biosynthetic process’ 
Object: CHEBI: ‘17beta-estradiol’  
Context: CL: ‘granulosa cell’  
Action: ‘Decreased.’ 
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Finally, according to property (4), it should be noted that this AOP’s taxonomic 
applicability is specific to fish, so mappings to ontologies such as MP and HP were excluded. 
 This AOP also illustrates several of the discussion points regarding the mapping of terms. 
For the MIE, the class chosen to best represent the key event term “Inhibition” was ‘catalytic 
activity’ with the Action modifier of ‘Decreased.’ When the key event text included “enzyme 
inhibition” or “enzyme activation”, it was determined that ‘catalytic activity’ was a more 
accurate representation than ‘signaling,’ though both terms convey the transmission of 
information within a biological system resulting in a cellular response: 
Process: GO: ‘catalytic activity’ 
Object: PRO: ‘cytochrome p450 19A1’  
Context: CL: ‘granulosa cell’  
Action: ‘Decreased.’ 
 
 A second discussion point is how best to describe processes involving transcription and 
translation. For the KE3, the key event text describes transcription of vitellogenin genes, being 
regulated by estrogens via their action on specific nuclear receptors (Villeneuve, 2016). ‘Gene 
expression’ was chosen to describe transcription of genes specific to vitellogenin, and 
‘translation’ to describe the synthesis of the protein vitellogenin. In the GO hierarchy, ‘gene 
expression’ is a parent class for ‘transcription, DNA-templated’ and for ‘translation’, so 
‘translation’ is the more specific of the two classes. ‘Translation’ was determined to be necessary 
to adequately describe the key event: 
Process: GO: ‘gene expression’ and GO: ‘translation’ 
Object: MESH: ‘vitellogenins’  
Context: CL: ‘hepatocyte’  
Action: ‘Decreased.’ 
  
 The third discussion point was for the KE2 and KE4, the use of the process class ‘blood 
circulation’ twice within one AOP. It was decided that reuse of processes within an AOP should 
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be allowed, as long as the same Process, Object, Action, and Context mapping of terms didn’t 
exist within non-identical key events. For KE2: 
Process: GO: ‘blood circulation’  
Object: CHEBI: ‘17beta-estradioll’  
Context: Uberon: ‘blood plasma’  
Action: ‘Decreased.’ 
 
 
and KE4: 
 
Process: GO: ‘blood circulation’  
Object: MESH: ‘vitellogenins’  
Context: Uberon: ‘blood plasma’  
Action: ‘Decreased.’ 
 
 
Figure 5. Graphical view of “Aromatase inhibition leading to reproductive dysfunction (in fish)” with 
key event terms mapped to ontology terms. CL, CHEBI, GO, MESH, PATO, PCO, PR, UBERON 
represent ontologies and their associated ID’s. 
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Case Example 2: Chronic binding of antagonist to N-methyl-D-aspartate receptors 
(NMDARs) during brain development induces impairment of learning and memory 
abilities. 
 
 N-methyl-D-aspartate receptors (NMDARs) are a member of a group of ionotropic 
receptors activated by the neurotransmitter, L-glutamate (Glu) (Sachana et al., 2016). Activation 
of NMDAR in the hippocampus of the developing rat brain results in synaptic functioning 
associated with learning and memory processes. Long term potentiation as a result of NMDAR 
activation results in increased synaptic strength, plasticity, and memory formation in the 
hippocampus. NMDAR enhances release of brain-derived neurotrophic factor (BDNF) resulting 
in neuronal survival, differentiation, and synaptogenesis. Blockage of NMDAR by chemical 
substances such as lead (Pb2+), is associated with disrupted neuronal network function and 
impaired learning and memory in the developing brain. 
The MIE, NMDARs, Binding of Antagonist, is followed by KE1, Inhibition of 
NMDARs. Following KEs are: KE2, Decreased calcium influx; KE3, Reduced release of BDNF; 
KE4, aberrant dendritic morphology; KE5, reduced presynaptic release of glutamate; KE6, Cell 
death; KE7, decreased synaptogenesis; KE8, decreased neuronal network function; and the AO 
of Impaired learning and memory.  
 KE5 illustrates data property 2. The object term ‘Glutamate’ is an endogenous entity, and 
was included despite the exclusion of chemicals from the mapping (Figure 5): 
Process: GO: ‘neurotransmitter secretion’  
Object: ChEBI: ‘glutamate’  
Context: Uberon: ‘blood plasma’  
Action: ‘Decreased.’ 
 
 This AOP brings up multiple points of discussion. First, using the structure to map the 
MIE and KE1 resulted in an identical mapping for both key events, with ‘signaling’ representing 
both of the event text terms “Inhibition” and “Binding.” As in the previous case example, shared 
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processes are included within a single AOP, but identical terms for Process, Object, Action, and 
Context shouldn’t result within an AOP. It was determined that one event at the molecular level 
should be chosen as the MIE, and that a discussion should be taken up with the AOP author to 
remove the extraneous key event. ‘Signaling’ provides the best process term to accurately 
portray this event, as inhibition and antagonism both can be described by increased or decreased 
signaling of the NMDA- receptor. For KE1,  
 
Process: GO: ‘signaling’  
Object: GO: ‘NMDA glutamate receptor complex’  
Context: Uberon: ‘hippocampus’  
Action: ‘Decreased.’ 
 
 Secondly, this AOP brings up a discussion regarding the selection of terms for inter- and 
intracellular transport. GO defines ‘transport’ as “The directed movement of substances into, out 
of or within a cell, or between cells, or within a multicellular organism by means of some agent 
such as a transporter or pore” (Ashburner et al., 2000). Subclasses of GO: ‘transport’ include 
‘extracellular transport’, ‘intracellular transport’, ‘intercellular transport’, and ‘vesicle-mediated 
transport.’ KE2 describes the directed movement of Ca2+ into the cell, where it functions as a 
signaling molecule to regulate synapse and neuronal cell function (Sachana et al., 2016). It was 
determined that for the majority of key events in the mapping, ‘transport’ was adequate. For 
KE2, 
Process: GO: ‘transport’  
Object: ChEBI: ‘Calcium (2+)’  
Context: CL: ‘neuron’  
Action: ‘Decreased.’ 
 
 For KE3, the key event text describes the transcription and release of BDNF from 
glutamatergic neurons (Sachana et al., 2016). The process ‘gene expression’ was chosen to 
describe BDNF expression and transcription of the protein. GO: ‘gene expression’ is a parent 
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class for GO: ‘transcription, DNA-templated’ and for GO: ‘translation,’ so it was determined that 
this process description would be sufficient to include the key event term “transcription”: 
Process: GO: ‘gene expression’  
Object: PR: ‘brain-derived neurotrophic factor’  
Context: CL: ‘neuron’  
Action: ‘Decreased.’ 
 
 KE5, KE7, and KE8 describe key events relating to synaptic function. For KE5, based on 
the key event text “reduced presynaptic release of Glutamate,” it was determined that 
‘neurotransmitter secretion’ was the most applicable process. In GO, ‘Neurotransmitter 
secretion’ is a subclass of ‘synaptic transmission,’ but it was appropriate to make this 
specification in order to include ‘Glutamate’ as the object. For KE7, GO: ‘synapse assembly’ 
was a synonym for the query term “synaptogenesis” from the key event text. GO: ‘synapse 
assembly’ is a subclass of GO: ‘cellular component assembly’ (Ashburner et al., 2000). For KE8, 
the query term “neuronal network communication” from the key event did not have an exact 
match in GO, but it was determined that the event was referring to glutamatergic 
neurotransmission (Sachana et al., 2016), so the process term was determined to be GO: 
‘synaptic transmission.’ For KE5: 
Process: GO: ‘neurotransmitter secretion’  
Object: ChEBI: ‘glutamate’  
Context: Uberon: ‘blood plasma’  
Action: ‘Decreased.’ 
 
For KE7,  
Process: GO: ‘synapse assembly’  
Object: GO: ‘synapse’  
Context: CL: ‘neuron’  
Action: ‘Decreased.’ 
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For KE8, 
Process: GO: ‘synaptic transmission’  
Object: n/a  
Context: Uberon: ‘brain’  
Action: ‘Decreased.’ 
 
 
 
Figure 6. Graphical view of “Chronic binding of antagonist to N-methyl-D-aspartate receptors 
(NMDARs) during brain development induces impairment of learning and memory abilities” with key 
event terms mapped to ontology terms. CL, CHEBI, GO, MP, PATO, PR, UBERON represent ontologies 
and their associated ID’s. 
 
Case Example 3: PPARa activation in utero leading to impaired fertility in males 
 PPAR is a ligand-activated nuclear receptor, a transcription factor in the 
steroid/thyroid/retinoid family of receptors (Nepelska et al., 2016). Activation of PPAR in the 
tissues responsible for fatty acid catabolism affects lipid metabolism. The key events of this AOP 
are: the MIE, PPAR activation; KE1, steroidogenic acute regulatory protein (STAR) decrease; 
KE2, translator protein (TSPO) decrease; KE3, reduced cholesterol transport in mitochondria; 
KE4, reduced testosterone synthesis; KE5, reduced testosterone levels; and the AO of male 
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reproductive tract malformation and impaired fertility. This is a reproductive AOP applicable 
only in males. Possible applications of the AOP are in identification of endocrine disrupting 
chemicals. 
 Examining the mapping for this AOP (Figure 6), KE1 and KE2 exhibit data property (1). 
For both STAR and TSPO proteins, the key event text identifies gene expression and reduced 
tissue levels of the protein, so the representative classes were ‘gene expression’ and 
‘accumulation.’ For KE1:  
 
Process: GO: ‘gene expression’ and PATO: ‘accumulation’ 
Object: PR: ‘STAR’  
Context: Uberon: ‘Leydig cell’  
Action: ‘Decreased.’ 
 
and KE2: 
Process: GO: ‘gene expression’ and PATO: ‘accumulation’ 
Object: PR: ‘translocator protein’  
Context: Uberon: ‘Leydig cell’  
Action: ‘Decreased.’ 
 
 KE4 brings up an example of selecting the correct class relating to “transport” as 
described earlier. The key event text describes reduced transport of cholesterol from intracellular 
stores to the inner mitochondrial membrane (Nepelska et al., 2016). GO: ‘mitochondrial 
transport’ is a subclass of GO: ‘transport,’ and as ‘transport’ was the more general and reusable 
term this was selected for the process field: 
Process: GO: ‘transport’ 
Object: ChEBI: ‘cholesterol’  
Context: Uberon: ‘Leydig cell’  
Action: ‘Decreased.’ 
 
 For KE5 and KE6, the challenge of how to correctly phrase reduced “testosterone 
synthesis or steroidogenesis”, followed by a reduction in circulating testosterone levels. The 
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terms GO:‘biosynthetic process’ and GO: ‘blood circulation’ were chosen for the process field, 
and the object for both was CHEBI: ‘testosterone.’ For KE5: 
Process: GO: ‘biosynthetic process’ 
Object: ChEBI: ‘testosterone’  
Context: Uberon: ‘Leydig cell’  
Action: ‘Decreased.’ 
 
and for KE6, 
Process: GO: ‘blood circulation’ 
Object: ChEBI: ‘cholesterol’  
Context: Uberon: ‘Leydig cell’  
Action: ‘Decreased.’ 
 
 The AO illustrates data property (1). AO is described by GO: ‘fertility’ and an action 
term of ‘Decreased,’ so having an object was not necessary. Since this KE was at the organism 
level, by the definition of context, a context was not necessary.  
For the AO: 
Process: PATO: ‘fertility’ 
Object: n/a 
Context: n/a 
Action: ‘Decreased.’ 
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Figure 7. Graphical view of “PPARa activation in utero leading to impaired fertility in males” with key 
event terms mapped to ontology terms. CHEBI, GO, MP, PATO, PR, UBERON represent ontologies and 
their associated ID’s. 
 
Case Example 4: AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma 
(HCC) 
 
 Aflatoxin B1 (AFB1) is an example chemical for the induction of hepatocellular 
carcinoma (HCC) via a mutagenic mode of action (Pottenger et al., 2016). In gene mutation 
assays, AFB1 induces mutations in codon 249 of the p53 gene in humans, responsible for cancer 
etiology of HCC (Pottenger et al., 2016). The MIE for this AOP is the formation of pro-
mutagenic DNA adducts. KE1, metabolism of AFB1 to produce reactive electrophiles; KE2, 
mutation induced in critical genes; KE3, clonal expansion/cell proliferation to form altered 
hepatic foci (AHF); KE4, insufficient or misrepair of DNA adducts; and the AO, hepatocellular 
carcinoma and tumorigenesis (Figure 7).  
 KE1 illustrates data property (2). Since AFB1 is the chemical initiator in this AOP, 
although it induces mutations in gene mutation assays it is intended as a case example of 
multiple chemicals that could act through this mode of action resulting in HCC (Pottenger et al., 
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2016). As an exogenous chemical entity, it was excluded from the mapping, and the object for 
this mapping was left blank. The AO, also has a blank object, because no modifiers were needed 
for the process ‘hepatocellular carcinoma.’ For KE1: 
Process: GO: ‘metabolic process’ 
Object: n/a 
Context: Uberon: ‘liver’ 
Action: ‘Increased.’ 
 
 The MIE for this AOP illustrates data property (3) of how to choose the most 
representative term illustrating the formation of pro-mutagenic DNA adducts by chemical 
metabolites.  The parent class of GO: ‘DNA alkylation’ is GO: ‘DNA modification.’ However, 
in order to include key events involving GO: ‘protein alkylation’, GO: ‘cellular macromolecule 
metabolic process’ was the overarching parent term. Thus, in order to remain sufficiently 
descriptive without losing connotation, the more specific term ‘DNA alkylation’ was chosen to 
represent this process. Likewise, FMA: ‘nuclear DNA’ rather than FMA: ‘DNA’ was chosen to 
represent the object for this event based on the key event text: 
Process: GO: ‘DNA Alkylation’ 
Object: FMA: ‘nuclear DNA’ 
Context: Uberon: ‘hepatocyte’ 
Action: ‘Altered.’ 
 
 Another discussion point brought up by KE2, was the choice of class for the key event 
terms “mutation”, “heritable mutation”, and “induced mutation”. Although this event describes 
an induced mutation in a codon for p53 gene in humans, it was decided that choosing a process 
representative of “mutation” should be maximally reusable for other key events. In querying the 
select list of ontologies, it was found that EFO: ‘induced mutation’ was a subclass of EFO: 
‘genetic modification,’ but ‘genetic modification’ did not accurately describe the key event 
terminology.  Therefore, the more general MI: ‘mutation’ was chosen to represent this key event: 
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Process: MI: ‘mutation’ 
Object: PR: ‘cellular tumor antigen p53’ 
Context: Uberon: ‘hepatocyte’ 
Action: ‘Altered.’ 
 
 Finally, this AOP specified the genetic mutation in human p53 gene, but the AO of HCC 
occurs in multiple species including birds, fish and mammals (Pottenger et al., 2016). According 
to property (4), the term EFO: ‘hepatocellular carcinoma’ was chosen rather than HP: 
‘hepatocellular carcinoma’ or MP: ‘hepatocellular carcinoma’: 
 
Process: EFO: ‘hepatocellular carcinoma’ 
Object: n/a 
Context: Uberon: ‘liver’ 
Action: ‘Increased.’ 
 
 
Figure 8. Graphical view of “AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma 
(HCC)” with key events mapped to ontology terms. CL, EFO, FMA, GO, MI, PR, UBERON represent 
ontologies and their associated ID’s. 
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Discussion 
 
 The benefits of applying our data model to the AOP-KB are that it provides the ability to 
attach scientific evidence in support of the AOP, including assays and biomarkers linked to 
KE’s. The model supports aggregation of data from HTS assays and experiments, supporting 
KE’s. It supports AOP networks, which can then be used for further AOP identification and 
evaluation (Oki et al., 2016). It also provides for the evaluation of taxonomic relevance of KE’s  
(Oki et al., 2016).  
 The network framework of AOP’s relies on the identification of shared AOP 
components, KE’s and KER’s, reusable between different AOP’s. Application of ontologies and 
controlled vocabularies provides a uniform description for events across datasets in a formalized 
language (Oki et al., 2016), promoting querying and data mining capabilities. Selecting a set of 
ontologies and a structured approach to their use, as applicable to the AOP framework at all 
levels of biological organization, will enhance cpAOP development as a basis for expert-derived 
AOP’s. Also, the set of ontologies and data framework arrived at through this project will inform 
user queries for the definition of KE’s, enhancing the capabilities of the AOP-Wiki application. 
 Hundreds of ontologies and controlled vocabularies representing different domains are 
publicly available on the web, and reviewing these for a standardized set to inform the AOP 
framework at the molecular, cellular, tissue, organ system, and organism levels of biological 
organization led to a standardized set of ontologies and vocabularies from which terms were 
queried. Mapping text terms from KE’s in AOP-Wiki to ontology terms from this minimum set, 
showed that the number of terms necessary to identify KE’s was a minimal set of the total 
number of terms represented by these ontologies. However, one limitation in restricting to this 
minimum list was that several ontologies, especially GO and MP, import from ontologies 
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external to this list and contain duplicate terms. Additionally, ontologies such as GO that covered 
more than one level of biological organization were counted for both levels of organization 
(Figure 2), and this may lead to duplicate terms.  Possible duplicates will be accounted for in the 
AOP-Wiki by ensuring that the imported subset of ontology terms, stored in a database, from 
which users can choose does not contain duplicates. 
Several of the ontologies from the minimum set were selected based on their 
characteristics and literature review, but not actually used in the mapping. These included 
Sequence Ontology (SO), Ontology for Genes and Genomes (OGG), and Ontology for 
Biomedical Investigations (OBI). This minimum set may change in the future, as ontologies 
useful at that level of organization are added and subtracted from the set. Analysis of the 
ontology terms used in the mapping showed that more than half of them were reused either in 
duplicate KE’s throughout the mapping, or in nonduplicate KE’s. 
 The data model with fields of Process, Object, Action, and Context for tying KE entities 
to ontologies was effective for the majority of AOP’s examined. Benefits of this approach were 
that it effectively described the majority of AOP’s reviewed, with few KE’s not mappable to this 
framework. The definition of data properties for each field, led to the formulation of restrictions 
and allowances for ontology terms in the mapping for better definition of the data framework. 
These properties will inform user choices of terms in the AOP-Wiki application. 
 The process of mapping KE entities to ontology terms also led to multiple discussions 
about the selection of terms and specific issues resulting from the mapping, such as terms that 
could not be found, or were undefined by authors. A discussion with experts, and bringing up 
these issues with individual authors of the AOP, led to decisions about these issues and 
refinement of terms in the mapping. 
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 One limitation was the manual curation of the terms selected; through the process of 
manual selection of KE text terms from AOP-Wiki, input into an ontology browser, and selection 
of the appropriate matching ontology class. Several tools available for ontology extraction 
include Ontodog, a web-based tool that can retrieve a set of terms and reasoners from an 
ontology file (Zheng et al., 2013). If the set of ontologies chosen for this project were to be 
integrated into a unique ontology, and for better integration with AOP-Ontology, software 
editors such as Protégé and Hermit should be used for integration, enrichment, and checking for 
logical consistency (Zheng et al., 2013). Ontology validation would ensure that the selected 
ontology classes are usable for other needs and applications. 
 Finally, the selection of case examples from the mapping highlights the usability of this 
framework for individual AOP’s and to further the AOP network view through the identification 
of shared components. Providing an annotation containing Process, Object, and Context terms 
from ontologies as well as manually identified Action terms for each KE at levels of biological 
organization encompassed by AOP’s, showed the variety in the types of information conveyed 
by the framework.  Additionally, it highlights how the framework might be used to guide future 
AOP development. 
 In addition to its use for the AOP framework, the future use of this data model for the 
AOP-Wiki application is through the selection of ontologies to inform user queries.  Currently, 
Wiki users select Taxonomic Applicability for a KE from a widget drop-down menu populated 
by NCBITaxon, and they select Organ Applicability from a menu populated by Uberon.  Future 
capabilities could include the ability to define properties of KE’s using the fields Process, Object, 
Action, and Context as derived from imported files from the selected set of ontologies and 
controlled vocabularies. 
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CHAPTER 4: APPLICATION OF THE DATA MODEL TO AOP DEVELOPMENT  
FOR REGULATORY ASSESSMENT 
 
Introduction 
In this chapter, we apply the data model developed previously to map ontology terms to 
AOP’s for the risk assessment of inorganic Arsenic. We discuss the benefits and limitations of 
this structured approach, and provide detailed instances of discussion points that the mapping 
brought up. Finally, we discuss future directions for this model and how it will be applied to the 
AOP-KB in the future. 
Inorganic Arsenic (iAs) is a commonly occurring environmental contaminant with 
adverse health effects, with more than 100 million people exposed worldwide to arsenic-
contaminated water exceeding WHO’s recommended limit of 10 ug/L (WHO, 2004). It has been 
associated with chronic health conditions in adults including cardiovascular disease, peripheral 
vascular disease, neurological effects, diabetes mellitus, and cancer in the lungs, liver, urinary 
bladder, prostate and skin (NRC, 2001; Rahman et al., 2009b).   Exposure during pregnancy has 
been associated with maternal and fetal health effects (Bailey et al., 2014). Additionally, prenatal 
and early childhood exposure has been associated with delayed or postnatal health effects 
including increased rates of mortality in young adults from noncancerous diseases 
(bronchiectasis, acute myocardial infarction) and cancers of the lung, urinary bladder, larynx, 
and liver (Farzan et al., 2013).   
 IRIS (Integrated Risk Information System) is the source of toxicity information for the 
EPA, state and local health agencies, federal agencies, and international health organizations 
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(USEPA, 2015). EPA uses the program in setting national standards and cleaning up hazard 
sites. 
According to EPA, the role of IRIS is in the first two steps of risk assessment: hazard 
identification and dose-response assessment (USEPA, 2015). Hazard identification involves 
identification of health hazards associated with response to a chemical. Dose-response 
assessment involves the quantitative relationship between a chemical exposure and a credible 
health hazard, and these quantitative relationships are used to derive toxicity values. The toxicity 
values derived are for health effects resulting from chronic exposure. They include the oral 
reference dose (RfD), the amount of a chemical one can ingest daily over a lifetime not 
anticipated to cause noncancer health effects, compared to exposure estimate in mg/kg-day; and 
the inhalation reference conference (RfC), the concentration of a chemical one can ingest daily 
over a lifetime not anticipated to cause noncancer health effects, compared to exposure estimate 
in mg/m^3. Additional values include cancer descriptors, describing levels of carcinogenicity to 
humans; oral slope factor, the estimate of increased cancer risk from oral exposure to 1 mg/kg-
day for a lifetime; inhalation risk unit, the estimate of increased cancer risk from oral exposure to 
1 mg/m^3 over a lifetime to lifetime cancer risk. 
According to EPA, in 1985, the EPA created agency-wide workgroups, the carcinogen 
risk assessment verification endeavor workgroup (CRAVE) and RfC/RfD workgroup in order to 
reach agency consensus on scientific positions for health effects resulting from chronic 
oral/inhalation exposure (USEPA, 2015). IRIS was created to provide an internal consensus on 
the agency’s positions in an internally accessible database regarding health effects. The database 
became available in 1988, and eventually available on the internet, now IRIS assessments use the 
(Health and Environmental Research Online) HERO database. In December 2015, IRIS released 
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its first multi-year agenda, identifying top priority chemical assessments with highest public 
health impacts for use in decision-making.  
 According to EPA, the IRIS process for developing human health risk assessments 
consists of: draft development, agency review, interagency science consultation, public comment 
& external peer review, revision, final agency review/interagency science discussion, and final 
assessment (USEPA, 2015). Draft development applies principles of systematic review for 
internal scoping, problem formulation of scientific questions, and applying the principles of 
systematic review to identify pertinent studies, evaluate study methods and quality, and derive 
toxicity values. Agency review involves review and revision of the draft assessment based on 
received comments. Interagency science consultation includes review of the draft assessment by 
federal agencies and revision based on received comments. The draft assessment is then released 
for public review and comment, and for external peer review. The assessment is revised 
according to peer review and public comments. The final agency review and interagency science 
discussion involves revision by EPA program offices, federal agencies, and the Executive Office. 
The final assessment is posted to the IRIS website at https://www.epa.gov/iris. 
 According to the NRC, problem formulation and protocol development are part of 
systematic reviews (2014). A broad literature search is used to identify evidence from human, 
animal, and mechanistic studies for an association between chemicals and health outcomes. 
Studies are evaluated and evidence is integrated on the basis of standardized approaches and 
guidelines. Finally, hazard identification and dose-response assessment are conducted, from 
which toxicity values are derived. RfC, RfD, and unit risks are used with exposure assessments 
to derive quantitative risk estimates. The IRIS assessment process is continuously undergoing 
updates and changes, as recommendations for future directions and improvements are made. 
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 The IRIS assessment for inorganic Arsenic is currently being reassessed, with an updated 
assessment being developed for both cancer and noncancer health effects (USEPA, NCEA, 
1988). The IRIS assessment for Arsenic was initially published in 1988, with major landmarks 
being the 1999 and 2001 NRC reports evaluating EPA drinking water standards for inorganic 
Arsenic and the 2010 release of a draft assessment for cancer health effects following oral 
exposure (USEPA, NCEA, 1988).  Scoping and problem formulation began in 2012 for 
reassessment.  
 The most current (2002) IRIS chemical assessment summary (USEPA, NCEA, 1988) 
provides information regarding the oral RfD and carcinogenicity assessment. The oral RfD, an 
estimate of daily exposure likely to be without deleterious effects over a lifetime, is based on the 
assumption that thresholds exist for certain toxic effects such as cellular necrosis, expressed in 
mg/kg-day, and given with an uncertainty factor. For inorganic Arsenic (CASRN 7440-38-2), 
there was no clear consensus on the oral RfD among scientists. For the critical effects of 
hyperpigmentation, keratosis, vascular complications, and human chronic oral exposure, the 
NOAEL, LOAEL, and RfD were given as .009 mg/L converted to .0008 mg/kg-day, .17 mg/L 
converted to .014 mg/kg-day, and 3E-4 mg/kg-day of Arsenic, respectively. An external panel 
found that “it is clear from epidemiological studies that arsenic is a human carcinogen via oral 
and inhalation routes” and that “one important mode of action is unlikely to be operative for 
arsenic” (ERG, 1997). Weight-of-evidence evaluation found sufficient evidence from human 
carcinogenicity data; increased lung cancer mortality observed in multiple human populations 
exposed through inhalation, and increased mortality from multiple internal organ cancers (liver, 
kidney, lung, and bladder), and skin cancer, from populations consuming drinking water high in 
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Arsenic. There was no consistent demonstration of carcinogenicity in test animals for arsenic 
(USEPA, NCEA, 1988).  
 The second part of the carcinogenicity assessment, quantitative estimates of risk from 
oral and inhalation exposure, presents three risk estimates: oral slope factor, unit risk, and 
drinking water or air concentration (USEPA, NCEA, 1988). Drinking water or air concentration 
was reported in concentration (ug/L or ug/cu.m) for cancer risks of 1 in 10,000, 1 in 100,000, or 
1 in 1,000,000. Finally, discussion of confidence of carcinogenicity and oral exposure for the 
studies discussed is included in the assessment.  
 Inorganic Arsenic is currently being reassessed and is in the draft development stage of 
assessment (USEPA, 2014a). Problem formulation for the toxicological review for cancer and 
noncancer effects follows an Assessment Development Plan (ADP), containing scoping 
information and assumptions from partners and stakeholders (USEPA, 2014b). Following the 
ADP, a literature search for health effects is conducted using natural language processing on the 
basis of similarities of titles and abstracts. Evidence from epidemiological and animal toxicity 
studies are summarized, and risk of bias evaluated. Finally, a literature search for mode of action 
information is conducted, and hypothesized Modes of Action summarized.  
 As defined by EPA, mode of action describes “a sequence of key events and processes, 
starting with the interaction of an agent with a cell, proceeding through operational and 
anatomical changes, and resulting in cancer formation [or other adverse outcomes]” (USEPA, 
2005). MOA’s form the basis for AOP development when data are sufficient. For IRIS 
assessments, qualitative MOA analyses are conducted to inform causal determinations for health 
effects.  For causal health effects, mechanistic and susceptibility information is organized into an 
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AOP. These AOP’s will then be used to inform dose-response analyses.  If data are insufficient 
to support an AOP, then mode of action may be used to organize data (USEPA, 2014b). 
 Potential MOA’s for Arsenic as identified in a preliminary draft assessment include: 
cytotoxicity and regenerative proliferation, generation of reactive oxygen species and depletion 
of antioxidant enzymes followed by oxidative stress, and alteration of epigenetic mechanisms 
such as DNA damage (USEPA, 2014b). In evaluating hypothesized MOA’s for Arsenic, some 
considerations relevant across multiple MOA’s are the metabolism of inorganic arsenic from 
pentavalent arsenic (As V) to trivalent metabolites (As III), and the oxidative methylation of 
trivalent species to pentavalent methylarsonic acid (MMA) and dimethylarsinic acid (DMA). 
Secondly, in looking at how Arsenic might affect populations at risk due to cumulative effects 
cotoxic and interactive effects should be examined, including life stage, nutrition, genetics, sex, 
pre-existing disease, smoking, alcohol consumption, and exposure to mixtures. Arsenic-induced 
health outcomes affect males and females differentially (NRC, 2013). Additionally, Arsenic has 
cotoxic effects with metals such as cadmium (Huang et al., 2009).  
To support the toxicological review of Arsenic for draft development, EPA’s NCEA is 
working with external organizations to develop AOP’s related to several health outcomes for 
Arsenic, namely bladder cancer, basal cell carcinoma, renal cell carcinoma, squamous cell 
carcinoma, diabetes, and adverse pregnancy outcomes (I. Cote, personal communication, 2016) 
based on hypothesized MOA’s (USEPA, 2014b). Initially, a causal determination for cancer 
(bladder, lung, skin, liver, and kidney) and noncancer (CVD, skin lesions, adverse pregnancy 
outcomes, diabetes, immune effects, neurodevelopmental effects, and respiratory) endpoints was 
conducted. AOP’s will be constructed for those endpoints determined to be causal. AOP 
development will consist of integrating information regarding the pathophysiology of specific 
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diseases with arsenic specific data from literature or from NCBI BioSystems 
(http://www.ncbi.nlm.nih.gov/biosystems/) (I. Cote, personal communication, 2016). Cytoscape, 
a software package for integrating, visualizing, and analyzing network data 
(http://www.cytoscape.org/), will be used for developing and visualizing these AOP’s. 
Methods 
 The definition of an AOP has a defined starting point, the MIE, and ending point, the AO 
of regulatory significance (OECD, 2012a). In this study, low birth weight was selected as the 
AO, and the production of reactive oxygen species was selected as the MIE. Identification of 
intermediate KE’s between the MIE and the AO was achieved by a literature review including 
preliminary assessments of inorganic Arsenic modes of action. Following the definition of KE’s 
as intermediate steps at different levels of biological organization that are toxicologically 
relevant to the AO and experimentally quantifiable (OECD, 2012a). For development of an AOP 
describing adverse pregnancy outcomes, a literature review of publications and IRIS draft 
development materials for inorganic Arsenic was conducted (USEPA, 2014b). AOP 
development was conducted using the methods outlined in the Users’ Handbook Supplement 
(OECD, 2013b). Consultation with experts was conducted in choosing the KE’s in the AOP and 
in reviewing the ontology mapping chosen (R. Fry, personal communication, 2016). Ontology 
terms were mapped to the KE’s of the adverse pregnancy outcome AOP’s following the methods 
outlined in Chapter 3.  
 A graphical representation was used to summarize the data including the MIE, KE’s and 
AO in a linear flow diagram (Ankley et al. 2010, OECD, 2012a). The graphical representation 
allows the visualization of the sequence of events in the AOP at different levels of biological 
organization (OECD, 2012a).  Finally, AOP evaluation of newly established AOP’s should be 
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conducted via the implementation of Bradford Hill criteria for weight of evidence assessment 
(Hill, 1965; OECD, 2012a) according to OECD guidelines (OECD, 2012a).  Weight of evidence 
assessment was not conducted as part of this study. 
Diagrams in Cytoscape of hypothesized modes of action for the outcomes under 
assessment were obtained from a collaborator (Source: Sciome, LLC). It was assumed that the 
events in MOA’s obtained from the preliminary draft materials were synonymous with the key 
events of the draft AOP’s created. Health outcomes being assessed were: bladder cancer, basal 
cell carcinoma, renal cell carcinoma, squamous cell carcinoma, and diabetes. Key events 
(nodes), relationships, and level of biological organization of events (biochemical, 
macromolecular, cellular/tissue, organism/population) were obtained from the diagrams. Using 
the final selection (Table 1) of ontologies and vocabularies chosen in Chapter 3, key event terms 
from the hypothesized MOA’s were mapped to terms from the chosen ontologies. Query phrases 
representative of key events from these pages were entered into three ontology web browser 
sites: Ontobee (http://www.ontobee.org/), NCBO Bioportal (http://bioportal.bioontology.org/), 
and the EMBL-EBI Ontology Lookup Service (http://www.ebi.ac.uk/ols/beta/index).  From the 
list of “hits” on the search browser output, matching ontology classes (entities) were reviewed 
for their match to query terms and the appropriate ontology class was chosen. When possible, the 
least specific class available to accurately portray the information was selected, to promote 
reusability of terms and minimize the number of classes chosen.  
The data model described in Chapter 3, containing the fields: Process, Object, Action, 
and Context and the data properties as described in Chapter 3 were used in the mapping of 
ontology terms to KE terms. Results were compiled and analyzed using Excel.  The mapping of 
key events to ontology terms was reviewed for accuracy by experts in the field.  
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Results 
 Case examples were chosen to illustrate the structured approach of the data model, and its 
utility to the AOP-KB. These examples were chosen to illustrate application of the AOP 
development process to create AOP’s based on hypothesized MOA’s, and because of the direct 
applicability of this set of hypothesized MOA’s to risk assessment for a chemical known to cause 
human health effects. The case examples bring up discussion points of how the data model works 
and its limitations for specific Processes, Objects, Actions, and Contexts. 
AOP Case Example 1: Low Birth Weight 
 Exposure to inorganic Arsenic during pregnancy has been associated with maternal and 
fetal outcomes, including preterm birth, low birth weight (full term infant <2.5kg), reduced 
postnatal growth and mortality defined as spontaneous abortion, stillbirth, and infant death 
(USEPA, 2014b).  
 Two AOP’s were outlined for adverse pregnancy outcomes (Figure 8, Figure 9), with the 
shared AO of low birth weight with the difference being that one of the AOP’s includes preterm 
birth as an AO. For the AO of low birth weight, occupational and environmental studies have 
shown an association between arsenic exposure through drinking water and low birth weight. 
Epidemiological studies have shown an association between arsenic exposure through drinking 
water during pregnancy and impaired fetal and infant growth and survival (NRC, 2013). 
Drinking water exposures in populations included high (>100 ug/L) exposure and lower 
exposures (up to 40 ug/L). Cross-sectional, cohort, and ecological studies (Ahamed et al., 2006; 
Ahmad et al., 2001; Chakraborti et al., 2003; Gelmann et al., 2013; Guan et al., 2012; Kippler et 
al., 2012; Kwok et al., 2006; Mukherjee et al., 2005; Rahman et al., 2005; Vall et al., 2012; 
Gardner et al., 2013; Hopenhayn et al., 2003; Huyck et al., 2007; Rahman et al., 2009; Saha et 
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al., 2012; McDermott et al., 2014; Aelion et al., 2012; Myers et al., 2010; Yang et al., 2003) 
show a consistent inverse association between maternal arsenic exposure and birth size, 
particularly birth weight. Two studies (Kwok et al. 2006; Myers et al. 2010) do not demonstrate 
an association with low birth weight. 
Working backwards from the AO, the tissue/organ level KE was identified as ‘Altered 
placental/fetal development and function.’ Evidence cited in the literature includes impaired 
placental function, including poor placental development as a result of placental trophoblast 
migration; and impaired placental vasculogenesis leading to reduced nutritional uptake by fetus 
and reduced birth weight. Placental effects could be via gene changes; upregulation of sFLT1 in 
female cord blood, a protein that inhibits placental angiogenesis, upregulation of AQP9, encodes 
membrane transporter contributing to arsenic uptake, and decrease in ENPP2 associated with 
decreased birth weight. Outcomes of placental effects as a result of maternal arsenic exposure 
include impaired function of the placenta, impaired vasculogenesis and gene changes. The effect 
of arsenic on the developing fetus could be due to effects on the placenta or effects within the 
fetus itself; whether maternal arsenic is taken up by the placenta and the fetus is unclear. Studies 
of effects on the placenta found that placental trophoblast migration is reduced by arsenic, 
causing poor placental development (Li and LochCaruso, 2007). Other studies showed that 
arsenic impaired placental vasculogenesis in pregnant mice, which could reduce nutritional 
uptake by the fetus and lead to low birth weight (He et al. 2007; Coffin et al. 2006). Other studies 
(Remy et al., 2014) found an association between upregulation of soluble fms-like tyrosine 
kinase-1 (SFLT1) in human cord blood, a protein that inhibits placental angiogenesis. Fei et al. 
(2013) found an association between maternal arsenic exposure and placental upregulation of 
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aquaporin 9 (AQP9), a gene encoding a transporter that contributes to arsenic uptake. A related 
decrease in ENPP2 was associated with decrease in birth weight. 
Working backwards, the next KE was determined to be “Altered gene expression of 
inflammation-related genes (NFKB, TNF, GCR) in placental/fetal cells” and “Altered gene 
expression of growth-related genes (KCNQ1) in placental/fetal cells.”  Studies have shown that 
iAs can act as an immunomodulatory agent in utero, causing the increased expression of 
proinflammatory genes in newborn cord blood (Ahmed et al., 2011; Fry et al., 2007).  The 
authors found a correlation between arsenic exposure and increased expression of genes related 
to DNA damage and oxidative stress in cord blood, but did not find an association between these 
effects and pregnancy outcomes. Studies in human placentas have shown the increased 
expression of TNF-alpha and IFN-gamma (Ahmed et al., 2011) and increased intracellular H2O2 
in placental cell lines (Massrieh et al., 2006). Another study showed a correlation between iAs 
metabolites in maternal urine (U-tAs) and increased TNF-related inflammatory proteins in 
newborn cord blood (Bailey et al., 2014). Another showed gene expression of disease-related 
genes in the glucocorticoid receptor pathway (Rager et al., 2014). Mo et al. found down 
regulation of n-channel genes CACNA1, KCNH2, KCNQ1 and KCNE1 in human 
cardiomyocytes by Arsenic exposure (2011). 
Inflammation, DNA damage, and epigenetic alterations were chosen as the molecular 
level KE’s for this AOP.  Evidence for the oxidative stress MOA for Arsenic includes studies of 
the effects on mouse embryonic cells showing that oxidative stress causes impaired fetal growth. 
Toxicological studies on mouse embryonic cells show that Arsenic induced oxidative stress  
(Ren et al., 2014; Singh et al., 2010; Zhang et al., 2010), cell death, and DNA damage (Mirkes 
and Little, 1998); but specific pathways by which stress and DNA damage affect pre and 
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postnatal growth are not clear (USEPA, 2014b). At the molecular level, the MIE was chosen as 
“Production of Reactive Oxygen Species, Increased” based on this hypothesized oxidative stress 
MOA. 
Bollati and Baccarelli (2010) and Jirtle and Skinner (2007) found an association between 
prenatal exposure to toxicants such as iAs and altered disease risk in adulthood, providing 
evidence for epigenetics through altered expression of key genes. Martin et al. found altered CpG 
methylation activated TGF-β-associated gene expression associated with preeclampsia (2015). 
Rojas et al. assessed changes in 5-methylcytosine methylation, and found that DNA methylation 
levels of genes were associated with birth outcomes, in a pregnancy cohort exposed prenatally to 
Arsenic in drinking water (2015). Howe et al. found sex-dependent correlations of altered post-
translational histone modifications in rodents associated with arsenic levels in drinking water 
(2016). 
Mapping the results of search queries for KE’s in these pregnancy AOP’s to ontology 
classes from the selected minimum list as described in Chapter 3 (Table 1), resulted in the 
mapping listed in Appendix C. 
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Figure 9. Graphical view of “Reactive Oxygen Species Production leading to Low Birth Weight” with 
KE terms mapped to ontology terms. & is used to represent instances in which more than one ontology 
class was used to represent a data entity. 
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Figure 10. Graphical view of “Reactive Oxygen Species Production leading to Low Birth 
Weight/Preterm Delivery” with KE terms mapped to ontology terms. & is used to represent instances in 
which more than one ontology class was used to represent a data entity. 
AOP Case Example 2: Low Birth Weight and Preterm Birth 
KE’s not shared by the two AOP’s and unique to the second AOP with the AO of low 
birth weight/preterm delivery, include at the cellular level, ‘Trophoblast cells fail to invade,’ at 
the organism level, ‘preeclampsia/pregnancy complications,’ ‘preterm birth,’ and ‘fetal growth 
restriction’.  Li and Loch-Caruso found an association between Arsenic exposure and the 
reduction of placental trophoblasts, which could lead to poor placental development (2007). 
Oxidative stress, inflammation, and differential gene expression have been previously associated 
with preeclampsia (Ahmed et al., 2011). Laine et al. examined the interactive effects of placental 
Cd, Se, and Zn from a pregnancy cohort in the US in association with preeclampsia; and found 
that essential metals may play a protective effect in reducing the odds of Cd-associated 
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preeclampsia (2015). According to Harrington et al., “the exact etiology of conditions like 
preeclampsia and the effects of fetal exposure to toxic metals has not been determined, making 
the assessment of trace element levels crucial to the elucidation of the causes of conditions like 
preeclampsia (2016).” No study was found in this literature review for direct effects between 
prenatal arsenic exposure and preeclampsia. 
Preterm birth, describing infants born alive before 37 weeks (WHO, 2015), is a common 
cause of infant morbidity and mortality. Inflammation during pregnancy, especially 
proinflammatory cytokines, are hypothesized to be associated with preterm birth but results are 
inconsistent (Lyon, D et al., 2010). Cross-sectional studies examined low birth weight and 
preterm birth/delivery (Ahamed et al., 2006; Chakraborti et al., 2003; Mukherjee et al., 2005; 
Rahman et al., 2005). Ahmad et al. (2001), found consistent positive observations across studies 
in regions with high environmental Arsenic in Bangladesh and India. Ecological studies (Aelion 
et al., 2012; Myers et al., 2010; Yang et al., 2003) on low birth weight and preterm birth 
associated with high arsenic in soil, drinking water, and well water, reported varying results. 
Ahmed et al. details Arsenic exposure during pregnancy associated with oxidative stress 
and inflammation and leptin in the placenta, a hormone involved in transfer of nutrients from the 
placenta to the developing fetus (2011). Leptin expression is increased during hypoxia and 
intrauterine conditions such as diabetes, preeclampsia, and intrauterine growth 
retardation (Spranger et al. 2008; Iwagaki et al. 2004; Mise et al. 1998). “Fetal growth 
restriction” was the KE chosen to describe decreased growth at the organism level resulting from 
poor or altered placental development.  
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Mapping of ontology terms to KE’s in Hypothesized MOA’s for Arsenic 
Mapping the results of search queries for KE’s in the hypothesized MOA’s for outcomes 
associated with iAs exposure (bladder cancer, basal cell carcinoma, renal cell carcinoma, 
squamous cell carcinoma, and diabetes) to ontology classes from the selected minimum list as 
described in Chapter 3 (Table 1), resulted in the of 100 KE’s, 94 of them unique, being mapped 
to 300 ontology classes, 129 of them unique (Appendix C). There were 3 instances in which the 
query term from the KE could not be found using the ontology browsers chosen, and mappings 
these KE’s were undefined or incomplete. Over half of ontology classes were duplicates, and 
only a small subsection of the total number of terms available in each ontology (Figure 2) was 
needed to accurately describe the chosen KE’s.  
For example, for the MOA for bladder cancer, KE “FGFR Activation” can be condensed into 
the query terms “gene expression,” and “FGFR” from the text description, with the modifier 
“Increased” and in the context of a “urothelial cell”, resulting in a mapping to ontology classes 
as: 
Process: ‘signaling’ (GO: 0023052)  
Object: ‘fibroblast growth factor receptor’ (PR: 00000134)  
Context: ‘urothelial cell’ (CL: 0000731)  
  Action: ‘Increased.’ 
 
Discussion 
Development of AOP’s describing adverse pregnancy outcomes (Figure 8, Figure 9) 
began with accumulating studies and evidence supporting hypothesized potential MOA’s at 
different levels of organization. Following the AOP development guidelines outlined by OECD 
(OECD, 2013b), it was determined that two AOP’s would best represent the AO’s of low birth 
weight and that a separate AOP detailing a preeclampsia MOA resulting in low birth weight and 
associated preterm birth would be most representative. Working backward, KE’s developed at 
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each level of organization were created with the intention of maximum overlap between the two 
AOP’s, with the only difference being that the second AOP contained the KE’s of ‘Trophoblast 
cells fail to invade,’ ‘preeclampsia/pregnancy complications,’ ‘preterm birth,’ and ‘fetal growth 
restriction.’ Oxidative stress resulting in the production of ROS was determined to be the MIE 
for both AOP’s, based on evidence for oxidative stress MOA for iAs.  
Evidence from primary literature was cited to support the KE’s developed; however a full 
Weight of Evidence Assessment according to Bradford Hill Criteria (OECD, 2013b) would need 
to be conducted in order to fully assess confidence in these AOP’s. For several of the KE’s, 
evidence from studies were either insufficient or inconclusive; as the mechanisms of KE’s and 
their relationships are not yet fully understood. Assessing evidence for these AOP’s has involved 
the aggregation of epidemiological from case-control, cross-sectional, and ecological cohorts and 
animal toxicity study types. One limitation to providing direct evidence for the KE of ‘Altered 
placental/fetal development and function,’ for example, was that the majority of studies 
examined gene and protein levels in newborn cord blood and not the placenta or fetus itself. 
Evidence from different study types is also complicated by the variety of environmental 
mediums (well water, drinking water, and soil) studied for Arsenic exposure, and temporality of 
exposure (prenatal and postnatal). 
Mapping ontology terms to KE’s for both pregnancy outcomes and hypothesized MOA’s for 
cancer and noncancer outcomes, led to a number of discussion points for the mapping. Several of 
the discussion points made included: 
1) Representation of gene/protein families  
For example, for the Event: “RAS Activation,” the object chosen was: ‘GTPase HRAS’ (PR: 
PR_000029705). Using the OLS Browser (EBI-EMBL OLS), in the PR ontology, there is no 
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more general class of “RAS proteins” but the user must specify either hRAS, RRAS, or MRAS 
(EBI-EMBL OLS). Thus, in order to choose the more general class we chose to use MESH 
rather than PR, the default for gene expression, since MESH contained a class for ‘ras Proteins’ 
(MESH: MESH_D018631). 
Process: ‘signaling’ (GO: GO_0023052) 
Object: ‘ras Proteins’ (MESH: MESH_D018631) 
Action: ‘Increased.’ 
Context: ‘urothelial cell’ (CL_0000731) 
 
2) Differentiation between gene expression and regulation of gene expression 
It was necessary to differentiate between key events in which genes were activated, and in 
which a specific receptor or factor was regulating gene expression. Thus, ‘gene expression’ (GO: 
GO_0010467) was chosen for gene activation, while ‘regulation of gene expression’ (GO: 
GO_0010468) was chosen to represent regulation of gene expression by a specific receptor or 
factor. For the Event: “Loss of p53 function,” the mapping was: 
Process: ‘regulation of gene expression’ (GO: GO_0010468) 
Object: ‘cellular tumor antigen p53’ (PR: PR_000003035) 
Action: ‘Decreased.’ 
Context: ‘basal cell’ (CL: CL_0000646) 
 
3) Representation of pathways. 
Although there is a specific ontology, the Pathway Ontology, for the representation of 
pathways, it was decided that pathway activation should be represented in terms of the individual 
factors or genes being activated. Thus, a key event of “PI3K AKT Activation” would be 
represented as separate genes: 
Process: ‘signaling’ (GO: GO_0023052) 
Object: ‘phosphatidylinositol 3-kinase complex’ (GO: GO_0005942) AND ‘AKT Kinase’ 
(PR: PR_000029189) 
Action: ‘Increased.’ 
Context: ‘urothelial cell’ (CL: CL_0000731) 
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4) Representation of specific cell types within the ‘Context’ field.  
In mapping the pregnancy AOP’s, cellular level KE’s occurred in placental and fetal 
cells. A query for “placental cell” in the OLS Browser resulted in multiple placental cell 
types, including ‘placental pericyte’ (CL: CL_2000078), ‘placental hematopoietic stem cell’ 
(CL: CL_0002359), or ‘placental epithelial cell’ (CL: CL_0002577). A search for “fetal cell” 
similarly returned very specific fetal cell types, but no general parent class for “fetal cell.”  
Generation of a mapping for this context necessitates a conversation with AOP authors about 
how to best define the cellular context for these events. 
5) Multiple ways to represent phenotype. 
For the KE “Altered placental/fetal development and function,” the event could either be 
represented as two processes ‘developmental process’ (GO: GO_0032502) and ‘function’ 
(MI: MI_0613) in the context of the placenta/fetus, or the KE could be represented as a 
phenotype of ‘abnormal placental development’ (MP: MP_ MP_0001712). This illustrates 
that there are multiple ways to represent the same KE, and the need for restrictions to ensure 
that KE’s are uniformly represented. 
Process: ‘developmental process’ (GO: GO_0032502) AND ‘function’ (MI: 
MI_0613) 
Object:  
Action: ‘Altered.’ 
Context: ‘placenta’ AND ‘fetus’ (UBERON: UBERON_0001987, FMA: 
FMA_63919) 
 
6) Terms for which a query returned no results. 
The KE “Glucolipotoxicity” returned no results when input into any of the browser sites used. Follow 
up would consist of consulting the Arsenic MOA workgroup to find alternate terms for representing 
this process. 
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These discussion points highlight the utility of the data properties and restrictions discussed 
in Chapter 3, as well as future needs for the data model. The utility of the model in attaching 
ontology terms to KE’s, thus making AOP’s computable, is the benefit of using this structured 
approach to annotate KE’s. In conducting these mappings, potential limitations and possible 
biases in the methods used should be considered as discussed in Chapter 3.  Attaching evidence 
for these hypothesized MOA’s in the form of assays and biomarkers, will inform the hazard 
identification and dose response steps of the IRIS assessment process.  
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CHAPTER 5: GENERAL DISCUSSION, LIMITATIONS, AND FUTURE DIRECTIONS 
The AOP Framework provides a construct to organize mechanistic data supporting 
chemical regulatory assessment. It supports the use of in vitro HTS methods to increase the 
number of chemicals tested and reduce the cost and time of testing as well as the use of live 
animals. Additionally, it supports attaching evidence from both traditional toxicity tests and new 
data streams including data from genomics, chemoinformatics, pathway, phenomics, ontology, 
metabolomics, and toxicogenomics (Oki et al., 2016). It accomplishes all this by connecting the 
toxicity pathway as defined by the NRC (NRC, 2007) to adverse effects at the higher levels of 
biological organization (Ankley et al., 2010), which correspond with criteria for regulation of 
environmental pollutants. 
 The AOP development process accounts for AOP’s with varying levels of 
documentation, ranging from AOP’s resulting from a limited review of the scientific literature, to 
more formally documented AOP’s resulting from an extensive review in which gaps in 
confidence are well documented (Villeneuve et al., 2014a). Thus, the development process 
accounts for uncertainties, inconsistencies and data gaps in supporting evidence.  
 The AOP-KB benefits knowledge management and computation on data supporting 
AOP’s at all levels of confidence. As the modules of the AOP-KB evolve to meet the needs 
identified by the OECD, including open access, standardized representation of data, and 
consistency in reporting (Oki et al., 2016), the need for a shared set of chemical, biological, and 
toxicological ontologies emerges as a way to unify information across the AOP-KB and provide 
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computational capabilities for components that are currently not computable, supporting steps in 
the AOP development process. 
Developing the data model of Process, Object, Action, and Context to extend the AOP-
Ontology (Figure 4) provides computability for AOP entities that are currently represented in 
text form in the AOP-Wiki module of the AOP-KB. The data model 1) Provides the ability to 
attach scientific evidence in support of the AOP, including assays and biomarkers linked to key 
events. 2) Supports aggregation of data from HTS assays and experiments, supporting KE’s. 3) 
Supports AOP networks, which can then be used for further AOP identification and evaluation 
(Oki et al., 2016). 4) Provides for evaluation of taxonomic relevance of KE’s (Oki et al. 2016).   
The properties of the data model, including restrictions and allowances described earlier, 
depend on its design. One desired property that arose in creating this model, was allowing 
multiple Events within one KE. For example, if a KE can have more than one Event, each with 
its inherent Process, Object, and Action, then a KE can have multiple Process, Object, and 
Action pairings. For example, for the KE of “Low birth weight/preterm delivery,” implementing 
this property would allow ‘Low birth weight’ and ‘Preterm delivery’ to each have its own set of 
Process, Object, Action, and Context, while remaining part of the same KE as an intermediate 
event in a series of events leading to the AO. This allows more flexibility for the author of the 
AOP in determining the correct level of abstraction for each KE without artificial restrictions 
introduced by the need for a more structured description of the biology. 
For the case examples analyzed here, multiple AOP’s have the same KE’s, promoting a 
network view in which KE’s are nodes and relationships are edges (Villeneuve et al., 2014a). In 
other words, multiple “events” in an MOA collapse into one KE in an AOP. For instance, in the 
hypothesized MOA for bladder cancer as a result of iAs exposure, multiple events describe the 
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activation of genes through signaling pathways (FGFR, ERBB2, HRAS, RAS, VEGF, PI3K-
AKT, MAPK, JAK-STAT). For the purposes of an AOP, a KE might be named “Altered gene 
expression of pro-inflammatory genes” with the Event mapping of Process, ‘gene expression,’ 
Object ‘pro-inflammatory genes’, and Action ‘Altered.’ Allowing more resolution would give 
the ability to specify the specific gene name and ‘Increased’ or ‘Decreased’ expression for the 
individual gene while retaining the properties of the Event. This proposed, more granular entity 
was named a “Sub-Event” and will be implemented in future versions of the data model. Thus, 
an Event can have multiple Sub-Events, each with its own Process, Object, and Action terms. 
The granularity of Key Event entities will proceed from least specific to most specific, from Key 
Event, to Event, to Sub-Event, to Process-Object-Action mapping. 
Another desired property that arose in creating the data model was the placement of the 
Context data field. It was decided that Context should be a property of Key Events, so that a Key 
Event must have one and only one Context. Secondly, this property allows reuse of Events in 
other biological contexts. For example, for a hypothetical KE entitled ‘activation of 
proinflammatory genes and proteins’, the KE would occur in the context of ‘urothelial cell’ for 
the Bladder Cancer AOP, and in ‘kidney cell’ for the Renal Cell Carcinoma AOP. Thus, having 
the Event not tied to Context, allows Events to be reused in different Contexts. If the Context is 
part of a Key Event, then its properties are the same as the KE and independently editable by the 
author of the individual KE. 
These properties differentiate between the user-driven, AOP Framework view of AOP’s 
and their relationships and components, and the computer language needed to interpret these 
relationships and components. The data model will contribute to the computational models 
underlying all phases of AOP development (Villeneuve et al., 2014a). Computationally predicted 
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AOP’s, as the basis for expert-driven AOP’s (Oki et al., 2016) which are then reviewed and used 
for regulatory decision-making, require a structured data approach to tie the AOP Framework to 
computable tools and applications. Future applications of the semantics of this model to the 
AOP-Wiki application within the AOP-KB will determine the database structure of AOP 
components and the properties of that structure. The choice of how ontology terms populate 
fields on the web page that users enter and edit, and how these terms populate from one entity to 
another, will be determined by the developer’s design. As new releases are made and the Wiki is 
updated, having set properties will ease the addition of new capabilities to the Wiki.  
Application of the data model to case studies of existing high-priority AOP’s within 
AOP-Wiki, as well as to AOP’s supporting a draft IRIS assessment for inorganic Arsenic, 
demonstrate the applicability of the model to these use cases. Shared biological, chemical, and 
toxicological ontologies will be useful not only to the Wiki, but across all components of the 
AOP-KB, providing computability to support AOP development for regulatory decision-making. 
Addressing the needs for the future of toxicity as outlined by the NRC’s 2007 report (Ankley et 
al., 2010) promoting the use and accessibility of the resources in the AOP-KB, and participation 
in the AOP development process by both regulators and scientists, will inform testing strategies 
for adverse outcomes of regulatory significance. 
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APPENDIX A: REVIEW OF ONTOLOGIES AND CONTROLLED VOCABULARIES FOR THEIR CHARACTERISTICS 
M C T O I P
Anatomical Entity Ontology (AEO) anatomy all kingdoms https://github.com/obophenotype/human-developmental- X X Y Y X X
Basic Formal Ontology (BFO)* OBO Foundry http://ifomis.org/bfo/
Beta Cell Genomics (BCGO) beta cell genomics studies mouse (Mus) https://github.com/obi-bcgo/bcgo Y Y X X X X
biological collections ontology (BCO) biodiversity data https://github.com/tucotuco/bco
BRENDA tissue/enzyme source (bto)* enzyme source organisms http://www.brenda-enzymes.info X Y Y Y X X
cardiovascular disease ontology (cvdo) health https://code.google.com/p/cvdo/ X X X Y Y X
Cell Line Ontology (CLO) in vitro cell line http://www.clo-ontology.org X Y X X X X
Cell Ontology (CL) cells animals http://cellontology.org/ X Y Y Y X X
Chemical Entities of Biological Interest (CHEBI) biochemistry http://www.ebi.ac.uk/chebi Y X X X X X
clinical measurement ontology (cmo) clinical human (Homo sapiens) http://rgd.mcw.edu/rgdweb/ontology/search.html X X X Y Y X
Common Anatomy Reference Ontology (CARO)* anatomy https://github.com/obophenotype/caro X X Y Y X X
eagle-I resource ontology (ERO)* resources http://code.google.com/p/eagle-i/
environment ontology (EnVO) environment http://environmentontology.org/ X X X X X Y
FlyBase Controlled Vocabulary phenotype Drosophila http://purl.obolibrary.org/obo/fbcv X X X X Y X
Foundational Model of Anatomy (FMA) anatomy human (Homo sapiens) http://sig.biostr.washington.edu/projects/fm/index.html X X Y Y X X
gazeteer (GAZ) geography http://gensc.org/gc_wiki/index.php/GAZ_Project X X X X X Y
GO biology all kingdoms http://purl.obolibrary.org/obo/go.owl Y Y X X X X
Human developmental anatomy, abstract (ehdaa2) anatomy human-developmental http://genex.hgu.mrc.ac.uk/ X X Y Y X X
Human Disease Ontology (DOID) disease human (Homo sapiens) http://diseaseontology.sourceforge.net X X X Y Y X
Human Phenotype Ontology (HP) phenotype human (Homo sapiens) http://www.human-phenotype-ontology.org/ X X Y Y Y X
Information Architect Ontology (IAO) information https://github.com/information-artifact-ontology/IAO/
Mammalian phenotype (MP) phenotype mammals http://www.informatics.jax.org/searches/MP_form.shtml X X Y Y Y X
Molecular Process Ontology (MOP) molecular process http://purl.obolibrary.org/obo/mop.owl Y X X X X X
Mouse Anatomy (MA) anatomy mouse (Mus) https://github.com/obophenotype/mouse-anatomy-ontology X X Y Y X X
Mouse gross anatomy and development,  abstract (emapa) anatomy mouse (Mus) http://emouseatlas.org/ X X Y Y X X
Mouse gross anatomy and development, timed (emap) anatomy mouse (Mus) http://emouseatlas.org/ X X Y Y X X
NCBI Taxon taxonomy all kingdoms https://github.com/obophenotype/ncbitaxon X X X X X Y
Neuro Behavior Ontology (NBO) behavioral phenotypes organisms http://code.google.com/p/behavior-ontology x x x x Y x
NCI Thesaurus (NCIt) cancer https://cabig.nci.nih.gov/concepts/EVS Y Y Y Y Y X
Ontology for Biomedical Investigations (OBI) experiments http://obi-ontology.org Y X X X X X
ontology for general medical science (ogms) medicine human (Homo sapiens) http://code.google.com/p/ogms/ X X X Y Y X
ontology of biological attirbutes (oba) phenotype all kingdoms https://github.com/obophenotype/bio-attribute-ontology X X X Y Y X
Ontology of genes and genomes (ogg)  genes and genomes of biological organisms organisms http://ogg.googlecode.com/ Y X X X X X
Pathway Ontology (PW) pathways rat(Rattus) http://rgd.mcw.edu/rgdweb/ontology/search.html Y X X X X X
Phenotypic Quality (PATO) phenotype https://github.com/pato-ontology/pato/ X X Y Y Y X
Population and Community Ontology (PCO) populations and communities https://github.com/PopulationAndCommunityOntology/pco X X X X X Y
Protein modification (PSI-MOD) protein modification http://www.psidev.info/MOD Y X X X X X
Protein Ontology (PRO) proteins http://proconsortium.org Y X X X X X
Protein-protein interaction (mi) experiments http://psidev.sf.net/ Y Y X X X X
rat strain (rs) rat strain rat(Rattus) http://rgd.mcw.edu/rgdweb/search/strains.html X X X X Y X
Relation Ontology (RO)* relations https://github.com/oborel/obo-relations/
RNA Ontology (RnaO) RNA sequence https://github.com/bgsu-rna/rnao Y X X X X X
Sequence types and features (SO) biological sequence all https://github.com/The-Sequence-Ontology/SO-Ontologies Y X X X X X
software ontology (swo) software www.ebi.ac.uk/efo/swo
Uberon anatomy animals- vetrebrate http://uberon.org X X Y Y X X
units of measurement (UO) units of measure https://github.com/bio-ontology-research-group/unit-ontology
Vertebrate Trait (VT) vertebrate trait vertebrates http://purl.obolibrary.org/obo/vt.owl X X Y Y X X
OBO Foundry Ontologies
Level of Biological 
Organization*
Domain Source LocationData Source Taxon
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M C T O I P
Xenopus anatomy and development anatomy Xenopus laevis http://www.xenbase.org/anatomy/xao.do?method=display X X X Y Y X
Zebrafish anatomy and development anatomy http://zfin.org/zf_info/anatomy/dict/sum.html X X X Y Y X
AOP-Ontology  adverse outcome pathways https://github.com/DataSciBurgoon/aop-ontology Y Y Y Y Y Y
BAO biological assay http://bioassayontology.org/ Y X X X X X
basic formal ontology (bfo) upper level http://ifomis.org/bfo/
Experimental Factor Ontology (EFO)* experiments http://www.ebi.ac.uk/efo/ X X Y Y Y X
OpenTox  Toxicology toxicological endpoint http://www.opentox.org/dev/Ontology Y X X X X X
OpenTox Organs and Effects organ system rodents http://www.opentox.org/dev/Ontology X X X Y X X
UMLS/Medical Subject Headings (MeSH) biomedical information human (Homo sapiens) https://www.nlm.nih.gov/mesh Y Y Y Y Y Y
International Classification of Diseases, Clinical Modification (ICD9CM) clinical http://www.cms.hhs.gov/ X X Y Y X X
Systematized Nomenclature of Medicine- Clinial Terms (SNOMEDCT) clinical http://ihtsdo.org/ X X X Y Y X
Common Terminology Criteria for Adverse Events (NCI CTAE) cancer drugs http://purl.bioontology.org/ontology/CTCAE X X X X Y X
Medical Dictionary for Regulatory Activities (MedDRA)
 clinically validated international medical 
terminology dictionary (and thesaurus) used 
by regulatory authorities in the 
pharmaceutical industry during the 
regulatory process http://www.meddra.org/ Y Y Y Y Y Y
Human Interaction Network Ontology (HINO)
 INO extension for the domain of human 
interaction networks. http://purl.bioontology.org/ontology/HINO X X X X X X
Online Mendelian Inheritance in Man (OMIM) Health/Disease, traits and phenotypes http://purl.bioontology.org/ontology/OMIM Y X X X X X
WikiPathways biological pathway http://www.wikipathways.org/index.php/WikiPathways Y X X X X X
FlyBase Drosophila flybase.org Y X Y Y Y X
Non-OBO Foundry 
Controlled Vocabulary
Level of Biological 
Organization*
Domain Source LocationData Source Taxon
*Molecular, Cellular, Tissue, Organ, Individual, Population
Y = definitely covers this level of organization.
X = definitely doesn’t covers this level of organization
*upper level data source
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APPENDIX B: MAPPING OF AOP’S TO ONTOLOGY CLASSES FROM THE MINIMUM LIST IN TABLE 1
 
AOP Long name
Level of 
Organisatio Key event name Process Ontology_ID Object Ontology_ID Action  Context Ontology_ID
25
Aromatase inhibition leading to 
reproductive dysfunction (in fish) Molecular Aromatase, inhibition catalytic activity GO_0003824 cytochrome P450 19A1 PR_000006100 Decreased granulosa cell CL_0000501
Cellular
17beta-estradiol synthesis by ovarian 
granulosa cells, Reduction biosynthetic process GO_0009058 17beta-estradiol CHEBI_16469 Decreased granulosa cell CL_0000501
Organ
Pl sma 17b ta-estradiol 
concentrations, Reduction blood circulation GO_0008015 17beta-estradiol CHEBI_16469 Decreased blood plasma UBERON_0001969
Cellular
Transcription and translation of 
vitellogenin in liver, Reduction gene expression GO_0010467 vitellogenins MESH_D014819 Decreased hepatocyte CL_0000182
translation GO_0006412
Organ
Plasma vitellogenin concentrations, 
Reduction blood circulation GO_0008015 vitellogenins MESH_D014819 Decreased blood plasma UBERON_0001969
Cellular
Vitellogenin uptake into oocytes and 
oocyte growth/development, 
receptor-mediated 
endocytosis GO_0006898 vitellogenins MESH_D014819 Decreased ooctye CL_0000023
Organism
Cumulative fecundity and spawning, 
Reduction fecundity PATO_0000273 egg UBERON_0007379 Decreased
Population Population trajectory, Decrease population growth rate PCO_0000008 Decreased
16
Acetylcholinesterase inhibition leading to 
acute mortality Molecular Acetylcholinesterase (AchE), Inhibition catalytic activity GO_0003824 acetylcholinesterase PR_000003626 Decreased synapse GO_0045202
Molecular
 in synapses, 
Accumulation accumulation PATO_0002269 acetylcholine CHEBI_15355 Increased synapse GO_0045202
Organ
trioventr cular block and bradycardia, 
Increased atrioventricular block MP_0010519 Altered cardiac muscle tissue UBERON_0001133
heart rate EFO_0004326 Decreased cardiac muscle tissue UBERON_0001133
Organ Respiratory distress/arrest, Increased respiratory distress MP_0001954 Increased respiration organ UBERON:0000171
Organ
Ataxia, paraly is, or Hyp ractivity, 
Induction ataxia MP_0001393 Increased skeletal muscle tissue UBERON_0001134
induced hyperactivity MP_0001399 Increased skeletal muscle tissue UBERON_0001134
paralysis MP_0000753 Increased skeletal muscle tissue UBERON_0001134
Organism Mortality, Increased mortality EFO_0004352 Increased
Organism Population trajectory, Decreased population growth rate PCO_0000008 Decreased
22
AHR1 activation leading to developmental 
abnormalities and embryolethality (in birds) Molecular AHR, Activation signaling GO_0023052 aryl hydrocarbon receptor PR_000003858 Increased hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Molecular UDP-GT, Up Regulation catalytic activity GO_0003824 UDP-glucuronosyltransferase 1-9 PR_000017056 Increased hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Molecular
Glutathione S-transferases, Up 
Regulation catalytic activity GO_0003824 glutathione S-transferase PR_000013420 Increased hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Tissue Thyroxine (T4) in serum, Decreased blood circulation GO_0008015 thyroxine CHEBI_30660 Decreased serum UBERON_0001977
Tissue Retanoids, Decreased blood circulation GO_0008015 retinoids CHEBI_26537 Decreased serum UBERON_0001977
Molecular
AHR nuclear translocator (ARNT)-
dependent pathways, Altered 
protein dimerization 
activity GO_0046983 AHR PR_000003858 Altered hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
ARNT PR_000004303 Altered hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Tissue Oxidative Stress, Increase oxidative stress MP_0003674 Increased hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Cellular
Arachadonic acid epoxide production, 
Increase
arachidonic acid metabolic 
process GO_0019369 epoxyicosatrienoic acid CHEBI_64007 Increased hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Molecular CYP1A5, Up Regulation gene expression GO_0010467 cytochrome p-450 cyp1a5 MESH_C108015 Increased hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Cellular Uroporphyrinogen oxidation, Increase oxidation MOP_0000568 uroporphyrinogen CHEBI_27258 Increased hepatoctye, cardiac muscle cell CL_0000182, CL_0000746
Organ
Cardi vascular development/function, 
Altered developmental process GO_0032502 cardiovascular system UBERON_0004535 Altered Heart UBERON_0000947
abnormal cardiovascular 
system physiology MP_0001544 cardiovascular system UBERON_0004535 Altered Heart UBERON_0000947
Organism Uroporphyria, n/a porphyria MP_0005654 porphyrin CHEBI_8337 Altered liver UBERON_0002107
Organism Embryotoxicity, N/A embryonic lethality MP_0008762 embryo UBERON_0000922 Increased
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27
Cholestatic Liver Injury induced by Inhibition 
of the Bile Salt Export Pump (ABCB11)
Molecular
Bile Salt Export Pump (ABCB11), 
Inhibition transport GO_0006810 bile salt export pump PR_O95342 Decreased hepatocyte CL_0000182
Cellular
Transcriptional change, Activation of 
specific nuclear receptors gene expression GO_0010467 bile acid receptor PR_000011396 Increased hepatocyte CL_0000182
nuclear receptor subfamily 1 group I member 2PR_000011397
nuclear receptor subfamily 1 group I member 3PR_000011398
Cellular
Pathological condition, Bile 
accumulation accumulation PATO_0002269 bile UBERON_0001970 Increased bile canaliculi UBERON_0001283
Cellular Cytokine, Release secretion GO_0046903 cytokine FMA_84050 Increased hepatocyte CL_0000182
Cellular Inflammation, Increase inflammatory response GO_0006954 Increased hepatocyte CL_0000182
Tissue Reactive oxygen species, Production biosynthetic process GO_0009058 reactive oxygen species CHEBI_26523 Increased hepatocyte CL_0000182
Cellular Oxidative Stress, Increase oxidative stress MP_0003674 Increased hepatocyte CL_0000182
Organism Pathology, Cholestasis cholestasis HP_0001396 Increased liver UBERON_0002107
46
AFB1: Mutagenic Mode-of-Action leading to 
Hepatocellular Carcinoma (HCC) Tissue
Pro-mutagenic DNA Adducts, 
Formation DNA alkylation GO_0006305 nuclear DNA FMA_67194 Altered hepatocyte CL_0000182
Organism
Production of Reactive Electrophiles, 
Metabolism of AFB1 metabolic process GO_0008152 Increased liver UBERON_0002107
Cellular
of DNA Adducts, Insufficient or Mis-
repair dna repair GO_0006281 nuclear DNA FMA_67194 Increased hepatocyte CL_0000182
Molecular Induced in Critical Genes, Mutation mutation MI_0118 cellular tumor antigen p53 PR_000003035 Altered hepatocyte CL_0000182
Cellular
to form Altered Hepatic Foci (AHF), 
Clonal Expansion/Cell Proliferation cell proliferation GO_0008283 Hepatocyte CL_0000182 Altered liver UBERON_0002107
Organism
Hepatocellular carcinoma, 
Tumorigenesis hepatocellular carcinoma EFO_0000182 Increased liver UBERON_0002107
30
Estrogen receptor antagonism leading to 
reproductive dysfunction Molecular Estrogen receptor, Antagonism signaling GO_0023052 estrogen receptor PR_000007204 Decreased hepatocyte CL_0000182
Tissue
Transcription and translation of 
vitellogenin in liver, Reduction gene expression GO_0010467 vitellogenins MESH_D014818 Decreased hepatocyte CL_0000182
translation GO_0006412
Organ
Plasma vitellogenin concentrations, 
Reduction blood circulation GO_0008015 vitellogenins MESH_D014819 Decreased blood plasma UBERON_0001969
Tissue
Vitellogenin uptake into oocytes and 
oocyte growth/development, 
Reduction
receptor-mediated 
endocytosis GO_0006898 vitellogenins MESH_D014819 Decreased ooctye CL_0000023
Organism
Cumulative fecundity and spawning, 
Reduction fecundity PATO_0000273 Decreased
spawning NCIT_C82476 Decreased
Population Population trajectory, Decrease population growth rate PCO_0000008 Decreased
15
Alkylation of DNA in male pre-meiotic germ 
cells leading to heritable mutations Molecular DNA, Alkylation DNA alkylation GO_0006305 CHEBI_16991 Increased male germ cells CL_0000015
Molecular Mutations, Increase mutation MI_0118 DNA CHEBI_16991 Increased male germ cells CL_0000015
Cellular
Insufficient or incorrect DNA repair, 
N/A dna repair GO_0006281 DNA CHEBI_16991 Altered male germ cells CL_0000015
Organism
Heritable mutations in offspring, 
Increase mutation MI_0118 DNA CHEBI_16991 Increased
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23
Androgen receptor agonism leading to 
reproductive dysfunction Molecular Androgen receptor, Agonism signaling GO_0023052 androgen receptor PR_000004191 Increased theca cell CL_0000503
Cellular
Testosterone synthesis by ovarian 
theca cells, Reduction biosynthetic process GO_0009058 testosterone CHEBI_17347 Decreased theca cell CL_0000503
Cellular
17beta-estradiol synthesis by ovarian 
granulosa cells, Reduction biosynthetic process GO_0009058 17beta-estradiol CHEBI_16469 Decreased granulosa cell CL_0000502
Organ
Plasma 17beta-estradiol 
concentrations, Reduction blood circulation GO_0008015 17beta-estradiol CHEBI_16469 Decreased blood plasma UBERON_0001969
Organ
Transcription and translation of 
vitellogenin in liver, Reduction gene expression GO_0010467 vitellogenins MESH_D014819 Decreased hepatocyte CL_0000182
translation GO_0006412
Organism
Cumulative fecundity and spawning, 
Reduction fecundity PATO_0000273 Decreased
Tissue
Plasma vitellogenin concentrations, 
Reduction blood circulation GO_0008015 vitellogenins MESH_D014819 Decreased liver UBERON_0002107
Tissue
Vitellogenin uptake into oocytes and 
oocyte growth/development, 
Reduction
receptor-mediated 
endocytosis GO_0006898 vitellogenins MESH_D014819 Decreased ooctye CL_0000023
Organism
Gonadotropins, circulating 
concentrations, Reduction blood circulation GO_0008015
luteinizing hormone, follicle 
stimulating hormone FMA_74642, CHEBI_81569Decreased pituitary gland UBERON_0000007
Population Population trajectory, Decrease population growth rate PCO_0000008 Decreased
6
Antagonist-binding causing stabilization of 
co-repressor (SMRT or N-CoR) to PPARalpha 
Ligand Binding Domain causing downstream 
starvation-like body-weight loss
Molecular
Antagonist-binding causing 
stabilization of co-repressor (SMRT or 
N-CoR) to PPARalpha ligand binding 
domain, Binding as antagonist signaling GO_0005102 PPAR-alpha PR_000013056 Decreased nucleus GO_0005634
Molecular
PPARalpha transactivation of gene 
expression, Decreased
regulation of gene 
expression GO_0010468 PPAR-alpha PR_000013056 Decreased nucleus GO_0005634
Organ
Mitochondrial Fatty Acid Beta 
Oxidation, Decreased fatty acid beta-oxidation GO_0006635 fatty acid CHEBI_35366 Decreased liver UBERON_0002107
Organ
Ketogenesis (production of ketone 
bodies), Decreased
ketone biosynthetic 
process GO_0042181 ketone body CHEBI_73693 Decreased liver UBERON_0002107
Tissue
Circulating Ketone Bodies, Not 
Increased blood circulation GO_0008015 ketone body CHEBI_73693 Altered blood plasma UBERON_0001969
Organ
Peroxisomal Fatty Acid Beta Oxidation 
of Fatty Acids, Decreased fatty acid beta-oxidation GO_0006635 fatty acid CHEBI_35366 Decreased peroxisome GO_0005777
Organ
Catabolism of Muscle Protein, 
Increased catabolism GO_0009056 muscle protein MESH_D009124 Increased
Organism Body Weight, Decreased muscle atrophy GO_0014889 skeletal muscle tissue UBERON_0001134 Increased
body weight loss EFO_0005245 Increased
38 Protein Alkylation leading to Liver Fibrosis Molecular Protein, Alkylation protein alkylation GO_0008213 protein CHEBI_16541 Increased hepatocyte CL_0000182
Cellular Cell death, N/A
cell death
GO_0008219 hepatocyte CL_0000182 Increased hepatocyte CL_0000182
Cellular
Hepatic macrophages (Kupffer Cells), 
Activation
macrophage activation
GO_0042116 Kupffer cell CL_0000091 Increased hepatocyte CL_0000182
Cellular TGFbeta1 expression, Up Regulation gene expression GO_0010467 TGF-beta PR_000000046 Increased parenchymal cell FMA_84638
Cellular Stellate cells, Activation cell activation GO_0001775 hepatic stellate cell CL_0000632 Increased hepatocyte CL_0000182
Tissue Collagen, Accumulation collagen metabolic process GO_0032963
collagen
CHEBI_3815 Increased liver UBERON_0002107
Organ Liver fibrosis, N/A fibrosis MESH_D005355
extracellular matrix structural 
constituent GO_0005201 Increased liver parenchyma UBERON_0001280
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48
Binding of agonists to ionotropic glutamate 
receptors in adult brain causes excitotoxicity 
that mediates neuronal cell death, 
contributing to learning and memory 
impairment. Molecular
Inotropic glutamate receptors, Binding 
of agonist signaling GO_0005102 ionotropic glutamate receptor complexGO_008328 Increased neuron CL_0000540
Cellular Mitochondrial dysfunction, N/A biosynthetic process GO_0009058 reactive oxygen speciesCHEBI_26523 Increased mitochondria  GO_0005739
Cellular Cell death, N/A
cell death
GO_0008219 Increased neuron CL_0000540
Tissue Neurodegeneration, N/A neurodegeneration MP_0002229 neuron CL_0000540 Increased brain UBERON_0000955
Molecular NMDARs, Overactivation signaling GO_0005102 NMDA selective glutamate receptor complexGO_0017146 Increased hippocampus UBERON_0002421
Cellular Calcium influx, Increased
store-operated calcium 
entry GO_0002115 calcium(2+) CHEBI_29108 Increased cell CL_0000000
Tissue
Neuronal network function in adult 
brain, Decreased synaptic transmission GO_0007268 neural network FMA_74616 Decreased brain UBERON_0000955
Tissue Neuroinflammation, N/A cell activation GO_0001775 glial cell CL_0000125 Increased brain UBERON_0000955
Organism Learning and memory, Impairment
abnormal 
learning/memory/conditio
ning
MP_0002063
Altered
13
Chronic binding of antagonist to N-methyl-D-
aspartate receptors (NMDARs) during brain 
development induces impairment of 
learning and memory abilities Molecular NMDARs, Inhibition signaling GO_0005102 NMDA selective glutamate receptor complexGO_0017146 Decreased hippocampus UBERON_0002421
Cellular Calcium influx, Decreased transport GO_0006810 calcium(2+) CHEBI_29108 Decreased neuron CL_0000540
Molecular Release of BDNF, Reduced gene expression GO_0005102 brain-derived neurotrophic factorPR_000004716 Decreased neuron CL_0000540
Cellular Dendritic morphology, Aberrant
dendrite development
GO_0009058 Altered dendrite GO_0030425
Molecular
Presynaptic release of glutamate, 
Reduced neurotransmitter secretion GO_0008219 Glutamate CHEBI_14321 Decreased blood plasma UBERON_0001969
Cellular Cell death, N/A
cell death
MP_0002230 Increased neuron CL_0000540
Cellular Synaptogenesis, Decreased synapse assembly GO_0005103 Synapse GO_0045202 Decreased neuron CL_0000540
Organ Neuronal network function, Decreased synaptic transmission GO_0012421 Decreased brain UBERON_0000955
Organism Learning and memory, Impairment
abnormal 
learning/memory/conditio
ning GO_0017574 Altered brain UBERON_0000955
40
Covalent Protein binding leading to Skin 
Sensitisation Molecular Protein, Covalent Binding protein binding GO_0005515 electrophilic reagant CHEBI_59739 Increased skin cell FMA_84783
Cellular Keratinocytes, Activation cell activation GO_0001775 Increased keratinocyte CL_0000312
Cellular Dendritic Cells, Activation cell activation GO_0001775 Increased dendritic cell CL_0000451
Tissue T-cells, Activation/Proliferation cell activation GO_0001775 T-cell CL_0000084 Increased lymph node UBERON_0000029
cell proliferation GO_0008283 T-cell CL_0000084 Increased lymph node UBERON_0000029
Organ skin, sensitisation
allergic contact dermatitis
MESH_D017449 skin of body UBERON_0002097
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18
PPARa activation in utero leading to 
impaired fertility in males Molecular PPAR alpha, Activation signaling GO_0023052 PPAR-alpha PR_000013056 Increased Leydig cell UBERON_0005212
Cellular
Steroidogenic acute regulatory protein 
(STAR), Decrease gene expression GO_0010467 STAR PR_000015715 Decreased Leydig cell UBERON_0005212
accumulation PATO_0002269 STAR PR_000015715 Decreased Leydig cell UBERON_0005212
Cellular Translator protein (TSPO), Decrease gene expression GO_0010467 translocator protein PR_000016757 Decreased Leydig cell UBERON_0005212
accumulation PATO_0002269 translocator protein PR_000016757 Decreased Leydig cell UBERON_0005212
Cellular
Cholesterol transport in mitochondria, 
Reduction transport GO_0006810 cholesterol CHEBI_16113 Decreased Leydig cell UBERON_0005212
Cellular Testosterone synthesis , Reduction biosynthetic process GO_0009058 testosterone CHEBI_17347 Decreased Leydig cell UBERON_0005212
Tissue testosterone level , Reduction blood circulation GO_0008015 testosterone CHEBI_17347 Decreased Testes UBERON_0000473
Organ Male reproductive tract, Malformation
malformation
PATO_0000646 Male reproductive systemUBERON_0000079 Altered Male reproductive system UBERON_0000079
Organism Fertility, impaired fertility PATO_0000274 Decreased
7
PPARγ activation leading to impaired fertility 
in adult female Molecular PPAR gamma, Activation signaling GO_0023052 PPAR-gamma PR_000013058 Increased granulosa cell CL_0000501
Cellular
17beta-estradiol synthesis by ovarian 
granulosa cells, Reduction biosynthetic process GO_0009058 17beta-estradiol CHEBI_16469 Decreased granulosa cell CL_0000501
Cellular
Aromatase (Cyp19a1), reduction in 
ovarian granulosa cells gene expression GO_0010467 cytochrome P450 19A1 PR_000006100 Decreased granulosa cell CL_0000501
accumulation PATO_0002269
Organ
Plasma 17beta-estradiol 
concentrations, Reduction blood circulation GO_0008015 17beta-estradiol CHEBI_16469 Decreased blood plasma UBERON_0001968
Organism Fertility, impaired fertility PATO_0000274 Decreased
Organism ovarian cycle, irregularities ovulation cycle GO_0042698 Altered
42
Xenobiotic Induced Inhibition of 
Thyroperoxidase and Subsequent Adverse 
Neurodevelopmental Outcomes in 
Mammals Molecular Thyroperoxidase, Inhibition catalytic activity GO_0003824 thyroid peroxidase PR_000016584 Decreased thyrocyte BTO_0003736
Molecular Thyroid hormone synthesis, Decreased biosynthetic process GO_0009058 thyroid hormone CHEBI_60311 Decreased thyrocyte BTO_0003736
Organ
Thyroxin (T4) in neuronal tissue, 
Decreased blood circulation GO_0008015 thyroxine CHEBI_30660 Decreased brain UBERON_0000955
Tissue Thyroxin (T4) in serum, Decreased blood circulation GO_0008015 thyroxine CHEBI_30660 Decreased serum UBERON_0001977
Tissue Hippocampal gene expression, Altered
regulation of gene 
expression GO_0010468 Altered hippocampus UBERON_0002421
Tissue Hippocampal anatomy, Altered
abnormality of brain 
morphology HP_0012443 Altered hippocampus UBERON_0002421
Tissue Hippocampal function, Decreased synaptic transmission GO_0007268 Decreased hippocampus UBERON_0002421
Organism Cognitive Function, Decreased
abnormal 
learning/memory/conditio
ning
MP_0002063
Altered
10
Binding to the picrotoxin site of ionotropic 
GABA receptors leading to epileptic seizures
Molecular
iGABAR chloride channel, Binding at 
picrotoxin site signaling GO_0023052 GABA receptor complexGO_1902710 Increased neuron CL_0000540
Cellular Chloride conductance, Reduction transport GO_0006810 Chloride ion CHEBI_17996 Decreased neuron CL_0000540
Tissue
A paroxysmal depolarizing shift, 
Occurrence membrane depolarization
GO_0051899
Altered brain UBERON_0000955
Cellular
Neuronal synaptic inhibition, 
Reduction
negative regulation of 
synaptic transmission
GO_0050805 GABA-A receptor complexGO_1902711 Decreased neuron CL_0000540
Tissue
Amplified excitatory postsynaptic 
potential, Generation
excitatory postsynaptic 
potential GO_0060079 Increased brain UBERON_0000955
Organism Epileptic seizure, Occurrence epilepsy EFO_0000474 Increased
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57 AhR activation leading to hepatic steatosis Molecular AHR, Activation signaling GO_0023052 aryl hydrocarbon receptorPR_000003858 Increased hepatoctye, cardiac muscle cellCL_0000182, CL_0000746
Cellular VLDL secretion, Suppression secretion GO_0046903 very-low-density lipoproteinCHEBI_39027 Decreased hepatocyte CL_0000182
Organ
Mitochondrial fatty acid beta-
oxidation, Inhibition fatty acid beta-oxidation GO_0006635 fatty acid CHEBI_35366 Decreased liver UBERON_0002107
Organ Fatty acid, Accumulation accumulation PATO_0002269 fatty acid CHEBI_35366 Increased liver UBERON_0002107
Cellular
PCK1 expression (control point for 
glycolysis/gluconeogenesis pathway), 
Decreased gene expression GO_0010467 PCK1 MGI_97501 Decreased hepatocyte CL_0000182
Cellular Triglyceride, Accumulation accumulation PATO_0002269 triglyceride CHEBI_17855 Increased hepatocyte CL_0000183
Molecular CD36, Up Regulation gene expression GO_0010467 Cd36 MGI_107899 Increased hepatocyte CL_0000183
Molecular SCD-1, Increased gene expression GO_0010467 Scd1 MGI_107899 Increased hepatocyte CL_0000183
Cellular FA Influx, Increased transport GO_0006810 fatty acid CHEBI_35366 Increased hepatocyte CL_0000183
Molecular
LDLR (low density lipoprotein 
receptor), Up Regulation gene expression GO_0010467 low density lipoprotein receptorPR_000009744 Increased hepatocyte CL_0000183
Cellular LDL uptake, Increased endocytosis GO_0006897 low density lipoprotein CHEBI_39026 Increased hepatocyte CL_0000183
Molecular CYP1A1, Up Regulation gene expression GO_0010467 Cyp1a1 MGI_88588 Increased hepatocyte CL_0000183
Organ Liver lipid, Accumulation hepatic steatosis MP_0002628 Increased liver UBERON_0002107
29
Estrogen receptor agonism leading to 
reproductive dysfunction Molecular Estrogen receptor, Agonism signaling GO_0023052 estrogen receptor PR_000007204 Increased
Organism
Cumulative fecundity and spawning, 
Reduction fecundity PATO_0000273 Decreased
Tissue
Plasma vitellogenin concentrations, 
Increase blood circulation GO_0008015 vitellogenins MESH_D014819 Increased blood plasma UBERON_0001969
Organism
Vitellogenin synthesis in liver, 
Increase gene expression GO_0010467 vitellogenins MESH_D014819 Increased hepatocyte CL_0000182
translation GO_0006412
Organ
Renal pathology due to VTG 
deposition, Increase kidney disease EFO_0003086 Increased kidney UBERON_0002113
Population Population trajectory, Decrease population growth rate PCO_0000008 Decreased
Organism Reproductive behaviour, Altered reproductive behavior GO_0019098 Altered
Organism Larval development, Altered larval development GO_0002164 Altered
Organism
Reproductive organs, Impaired 
development of developmental process GO_0032502 reproductive organ UBERON_0003133 Altered
4
Ecdysone receptor (EcR) activation leading to 
mortality in Daphnia magna Molecular Ecdysone receptor, Activation signaling GO_0023052 ecdysone receptor holocomplexGO_0008230 Increased epidermal cell CL_0000362
Organism Pre-mature molting, Induction molting cycle process GO_0022404 Altered dermal skeleton UBERON_0010364
Organ Chitin synthesis, Induction chitin biosynthetic process GO_0006031 chitin CHEBI_17029 Increased dermal skeleton UBERON_0010364
Organ
Chitin degradation and resorption, 
Induction chitin degradation GO_0006032 chitin CHEBI_17029 Increased dermal skeleton UBERON_0010364
Population Population, Decline population growth rate PCO_0000008 Decreased
Organism Fecundity, Reduction fecundity PATO_0000273 Decreased
Organism Mortality, Increase mortality EFO_0004352 Increased
28
Cyclooxygenase inhibition leading to 
reproductive failure Molecular Cyclooxygenase activity, Inhibition catalytic activity GO_0003824 coproporphyrinogen-III oxidase, mitochondrialPR_000005826 Decreased
Tissue
Prostaglandin E2 concentration, 
Reduction blood circulation GO_0008015 prostaglandin E2 CHEBI_606564 Decreased blood plasma UBERON_0001969
Tissue
Ca and HCO3 transport to shell gland, 
Reduction transport GO_0006810 calcium ion CHEBI_29108 Decreased blood plasma UBERON_0001969
hydrogen carbonate ionCHEBI_17544
Tissue Eggshell thickness, Reduction
 chorion-containing 
eggshell formation GO_0007304 Altered ovarian follicle cell CL_0000477
Tissue Gap, N/A
Organism Reproductive failure, N/A reproduction GO_0000003 Altered
Under Development
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APPENDIX C: MAPPING OF HYPOTHESIZED AOP’S TO ONTOLOGY CLASSES FROM THE  
MINIMUM LIST IN TABLE 1 FOR ARSENIC HEALTH OUTCOMES 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
Low 
Birth 
Weight 
Macro-
molecu
lar 
Reactive 
Oxygen Species, 
Production 
biosynthetic 
process 
GO_0009058 reactive 
oxygen 
species 
CHEBI_ 
26523 
Increased placental 
cell, fetal 
cell* 
 
 Macro-
molecu
lar 
Inflammation inflammatory 
response 
GO_0006954   Increased placental 
cell, fetal 
cell* 
 
 Macro-
molecu
lar 
DNA damage DNA damage MESH_ 
D004249 
nuclear DNA FMA_67194 Altered placental 
cell, fetal 
cell* 
 
 Macro-
molecu
lar 
Epigenetic 
alterations 
regulation of 
gene 
expression, 
epigenetic 
GO_ 
0040029 
  Altered placental 
cell, fetal 
cell* 
 
 Cell 
ular 
Altered gene 
expression, 
growth related 
genes (KCNQ1) 
gene 
expression 
GO_0010467 voltage-
gated  
potass-ium 
channel 
subunit 
KCNQ1 
PR_0000007
28 
Decreased placental 
cell, fetal 
cell* 
 
 Cell 
ular 
Altered gene 
expression, 
inflammation 
related genes 
(nfkb, tnf, gcr) 
gene 
expression 
GO_0010467 NFKB 
p105:TPL2:A
BIN2 
(human) 
PR_0000284
44 
Increased placental 
cell, fetal 
cell* 
 
   gene 
expression 
GO_0010467 Tumor 
necrosis 
factor alpha 
(human) 
PR_P01375 Increased placental 
cell, fetal 
cell* 
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Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
   gene 
expression 
GO_0010467 glucocorticoi
d receptor 
PR_0000114
06 
Increased placental 
cell, fetal 
cell* 
 
 Organ Altered 
development 
and function 
development
al process 
GO_0032502   Altered placenta, 
fetus 
UBERON_
0001987, 
FMA_ 
63919 
   function MI_0613   Altered placenta, 
fetus 
UBERON_
000198, 
FMA_ 
63919 
 Organ 
ism 
Low birth 
weight 
  small for 
gestational 
age 
HP_0001518 Altered placental 
cell, fetal 
cell* 
 
 Low 
Birth 
Weight
/ 
pre 
term 
deliv 
ery 
Macro
molecu
lar 
Reactive 
Oxygen Species 
biosynthetic 
process 
GO_0009058 reactive 
oxygen 
species 
CHEBI_ 
26523 
Increased placental 
cell, fetal 
cell* 
 
 Macro
molecu
lar 
Inflammation inflammatory 
response 
GO_0006954   Increased placental 
cell, fetal 
cell* 
 
 Macro
molecu
lar 
DNA damage DNA damage MESH_D0042
49 
nuclear DNA FMA_67194 Altered placental 
cell, fetal 
cell* 
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Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Macro
molecu
lar 
Epigenetic 
alterations 
regulation of 
gene 
expression, 
epigenetic 
GO_0040029   Altered placental 
cell, fetal 
cell* 
 
 Cell 
ular 
Fail to invade regulation of 
gene 
expression, 
epigenetic 
GO_0061450   Decreased placental 
cell, fetal 
cell* 
 
 Macro
molecu
lar 
Altered gene 
expression, 
growth factors 
gene 
expression 
GO_0010467 Vascular 
endothelial 
growth 
factor 
EFO_ 
0003276 
Decreased placental 
cell, fetal 
cell* 
 
 Macro
molecu
lar 
Altered gene 
expression, 
inflammation 
related genes 
gene 
expression 
GO_0010467 NFKB 
p105:TPL2:A
BIN2 
(human) 
PR_0000284
44 
Increased placental 
cell, fetal 
cell* 
 
   gene 
expression 
GO_0010467 Tumor 
necrosis 
factor alpha 
(human) 
PR_P01375 Increased placental 
cell, fetal 
cell* 
 
   gene 
expression 
GO_0010467 Glucocorti 
coid receptor 
PR_0000114
06 
Increased placental 
cell, fetal 
cell* 
 
 Organ Altered 
development 
and function 
development
al process 
GO_0032502   Altered placenta, 
fetus 
UBERON_
0001987, 
FMA_639
19 
   function MI_0613   Altered placenta, 
fetus 
UBERON_
0001987, 
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Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
FMA_639
19 
 Organ 
ism 
Preeclampsia/p
reg 
nancy 
complications 
  preeclampsia HP_0100602 Increased   
     abnormal 
pregnancy 
MP_ 
0009661 
Increased   
 Organ 
ism 
Preterm birth   premature 
birth 
HP_0001622 Increased   
  Fetal growth 
restriction 
  fetal growth 
restriction 
EFO_000049
5 
Altered   
 Organ 
ism 
Low birth 
weight/preterm 
delivery 
  small for 
gestational 
age 
HP_0001518 Altered   
     premature 
birth 
HP_0001622 Altered   
Bladde
r 
Cancer 
Macro
mole 
cular 
Reactive 
Oxygen Species 
biosynthetic 
process 
GO_0009058 reactive 
oxygen 
species 
CHEBI_ 
26523 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
FGFR_Activatio
n 
signaling GO_0023052 fibroblast 
growth 
factor 
receptor 
PR_ 
00000134 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
ErbB2_Activatio
n 
signaling GO_0023052 receptor 
tyrosine-
protein 
kinase erbB-2 
PR_0000020
82 
Increased urothelial 
cell 
CL_00007
31 
  
 
1
1
3
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Macro
molecu
lar 
hRAS_Activatio
n 
signaling GO_0023052 GTPase Hras PR_0000297
05 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
RAS_Activation signaling GO_0023052 ras Proteins MESH_D018
631 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
p53_Mutation mutation MESH_D0091
54 
cellular 
tumor 
antigen p53 
PR_0000030
35 
Altered urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
VEGF_Activatio
n 
signaling GO_0023052 vascular 
endothelial 
growth 
factor A 
PR_0000172
84 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
P13K_AKT_Acti
vation 
signaling GO_0023052 phosphatidyli
nositol 3-
kinase 
complex 
GO_ 
0005942 
Increased urothelial 
cell 
CL_00007
31 
   signaling GO_0023052 AKT kinase PR_0000291
89 
Increased   
 Macro
molecu
lar 
MAPK_Activatio
n 
catalytic 
activity 
GO_0003824 mitogen-
activated 
protein 
kinase 
PR_0000000
19 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
MMP_Stimulati
on 
catalytic 
activity 
GO_0003824 Matrix 
Metalloprote
inases 
MESH_D020
782 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
CDKN2A gene 
expression 
GO_0010467 CDKN2A 
gene 
translation 
product 
PR_0000290
97 
Increased urothelial 
cell 
CL_00007
31 
  
 
1
1
4
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Macro
molecu
lar 
COX-2 gene 
expression 
GO_0010467 prostaglandi
n G/H 
synthase 2 
PR_0000134
28 
Increased urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
Rb1_Mutation mutation MESH_D0091
54 
retinoblasto
ma-
associated 
protein 
PR_0000137
73 
Altered urothelial 
cell 
CL_00007
31 
 Macro
molecu
lar 
JAK-
STAT_Activatio
n 
signaling GO_0023052 janus kinase PR_0000257
48 
Increased urothelial 
cell 
CL_00007
31 
   signaling GO_0023052 STAT dimer PR_0000279
35 
   
 Cell 
ular_ 
Tissue 
Growth_Factor
_and_Cytokine
_Activation 
signaling GO_0023052 cytokine FMA_84050 Increased urothelial 
cell 
CL_00007
31 
 Cell 
ular_ 
Tissue 
Cell_Proliferatio
n 
cell 
proliferation 
GO_0008283 bladder 
tumor 
EFO_ 
0000294 
 urotheliu
m 
UBERON_
0000365 
 Cel 
lular_ 
Tissue 
Angiogenesis_S
urvival_Metast
asis 
angiogenesis GO_0001525   Increased urinary 
bladder 
UBERON_
0001255 
   cell survival MESH_D0024
70 
  Increased   
   neoplasm 
metastasis 
MESH_D0093
62 
  Increased   
 Organis
m_Pop
ulation 
Bladder Cancer        
  
 
1
1
5
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Molecu
lar 
Thiol Binding, 
Skin 
Accumulation 
binding GO_0005488 thiol group CHEBI_ 
29917 
Increased basal cell CL_00006
46 
 Cell 
ular_ 
Tissue 
 accumulation PATO_ 
0002269 
  Increased skin of 
body 
UBERON_
0002097 
Basal 
Cell 
Carci 
noma 
Macro-
molecu
lar 
Reactive 
Oxygen Species 
biosynthetic 
process 
GO_0009058 reactive 
oxygen 
species 
CHEBI_ 
26523 
Increased urothelial 
cell 
CL_00007
31 
 Organis
m_Pop
ulation 
Basal Cell 
Carcinoma 
  Basal Cell 
Carcinoma 
MPATH_234 Increased   
 Macro
molecu
lar 
Signal 
Transduction 
Pathway 
Crosstalk 
cell commun 
ication 
GO_0007154   Altered basal cell CL_00006
46 
 Macro
molecu
lar 
SMO/Su(Fu) 
Mutations 
mutation MI_0118 SUFU PR_ 
000003324 
Increased basal cell CL_00006
46 
 Macro
molecu
lar 
Loss of p53 
Function 
regulation of 
gene 
expression 
GO_0010468 cellular 
tumor 
antigen p53 
PR_0000030
35 
Decreased basal cell CL_00006
46 
 Macro
molecu
lar 
PTCH1 
Mutations 
mutation MI_0118 PTCH1 PR_0000134
12 
Increased basal cell CL_00006
46 
Renal 
Cell 
Carci 
noma 
Cell 
ular_ 
Tissue 
Cell 
Proliferation 
cell 
proliferation 
GO_0008283 neoplasm EFO_ 
0000616 
Increased kidney UBERON_
0002113 
  
 
1
1
6
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Organis
m_Pop
ulation 
Renal Cell 
Carcinoma 
  Renal Cell 
Carcinoma 
EFO_ 
0000681 
Increased   
 Cell 
ular_ 
Tissue 
Cell 
Proliferation 
and Survival 
cell 
proliferation 
GO_0008283 neoplasm EFO_ 
0000616 
Increased kidney UBERON_
0002113 
   cell survival MESH_D0024
70 
  Increased kidney UBERON_
0002113 
 Macro
molecu
lar 
S6K gene 
expression 
GO_0010467 ribosomal 
protein S6 
kinase beta-1 
PR_0000001
23 
Increased kidney cell CL_10000
497 
 Macro
molecu
lar 
mTOR:Raptor gene 
expression 
GO_0010467 regulatory-
associated 
protein of 
mTOR 
PR_0000137
35 
Increased kidney cell CL_10000
497 
 Macro
molecu
lar 
Rheb gene 
expression 
GO_0010467 GTP-binding 
protein Rheb 
PR_0000139
75 
Increased kidney cell CL_10000
497 
 Macro
molecu
lar 
TSC2/1 gene 
expression 
GO_0010467 testis-
expressed 
sequence 37 
protein 
PR_0000167
10 
Increased kidney cell CL_10000
497 
 Macro
molecu
lar 
PI3K gene 
expression 
GO_0010467 phosphatidyli
nositol 3-
kinase 
complex 
GO_ 
0005942 
Increased kidney cell CL_10000
497 
 Macro
molecu
lar 
PTEN gene 
expression 
GO_0010467  phosphatidyl
inositol 
3,4,5-
trisphosphat
PR_0000287
46 
Increased kidney cell CL_10000
497 
  
 
1
1
7
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
e 3-
phosphatase 
and dual-
specificity 
protein 
phosphatase 
PTEN 
 Macro
molecu
lar 
ERK gene 
expression 
GO_0010467 ephrin type-B 
receptor 2 
PR_0000071
30 
Increased kidney cell CL_10000
497 
 Macro
molecu
lar 
Akt gene 
expression 
GO_0010467 AKT kinase PR_0000291
89 
Increased kidney cell CL_10000
497 
 Cell 
ular_ 
Tissue 
Angiogenesis angiogenesis GO_0001525 blood vessel UBERON_00
01981 
Increased kidney 
interstitiu
m 
UBERON_
0005215 
 Cell 
ular_ 
Tissue 
Cell Migration 
and Invasion 
cell migration GO_0016477 neoplasm EFO_ 
0000616 
Increased kidney 
interstitiu
m 
UBERON_
0005215 
   neoplasm 
invasiveness 
MESH_D0093
61 
     
 Cell 
ular_ 
Tissue 
Loss of ECM extracellular 
structure 
organization 
GO_0043062 intercellular 
matrix 
FMA_9672 Altered kidney cell CL_10000
497 
 Cell 
ular_ 
Tissue 
Cystogenesis   cystic PATO_0001
673 
Increased kidney 
interstitiu
m 
UBERON_
0005215 
 Cell 
ular_ 
Tissue 
Dysregulated 
Signaling 
regulation of 
signaling 
GO_0023051   Decreased kidney cell CL_10000
497 
  
 
1
1
8
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Macro
molecu
lar 
VEGF PGF gene 
expression 
GO_0010467 vascular 
endothelial 
growth 
factor 
EFO_ 
0003276 
Increased kidney cell CL_10000
497 
   gene 
expression 
GO_0010467 placental 
growth 
factor 
PR_0000126
05 
Increased kidney cell CL_10000
497 
 Macro
molecu
lar 
MMP 2 MMP9 gene 
expression 
GO_0010467 MMP2 PR_0000104
79  
Increased kidney cell CL_10000
497 
   gene 
expression 
GO_0010467 MMP9 PR_0000104
91 
Increased kidney cell CL_10000
497 
 Cell 
ular_ 
Tissue 
Loss of Primary 
Cilia 
  primary 
cilium 
GO_ 
0072372 
Decreased kidney 
interstitiu
m 
UBERON_
0005215 
 Macro
molecu
lar 
HIF 
Translocation 
and Signaling 
Activation 
translocation SO_0000199 hypoxia-
inducible 
factor 1-
alpha 
PR_0000085
55 
Altered kidney cell CL_10000
497 
   signaling GO_0023052 hypoxia-
inducible 
factor 1-
alpha 
PR_0000085
55 
Increased   
 Macro
molecu
lar 
Loss of VHL   loss of 
function 
variant 
SO_0002054 Altered kidney cell CL_10000
497 
 Cell 
ular_ 
Tissue 
Cell 
Differentiation 
& Oncogenesis 
cell 
differentiatio
n 
GO_0030154   Altered squamous 
epithelium 
UBERON_
0006914 
  
 
1
1
9
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
     tumorigenesi
s 
MP_ 
0002006 
Increased   
Squam 
ous 
Cell  
Carci 
noma 
Macro
molecu
lar 
cMyc gene 
expression 
GO_0010467 c-myc 
protein 
PR_0000000
84 
 squamous 
cell 
FMA_667
69 
 Macro
molecu
lar 
Activation of 
STAT Pathways 
STAT cascade GO_0097696   Increased squamous 
cell 
FMA_667
69 
 Organis
m_Pop
ulation 
Squamous Cell 
Carcinoma 
  Squamous 
Cell 
Carcinoma 
MP_ 
0004207 
Increased   
 Macro
molecu
lar 
Loss of Rb gene 
expression 
GO_0010467 retinoblasto
ma-
associated 
protein 
PR_0000137
73 
Decreased   
 Cell 
ular_ 
Tissue 
Cell 
Survival/Evasio
n of Apoptosis 
cell survival MESH_D0024
70 
  Increased squamous 
cell 
FMA_667
69 
   negative 
regulation of 
apoptotic 
process 
GO_0043066   Increased squamous 
cell 
FMA_667
69 
 Macro
molecu
lar 
PI3K/Akt signaling GO_0023052 phosphatidyli
nositol 3-
kinase 
complex 
GO_ 
0005942 
Increased   
     AKT kinase PR_0000291
89 
   
  
 
1
2
0
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Macro
molecu
lar 
RAF/Mek/Erk signaling GO_0023052 RAF proto-
oncogene 
serine/threo
nine-protein 
kinase 
PR_0000032
44 
Increased squamous 
cell 
FMA_667
69 
     dual 
specificity 
mitogen-
activated 
protein 
kinase 1 
PR_0000101
25 
Increased   
     ephrin type-B 
receptor 2 
PR_0000071
30 
Increased   
 Macro
molecu
lar 
Activation of 
Ras Pathways 
signaling GO_0023052 ras Proteins MESH_D018
631 
Increased squamous 
cell 
FMA_667
69 
 Macro
molecu
lar 
Loss of p16 gene 
expression 
GO_0010467 CDKN2A 
gene 
translation 
product 
PR_0000290
97 
Decreased squamous 
cell 
FMA_667
69 
 Macro
molecu
lar 
Loss of p53 gene 
expression 
GO_0010467 cellular 
tumor 
antigen p53 
PR_0000030
35 
Decreased squamous 
cell 
FMA_667
69 
 Cell 
ular_ 
Tissue 
Actinic 
Keratoses 
actinic 
keratosis 
EFO_0002496   Increased epithelium UBERON_
0000483 
 Macro
molecu
lar 
C to T or CC to 
TT mutations 
C_to_T_transi
tion 
SO_1000011   Increased squamous 
cell 
FMA_667
69 
  
 
1
2
1
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Macro
molecu
lar 
Polymorphisms 
in p53 (codon 
72) or H-ras 
(codon 27) 
substitution SO_1000002 cellular 
tumor 
antigen p53 
PR_0000030
35 
Increased squamous 
cell 
FMA_667
69 
     GTPase Hras PR_0000297
05 
   
Diabet
es 
Organis
m_Pop
ulation 
Diabetes   diabetes 
mellitus 
EFO_ 
0000400  
Increased   
 Cell 
ular_ 
Tissue 
Beta Cell 
Exhaustion 
abnormal cell 
physiology 
MP_0005621   Altered beta cell FMA_857
04 
 Individ
ual 
Insulin 
Resistance 
  insulin 
resistance 
EFO_ 
0002614 
Increased   
 Individ
ual 
Systemic 
Proinflammator
y Response 
inflammatory 
response 
GO_0006954   Increased   
 Macro
molecu
lar 
Increased TNF-
alpha 
  tumor 
necrosis-
factor alpha 
PR_0000001
34 
Increased beta cell FMA_857
04 
 Cell 
ular_ 
Tissue 
Beta Cell 
Apoptosis 
type B 
pancreatic 
cell apoptotic 
process 
GO_0097050   Increased beta cell FMA_857
04 
 Cell 
ular_ 
Tissue 
Impaired FA 
Oxidation 
Ectopic Lipid 
Deposition and 
Lipotoxicity* 
fatty acid 
oxidation 
GO_0019395   Altered beta cell FMA_857
04 
  
 
1
2
2
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
   accumulation PATO_ 
0002269 
fatty acid CHEBI_ 
35366 
Increased beta cell FMA_857
04 
 Macro
molecu
lar 
Decreased 
Insulin Signaling 
signaling GO_0023052 insulin PR_0000090
54 
Decreased beta cell FMA_857
04 
 Cell 
ular_ 
Tissue 
Beta Cell 
Dysfunction 
abnormal cell 
physiology 
MP_0005621   Altered beta cell FMA_857
04 
 Macro
molecu
lar 
Increased IL-6, 
CRP 
gene 
expression 
GO_0010467 interleukin-6 PR_0000013
93 
Increased beta cell FMA_857
04 
   gene 
expression 
GO_0010467 C-reactive 
protein 
PR_0000058
97 
Increased beta cell FMA_857
04 
 Cell 
ular_ 
Tissue 
Altered Skeletal 
Muscle 
Mitochondria 
Beta Oxidation 
and 
Mitochondria 
Number 
fatty acid 
beta-
oxidation 
GO_0006635 Mitochon 
drion 
GO_ 
0005739 
Altered skeletal 
muscle 
tissue 
UBERON_
0001134 
     abnormal 
mitochon 
drion 
morphology 
MP_ 
0006035 
Altered skeletal 
muscle 
tissue 
UBERON_
0001134 
 Cell 
ular_ 
Tissue 
Accumulation 
and Activation 
of 
Macrophages 
accumulation PATO_ 
0002269 
macrophage CL_0000235 Increased skeletal 
muscle 
tissue 
UBERON_
0001134 
   cell activation GO_0001775      
  
 
1
2
3
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
 Cell 
ular_ 
Tissue 
Oxidative and 
ER Stress 
  oxidative 
stress 
MP_ 
0003674 
Increased beta cell FMA_857
04 
   response to 
ER stress 
GO_0034976 endoplasmic 
reticulum 
GO_0 
005783 
Altered beta cell FMA_857
04 
 Cell 
ular_ 
Tissue 
  Amyloid 
Deposition 
MPATH_34   Increased skeletal 
muscle 
tissue 
UBERON_
0001134 
 Cell 
ular_ 
Tissue 
Dysregulation 
of 
Mitochondrial 
Oxidation of 
Beta Fatty Acids 
regulation of 
fatty acid 
beta-
oxidation 
GO_0031998  beta-amino-
fatty acid 
CHEBI_ 
59754 
Decreased skeletal 
muscle 
tissue 
UBERON_
0001134 
 Init 
iator** 
Obesity obesity EFO_0001073   Increased   
 Cell 
ular_ 
Tissue 
Glucoliptoxicity
* 
       
 Cell 
ular_ 
Tissue 
Ectopic Lipid 
Deposition in 
Skeletal Muscle 
and Liver* 
       
 Cell 
ular_ 
Tissue 
Expansion of 
Adipose Tissue 
adipose tissue 
development 
GO_0060612   Increased pancreas UBERON_
0001264 
 Macro
molecu
lar 
Alterations DNA 
Methylation or 
Histone 
Methylation 
dna 
methylation 
GO_0006306   Altered beta cell FMA_857
04 
  
 
1
2
4
 
Health 
Out-
come 
Level 
of 
Organi-
sation 
Key Event  Process Ontology_ID Object Ontology_ID Action Cellular/ 
Organ 
Context 
Ontology
_ID 
   histone 
methylation 
GO_0016571   Altered beta cell FMA_857
04 
 Init 
iator** 
High Fat Diet high fat diet EFO_0002757      
*undefined  ** these were labeled as initiating factors (not a level of organization of the AOP) as part of hypothesized MOA's 
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